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Summary 
This thesis describes the isolation, structure elucidation, anti-trypanosomal activity and molecular mo-
delling of the aporphine alkaloids obtained from Enantia chlorantha. 
Phytochemical studies on the Enantia chlorantha stem bark yielded six dimeric and one monomeric 
aporphine alkaloid along with one protoberberine type alkaloid, palmatine. Three  dimeric aporphine 
alkaloids were novel namely: 1,1',2,2',3-pentamethoxy-6-methyl-5,5',6,6'-tetrahydro-4H,4'H-7,7'-
bidibenzo[de,g]quinoline, ECP-19 (89),8-(1,2,3-trimethoxy-5,6-dihydro-4H-dibenzo[de,g]quinolin-7-
yl)-6,7-dihydro-5H-[1,3]dioxolo[4',5':4,5]benzo[1,2,3-de]benzo[g]quinoline, ECHE-45 (90), and 7-
methyl-8-(1,2,3-trimethoxyl-5,6-dihydro-4H-dibenzo(de,g)quinolin-7-yl)-6,7-dihydro-5H-
(1,3)dioxolo(4’5’:4,5)benzo(1,2,3-de) benzo(g)quinoline ECH-56 (91). The structures of the alkaloids 
were determined using 2D NMR experiments and their masses confirmed using ESI Mass Spectrome-
ter. 
 Anti-trypanosomal screening of these alkaloids for activity against  the non-virulent bloodstream form 
of T.brucei brucei ,carried out using a modified microplate Alamar blue TM assay revealed that these 
alkaloids had excellent anti-trypanosomal activity, with MICs 1.27 to 10.96 nanomolar compared to  
the positive control Suramin with MIC of 9.6 nanomolar. Of the three novel dimeric alkaloids, ECP-19 
(89) was the most active with MIC of 1.27 nanomolar. 
Molecular modelling was carried out for all of these alkaloids as well as their derivatives monomeric 
aporphine alkaloids using the GRIP technique with Vlife molecular Design Suite (V life MDS 4.2) on 
seven validated Trypanosoma brucei protein targets from the Protein Data Bank (PDB). These protein 
targets were: T. brucei Glutathione Synthetase , Glutathione peroxidase-type tryparedoxin peroxidase, 
oxidized form ,Glutathione peroxidase-type tryparedoxin peroxidase, reduced form , Sterol 14-alpha 
demethylase (CYP51) from T. brucei in complex with the tipifarnib derivative 6-(4-
chlorophenyl)(methoxy)(1-methyl-1H-imidazol-5-yl)methyl)-4-(2,6-difluorophenyl)-1-methylquinolin-
2(1H)-one , T. brucei Ornithine Decarboxylase , Riboflavin kinase ,and Trypanothione reductase from 
T. brucei.  
The inhibition of T. brucei ornithine decarboxylase was the most significant, hence the possibility of it 
being a likely mechanism of action for these alkaloids.  Further molecular modelling studies  of the 
eight alkaloids whose structure were elucidated in this thesis, as well as six derivate monomeric alka-
loids were carried out to pinpoint the “best fit “alkaloids to Ornithine decarboxylase’s active site Ly-
sine 69 using the GOLD 5.5.2 software. This revealed the dimeric aporphine alkaloids isolated in this 
study had  docking score as a function of GOLD.PLP.Fitness which ranged from  -95.1384 to 27.8819 
for dimers,which is not as good as the docking scores ranging from 26.5959 - 38.4616 for monomers 
[16] 
 
isolated in this study, as well as monomeric derivatives of the dimers. Derivative monomer, Compound 
95 had the best docking score of  38.4616. 
This set of results in terms of the novelty of the dimeric alkaloids, their excellent anti-trypanosomal 
activity in vitro, significant results in molecular models and the fact that anecdotal evidence of use of 
Enantia chlorantha extracts in vivo for treatment of ailments traditionally in rural West Africa for cen-
turies may form a basis for further drug development studies. As it is the norm in drug discovery syn-
thetic analogues developed from a natural product scaffold tend to provide a vast number of molecules 
to test and develop further, therefore future molecular modelling studies are currently being tailored to 
optimising the “best fit” monomeric alkaloids to hybrid modelled synthetic analogues for further drug 
development studies beyond the scope of the PhD study. 
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Introduction  
Humans have since time immemorial relied on nature to cater for their basic needs, including tradition-
al medicines for the treatment of a wide variety of diseases. Plants, most especially, have formed the 
basis of age-long traditional medicine systems.  Newman et al., (2000) reported the people of Mesopo-
tamian times recorded use of drugs using clay tablets in cuneiform writings around 2600 BC.  Among 
which were  Cedrus species (cedar) and Cupressus sempevirens (cypress) oils, Glycyrrhiza gla-
bra (licorice),Commiphora species (myrrh), and Papaver somniferum (poppy juice), all of which are 
still used today in traditional medicine for the treatment of ailments ranging from coughs, colds to par-
asitic infections and inflammation. Newman et al., (2000) also documented the Egyptians reported 
Pharmaceutical agent called “Ebers Papyrus” from 1500 BC comprising of over 700 medicines. Also 
in India as far back as 1000 BC writings of Indian Ayurvedic medicine reported 394 Charaka medi-
cines and 516 Sushruta medicines according to Kapoor (1990). The Chinese Materia Medica docu-
mented records dating from about 1100 B. C. by Wu Shi Er Bing Fang, containing 52 medicines, fol-
lowed by works such as the Shennong Herbal at about 100 B. C containing 895 drugs and the Tang 
Herbal 659 A. D containing 850 drugs as reported by Huang (1999). 
More recently, the Greeks and Romans contributed immensely to the use of herbal drugs in the ancient 
western world. Dioscorides, a Greek physician (100 CE), documented the collection, storage, and use 
of medicinal herbs during his travels with Roman armies throughout the then “known world”, whilst 
Galen (130–200 CE.), a practitioner and teacher of pharmacy and medicine in Rome, was well known 
for his complex prescriptions and formulae used in compounding medicines according to NIH report 
(2002). 
West Africa, the westernmost part of Africa comprises of seventeen countries namely Benin, Burkina 
Faso, Cape Verde,Cote d’Ivoire,Gambia, Ghana, Guinea, Guinea-Bissau, Liberia, Mali, Mauritana, 
Niger, Nigeria, Island of Saint Helena, Senegal, Sierra Leone, Sao Tome and Principe, Togo. Enantia 
chlorantha also known as “African Yellow Wood” is a dense forest tree found in the coastal and rain-
forest areas of several of the listed West Africa countries.  
Human African Trypanosomiasis (HAT) comprises of two forms: T.brucei gambiense which is found 
in Western and Central Africa, T.brucei rhodesiense in Eastern and Southern Africa. There is also the  
South American variety known as Chagas disease. They continue to place a huge health burden on mil-
lions of lives in Sub-Saharan Africa, North and Latin American countries.  Present treatment regimens 
are hardly effective and saddled with severe adverse side effects; hence the need for new therapeutic 
agents to combat this deadly scourge, one from natural sources such as Enantia Chlorantha could be a 
[18] 
 
possible option. It is a medicinal herb that belongs to the family Annonaceae, which has been in tradi-
tional use in West and Central Africa for several centuries. 
1.1. Aims and objectives of the study 
Aims and Objective of the study 
Research aims 
To investigate the phytochemistry and bioactivity of compounds derived from traditional Nigerian 
medicine herb, Enantia chlorantha known for its potential anti-parasitic traditional uses in Africa using 
various chromatographic separation and molecular modelling techniques. 
Objectives 
1. To test the initial extracts for anti-cancer, anti-parasitic, and anti-microbial activity to decipher 
which activity the extracts have, this turned out to be anti-trypansomal with no carcinogenic 
activity, see Masters’ thesis summary in the appendix. 
2. To determine which class of bioactive compounds among tannins, fats, alkaloids, flavonoids, 
sugars and saponins had the anti-trypanosomal activity of interest, this turned out to be the al-
kaloids. 
3. To use a bioassay guided approach in isolating alkaloids obtained from Enantia chlorantha, by 
testing the extracts as well as alkaloids obtained from the extracts for their anti-trypanosomal 
properties. An earlier study on Enantia Chlorantha was carried out on aqueous extracts, Ades-
okan et al., (2007) investigated the anti-bacterial effects of the stem bark extract on Staphylo-
coccus aureus, Bacillus subtilis, Escherichia coli, Salmonella typhi and Pseudomonas aeru-
ginosa. However aqueous extracts tend to be non-specific in extraction of compounds, thus ne-
cessitating a gradient approach for extraction based on polarity of constituents. Hexane ex-
tracted the non-polar compounds; ethyl acetate extracted the medium polar compounds, while 
methanol extracted the highly polar compounds. 
4. To see if there is variation in types of alkaloids isolated based on season of collection of the plant 
materials. It is a known fact among traditional herbalists in Africa and Amazon that their herbs tend to 
contain different bioactive extracts at different time of the year . This is  based on the premise that dif-
ferent parasites, weather or similar challenges are poised at different times of the year. In response to  
these different kinds of stress, plants are known to synthesize different bioactive substances for surviv-
al based on seasonal variation. Thus this study was tailored along similar lines to see if there were dif-
ferences in the kinds of compounds isolated in plant materials collected in summer, compared to those 
collected in winter. 
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5. To use different separation techniques to attempt to purify the alkaloids obtained from the Enantia 
chloratha extracts. The intention was to try several methods to see those that would yield the purest 
fractions for further bioactivity studies 
6. Subject the isolated  bioactive alkaloids to molecular modelling studies to determine which one were 
best bound to protein trypanosomes targets . We modelled the alkaloids ligands against  several protein 
targets, picked the best of the lot of the protein targets in terms of binding affinity and proceeded to 
further model the alkaloids and their derivative alkaloids to see which ones would have the best fit into 
the pocket of the active site of the most actively bound  protein trypanosomes target, Ornithine decar-
boxylase. 
7. To attempt to optimise the best docked “best perfect fit” alkaloid (ligand) into the active site of Or-
nithine decarboxylase (Lysine 69) to generate hybrid alkaloid(s) for synthesis and further in-vivo activ-
ity and pharmacokinetics studies. 
Thus these lead bioactive alkaloids isolated in this study could serve as leads with potential to treat 
human diseases. This is especially in the area of antimicrobials and anti-parasitic agents in the face of 
common evolving drug resistance and intolerable severe side effects of presently available treatment 
regimens especially for neglected diseases like HAT (see section 1.11 on page 53  for more infor-
mation on present drugs for treating HAT). 
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Study’s step-wise action plan in a flowchart 
                            Extraction from plant material using the soxhlet extractor 
 
Various anticancer, antimicrobial, and anti-parasitic activity testing of extracts for activity 
                                         
Isolation of bioactive compounds from Enantia chlorantha extracts. 
 
Structure elucidation and molecular weights determination using NMR and Mass Spectroscopy. 
                                                                     
Purification of the isolated alkaloids using various chromatographic techniques and subsequent anti-
trypanosomal activity testing 
 
 
Molecular modelling and other Translational Chemistry approaches to define drug targets in terms of 
most potent alkaloid’s binding affinity for proven anti-trypanosomal enzyme target(s). 
 
*Synthesis of the novel modelled lead compounds and analogues 
 
                   *In-vivo parasitized mouse model activity studies 
  *Further parasitic activity screening looking at the synthesized compounds activity against a variety 
of parasitic infections bioassay templates like malaria, leishmaniasis in addition to trypanosomiasis. 
*Pharmacokinetics and lead compounds safety studies using stem cell models to predict the bioactive 
alkaloids’ metabolism and toxicity profile in vivo and vitro (this technology is extremely efficient and 
is now replacing the laborious use of animals to a large extent in pre-clinical activity, toxicity and 
pharmacokinetics screening)   
*Written in blue beyond scope of the PhD study 
 
1.2 The plant: Enantia chlorantha 
Enantia chlorantha according to the Thesaurus of Agricultural Organisms (1990) is otherwise known 
as ‘African whitewood’.  It is an ornamental tree found in the rainforests of Nigeria, Liberia, and Cote 
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d’ Ivoire, Gabon, Democratic Republic of Congo and Cameroun among others. The tree grows to about 
30m high with dense foliage and spreading crown with fluted stem which produces a sulfurous yellow 
dye as reported by Iwu (1993). It is used locally across Africa to make unpainted furniture and veneers. 
It is referred to locally by the Nigerian Yoruba tribe as “Dokita Igbo” which literally means “Doctor of 
the forest” due to medicinal use in rural West Africa to treat several ailments. In Nigeria, traditionally 
it is used in the treatment of malaria as reported by Gbadamosi and Oni (2005). 
Gill and Akinwunmi (1986) also reported the use of the infusion of E. chlorantha stem bark for the 
treatment of pulmonary tuberculosis and infected wounds. The stem bark is made up of an inner bark 
which is bright yellow and an outer cork which is dark brownish. 
 
 
 
                                            Figure 1.1  Cork of Enantia chlorantha used for the study. 
In the 1980s, Virtanen et al., (1988) showed that a mixture of protoberberines from Enantia chlorantha 
had preventive and curative effects on CCl4- and glucosamine – induced liver injury.  Adjanohoun et 
al., (1996) reported the extract’s effectiveness in treating jaundice and urinary tract infections.  Agbaje 
and Onabanjo (1998) also documented the potential of E. chloranthastem bark in relieving pyrogen-
induced fever in vivo in albino rats. Oyewopo et al., (2012) reported the testiculo-protective effect of 
stem bark extract of E. chlorantha on lead induced toxicity in adult wistar rats (Rattus norvergicus).  It 
has also been documented by Hutchings et al., (2003) that sick animals tend to forage plants rich in 
tannins and alkaloids such as E. chlorantha. 
In the Western world, E. chlorantha stem bark extract has been included in dermatologic preparations 
like Dermalogica Clean Start Kit, cosmetics like Ultra Beauty and anti-acne preparations; this is due to 
the protoberberine content which act on the pilosebaceous units by inhibiting growth of hair follicles of 
the face and /or the body. 
1.3 Alkaloids 
 Alkaloids are a class of unique naturally occurring organic nitrogen-containing bases. They are well 
known for their diversity and role in important plants, animal and humans physiologic functions. 
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About 3,000 different types of alkaloids have been identified in a total of more than 4,000 plant spe-
cies. In general these alkaloids belong to unique families notable among them are Papaveraceae from 
which the opium poppy plant was derived, the Claviceps from which ergot fungus was obtained. Other 
are the Ranunculaceae which gave rise to buttercups, Solanaceae from which nightshades arise, and 
Amaryllidaceae which gave rise to amaryllis.  Few alkaloids have also been reported to be derived 
from animal species notable examples are New World beaver (Castor canadensis) and poison-dart 
frogs (Phyllobates). 
Despite been around for umpteenth years the function of alkaloids in plants is still yet to be fully un-
derstood. They are believed to serve specific biologic functions, it has been suggested that they are 
simply waste products of plants’ metabolic processes. In some plants, the concentration of alkaloids 
increases just prior to seed formation and then drops when the seed is ripe, suggesting that alkaloids 
may play a role in this process. Alkaloids may also protect some plants from being infested by certain 
parasitic insect species. 
In terms of chemistry the structures of alkaloids are extremely variable. Generally, an alkaloid contains 
at least one nitrogen atom in an amine fashion, that is one derived from ammonia by replacing hydro-
gen atoms with hydrogen-carbon groups called hydrocarbons. This or another nitrogen atom can be 
active as the base in acid-base reactions. The name alkaloid (“alkali-like”) was originally used because 
they react with acids as bases to form salts. Most alkaloids have one or more of their nitrogen atoms as 
part of a ring of atoms in cyclic systems. Alkaloid names generally end in the suffix -ine, a reference to 
their original chemical classification as amines. In their pure form most alkaloids are colourless, non-
volatile, crystalline solids. Majority of them tend to have a bitter taste. 
The first alkaloid to be isolated and crystallized was morphine (1) in 1804 as the potent active constitu-
ent of the opium poppy plant. 
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Alkaloids are generally are classified based on of their chemical structures. For example Indole alka-
loids contain a ring system are known as Indole (2).  
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                                                                 (2): Indole core of alkaloids 
On this basis, other notable principal classes of alkaloids are the pyrrolidines, pyridines, tropanes, pyr-
rolizidines, isoquinolines, indoles, quinolines, and the terpenoids and steroids.  
Alternative means of classification of alkaloids is along the biological system in which they occur. For 
example, the opium alkaloids occur in the opium poppy (Papaver somniferum).  
Despite belonging to the same class of compounds alkaloids are known to have diverse biologic func-
tions. Morphine (1) is a powerful narcotic used for severe pain relief but used with caution because of 
its addictive and sedating properties. Codeine (3) is a methyl ether derivative of morphine, it is an ex-
cellent analgesic however is non-addictive.  
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Certain alkaloids are used clinically as cardiac or respiratory stimulants. Quinidine (4) from the plant 
genus Cinchona is used to treat arrhythmias. 
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Ergonovine also known as Ergometrine (5) is used to reduce uterine haemorrhage after childbirth was 
derived from the fungus Claviceps purpurea and Ephedrine (6) used in many anti-cold preparation was 
derived from Ephedra species, both have vasoconstriction properties. Ephedrine (6) is commonly used 
to relieve the discomfort of common colds, sinusitis, hay fever, and bronchial asthma. 
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Many alkaloids possess local and general anaesthetic  properties, though clinically they are seldom 
used for this purpose.  D-tubocurarine (7) derived from South American poison curare, is used as a 
muscle relaxant in surgery. Quinine (8) derived from Cinchona species is a powerful antimalarial agent 
especially in the paediatric age group, though this has been largely replaced by Artemisinin based 
Combination Therapy (ACT). Vincristine (9) and Vinblastine (10) from Vinca rosea are widely used as 
chemotherapeutic agents in the treatment of breast, ovarian and other types of cancer. 
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The tobacco plant (Nicotiana tabacum) gave rise to Nicotine (11), which is the principal alkaloid and 
chief addictive ingredient of the tobacco smoked in cigarettes, cigars, and pipes. This unique molecule 
contains both pyridine benzene-like and pyrrolidine ring as shown below in Compound 11. 
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 Some alkaloids are well known illicit drugs, these include the hallucinogenic drugs such as mescaline 
(12) from Anhalonium species and psilocybin (13) from Psilocybe mexicana. Synthetic derivatives of 
the alkaloids morphine (1) and lysergic acid (14) were derived from C. purpurea which gave rise to 
heroin (15) and LSD (14) respectively. 
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In terms of monomeric alkaloids common classes include: 
1. Pyrrolidines (16) a good example is Strachydrine (17) 
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2. Tropane derivatives (18) good examples are the common used drug to treat symptomatic  
bradycardia, that is atropine (19) and narcotic cocaine (20) 
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Other monomeric classes include pyrrolizidine derivatives (21), Piperidine derivatives (22), Quin-
olizidine derivatives (23), Indolizidine derivatives (24), Pyridine derivatives (25), the Isoquinoline 
(26) which the aporphine alkaloids described in detailed in this thesis belong. Other notable clas-
ses are Oxazole derivatives(27),Thiazole derivatives(28), Quinazoline derivatives(29) , Acridine 
derivatives(30), the Quinoline derivatives(31) to which the antimalarial ,Quinine(8) belongs: oth-
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ers are Imidazole derivatives(32), Purine derivatives(33),  Colchicine alkaloids(34)  to which con-
ventional anti-gout agent colchicine(35) belongs and the Benzylamine derivatives(89) from which  
analgesic capsaicin(90) cream widely used for knee and hand osteoarthritis was derived. 
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In majority of cases there is need to extract, isolate and purify alkaloids from their plants sources. Spe-
cial methods have been developed for isolating commercially useful alkaloids. In most cases, plant ma-
terials are subjected to extraction in aqueous or appropriate solvent system.  The alkaloids are thereaf-
ter be separated and purified from the mixture of alkaloids in solution using appropriate separation 
techniques such as chromatography. Chromatography tend to take advantage of the different degrees of 
adsorption of the various alkaloids on solid material such as alumina or silica.   
Alkaloids are usually obtained in crystalline form using appropriate solvents. 
 
1.4 Alkaloids and activities previously reported from E. chlorantha stem bark 
A protoberberine alkaloid 7, 8 -dihydro -8-hydroxy palmatine (91) was isolated from E.  
chlorantha stem bark. It demonstrated some in vivo activity against Helicobacter pylori in mice as re-
ported by Tan (2000). 
N
OCH3
OCH3
OH
H3CO
OCH3  
                                                                      (91) 
Two aporphine alkaloids; 6a, 7-dihydro-1, 2-dimethoxy-7-hydroxy-N-methyl aporphine (92) and 6a, 7-
dehydro-1, 2-dimethoxy-7-hydroxyaporphine (93) were also reported to have been isolated from the 
stem bark of E. chlorantha by Wafo et.al. (1999). 
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(92) R= CH3,  (93) R=H 
[35] 
 
1.5 The Family Annonaceae 
The Annonaceae is a large family of trees, shrubs or climbers generally pantropic according to Oliver 
(1868). The Annonaceae family comprises of about 130 genera with more than 2,000 species. The fam-
ily is commonly known for production of isoquinoline type alkaloids, though non-alkaloidal com-
pounds have also been isolated from the family by Yang-Chang Wu (2006) and many others. To the 
local people where this family species are found economically, it is an important source of edible fruits 
and oils, as well as raw material for perfumery.  
1.6   Reported anti-parasitic properties in E. chlorantha protoberberine alkaloids 
Palmatine (41) and berberine derivatives have been reported to possess anti-leishmanial properties by 
Vennerstrom et al., (1990). 
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128 plants extracts were screened for anti-leishmanial and anti-trypanosomal activities, isolating proto-
berberine-type alkaloids; jatrorrhizine (42) and palmatine (41) which were found to be active Bahar 
(2012). Jatrorrhizine (42) has been reported with palmatine to have potent anti-malarial properties 
Vennerstrom and Klayman (1988). Anti-babesial activity has also been reported Subeki et al., (2005), 
for palmatine and other protoberberine alkaloids isolated from an Indonesian medicinal plant Arcange-
lisia flava ,used in the treatment of malaria. 
1.7 Bisbenzylisoquinolinealkaloids: pharmacological properties 
Aporphine alkaloids of the bisbenzylisoquinoline class represent a large group among the Iso-
quinoline alkaloids. This interesting group of alkaloids comprises of compounds like the Non-
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depolrizing neuromuscular blocking agent tubocurarine (7) discovered as a toxic alkaloid 
found to have skeletal muscle relaxant properties, thus it’s use in clinical medicine as an ad-
junct anaesthetic agent  in surgery and mechanical ventilation. There are also a wide range of 
others with important pharmaceutical pharmacological activity like thalicarpine (43) an apor-
phine-benzyltetrahydroisoquinoline alkaloid found to have tumour inhibitory activity Kupchan 
et al., (1963), tetrandrine (44) and cepharanthine (45) as reported by Wu and Huang (2006). 
Isolated as natural products, this group of alkaloids as leads have led to synthesis of much im-
proved analogues in clinical use today such as atracurium (46).   
Atracurium (46) was synthesized in 1981 by Stenlake and his colleagues at the University of Strath-
clyde Stenlake et. al., (1981). 
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Other notable bisbenzylisoquinolines like daphnoline (47) and an anti-parasitic agent benznidazole 
(48) have been reported as active against Trypanosoma cruzi through trypanothione reductase inhibi-
tion by Fournet et al., (2000). 
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Several other bisbenylisoquinolines have been reported with skeletal muscle relaxant, anti-
inflammatory, platelet aggregation inhibition and antimicrobial properties by Schiff (1987). 
1.8 Natural products in drug discovery 
The World Health Organisation (WHO) 2008 states that approximately 25% of modern drugs used in 
the United States of America were developed from plants. It is worthy to note that many drugs in  
clinical use today are from natural products. Examples include digoxin (49) obtained from foxglove 
(Digitalis lanata) for treatment of cardiac arrhythmia and congestive heart failure. 
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Morphine from the Opium poppy plant, Papaver somniferum is clinically used for alleviating severe 
pain (1).  Malaria remains a global health challenge with its huge mortality and morbidity profile. The 
isolation of the antimalarial drug, Quinine (8) from the bark of Cinchona officinalis, was reported in 
1820 by the French pharmacists, Caventou and Pelletier, however cinchona’s bark have documented to 
in use by indigenous people in the Amazon region for the treatment of fevers for a long time, and was 
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in early 1600s first introduced into Europe for the treatment of malaria. Subsequently Quinine (8) 
formed the basis for the synthesis of the commonly used antimalarial drugs, chloroquine (50) and mef-
loquine (51) which largely replaced Quinine (8) in the mid-20th century as reported by Wongsrichana-
lai et al.,(2002).  However due to  the emergence of resistance, another plant long used in the treatment 
of fevers and malaria in Traditional Chinese Medicine (TCM), Artemisia annua gave rise to a new an-
timalarial Artemisinin (52) and its derivatives according to O’Neil and Posner (2004) widely used to-
day in combating resistance in form of ACT (Artemisinin-based Combination Therapy) . 
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 Another good example is paclitaxel (53), the anti-cancer agent which was obtained from the Pacific 
Yew tree , Taxus brevifolia  as reported by Stierle A et al.,(1995).  About 56% of the leading com-
pounds used for medicines in the British National formulary (BNF) are either natural products or their 
derivatives as reported by Pitchaimani (2012). For example, vincristine (9) and vinblastine (10), well 
known anti-cancer agents are from the plant Catharanthus roseus (Madagascar periwinkle), formerly 
known as Vinca rosea. 
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 Other notable examples are khellin, from Ammi visnaga (L) Lamk., which led to the development of 
chromolyn widely known as sodium chromoglycate (54) used clinically as a bronchodilator; galegine, 
from Galega officinalis L., which was the lead source for the synthesis of metformin (55) and other 
bisguanidine-type antidiabetic drugs. Papaverine from Papaver somniferum  formed the basis for vera-
pamil (56) synthesis used in the treatment of atrial fibrillation. Other notable clinical entities developed 
from traditional medicinal plants include: the antihypertensive agent, reserpine (57), isolated 
from Rauwolfia serpentina and ephedrine(6) isolated  from Ephedra sinica (Ma Huang), a  traditional 
Chinese medicinal plant and this formed the basis for the synthesis of the widely used  anti-asthma 
agents Beta2-adrenergic  agonists: salbutamol (58). 
  Microorganisms over the year have been a rich sources of antimicrobials, notable examples include: 
antibacterial agents, such as the penicillin (59) from Penicillium species, cephalosporin (60) from 
Cephalosporium acremonium. Widely used drugs in clinical use like cholesterol lowering agents, 
statins such as mevastatin (61) were developed from Penicillium species, lovastatin (62) was developed 
from Aspergillus species. Other natural products derived clinical entities includes: ACE inhibitors cap-
topril (63) used in the treatment of cardiovascular disease derived from Teprotide, isolated from the 
venom of the pit viper, Bothrops jaracaca. A further notable example  are incretin mimetics extenatide 
polypeptide, Byetta (64), a parenteral drug used  as an adjunct to improve glucose (blood sugar) control 
in adults with type 2 diabetes which was developed following the  isolation of exendin-4 from the ven-
om of the Gila monster, Heloderma suspectum. 
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Drugs from natural sources still have a role in the present day drug discovery, as the search for new 
therapeutic clinical entities from natural products have yielded appreciable successes in the last thirty 
years. Table 5.11  on page 245 in  the appendix shows a list of twenty four natural products-derived 
clinical entities discovered since 1970 and approved between 1981-2006 (Ganesan,2008). 
 
1.9   Human African Trypanosomiasis (HAT):  Health burden, clinical course, and current ther-
apy. 
Seventy million people are said to be at risk of contracting HAT in sub-Saharan Africa (SSA) as 
reported by Simarro et al., (2012), while an estimated 7-8 million people worldwide  mostly  in Lat-
in America are infected with Trypanosoma cruzi according to the World Health Organisation 
(WHO) 2014.  
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Chagas disease occurs through Vector-borne transmission. The insect vector is a triatomine bug that 
carries the parasite Trypanosoma cruzi,the disease causative agent. Unlike HAT, Chagas disease is 
curable if treatment is initiated soon after infection.  According to WHO report (2014) up to 30% of 
chronically infected people develop cardiac complications and up to 10% develop digestive, neuro-
logical or mixed manifestations which may require specific treatment.Vector control is the most 
useful method to prevent Chagas disease in Latin America. It is important to prevent infection 
through transfusion and organ transplantation by blood screening. It runs a more severe course in 
infections in pregnant women and their newborns, so diagnosis of infection is of paramount im-
portance in this suspectible group. Also infected persons shoud have contact particularly siblings 
tested WHO report (2014). HAT, otherwise known as sleeping sickness is caused by infection with 
one of two extra-cellular protozoan parasites: Trypanosoma brucei rhodesiense or brucei gambi-
ense. 
.  
Figure 1.2: Distribution of Human African Trypanosomiasis with incidences and risk for  
Travellers. The black line divides the areas in which Trypanosoma brucei gambiense prevails 
from areas in which Trypanosoma brucei rhodesiense predominates: Blum(2009). 
The causative parasites of HAT are transmitted by Tse tse flies; the insect vectors of the genus Gloss-
nia mainly in Sub-Saharan Africa (SSA) where the vector, the parasite, reservoir hosts and humans co-
exist.  HAT creates a huge public health and economic burden in SSA. It accounts for over 1.5 million 
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Disability-Adjusted Life Yearly (DALY) in 2002, affecting mainly the rural poor.  DALY is a measure 
of overall disease burden, expressed as the number of years lost due to pre mature death, ill-health or 
disability. It is becoming an increasingly important concept in public health and health impact assess-
ment (HIA).  It defines the concept of potential years of life lost due to premature death poor health or 
disability. Prevalence estimates from the World Health Organization (WHO) are 50,000–70,000 cases, 
based on a total number of 17,500 new cases reported per year worldwide by the WHO report (1998). 
Of the three major forms of human disease causative trypanosome parasites known: T.brucei gambi-
ense found in Western and Central Africa, accounts for 95% of cases, running a chronic infection 
course. T.brucei rhodesiense found in Eastern and Southern Africa; accounts for 5% of cases, causing 
acute infection which rapidly invades the central nervous system. T.cruzi is the only other form of hu-
man trypanosomiasis, it is prevalent in twenty one Latin American countries causing Chagas disease.  
It typically causes inflammation of the heart known as myocarditis.  
The name ”sleeping sickness” stems from the typical clinical presentation of drowsiness during the 
day, and insomnia at night, victims are known to have frequent REM (Rapid Eye Movement) sleep at 
onset of  the disease and this helps to determine the stage of the disease and evaluate the effectiveness 
of new  treatments.  REM sleep is one of the five stages of sleep humans experience at night which is 
characterized by quick, random movements of the eyes and paralysis of the muscles. In stage 2 of HAT 
, as shown in Figure 1.4, the parasites proliferate in the haemolymphatic system (haemolymphatic 
stage).  In stage 3 in Figure 1.4 (meningoencephalitic stage), they invade the central nervous system 
and brain provoking progressive neurological dysfunction leading to symptoms that include the dis-
rupted sleep wake patterns that typify HAT, thus the common name of “sleeping sickness”. 
When the Tsetse fly bites “chancre” appears on the skin, this has a typical characteristic appearance as 
shown in Figure 1.3 below. Three weeks later trypanosomes invade the bloodstream, lymph glands 
and other internal organs, so the victim manifests swollen lymph nodes commonly cervical, other man-
ifestations though rare include myocarditis and eventually heart failure. Less commonly it affects the 
endocrine system to cause loss of libido and impotence in males, other less common features are orchi-
tis, gynecomastia in men, abortion and infertility in women. Common symptoms include fever, head-
ache, hirsutism, anxiety and coma.  
HAT occurs predominantly in rural populations dependent on farming, fishing and animal husbandry. 
The health burden is worsened by the fact that diagnosis and treatment of the disease are complex.  
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Figure 1.3: Tse tse fly and  characteristic skin appearance “chancre” following infected fly’s bite 
:Fidssa bulletin (2012) 
1.10. Life cycle of Trypanosoma parasite 
The unique lifecycle of the trypanosome parasite correlates to the clinical features of HAT. There is an 
immune response causing inflammation at site of bite, this is the basis for the skin appearance known 
as “trypanosomal chancre”. Trypomastigotes move via  the host lymphatics to the lymph nodes before 
proceeding into the  bloodstream , in the process swollen cervical lymph nodes manifest as what is 
known as “Winterbottom’s sign” named after the physician; Dr. Thomas Masterman.  
Winterbottom (1766-1859), born in England, studied in Edinburgh, later Glasgow, who discovered the 
sign (‘small glandular tumours’ in the neck)  in weak and less productive slaves later  found to be in-
fected in Sierra Leone’s native population in 1803. He termed it ‘negro lethargy’ Kennedy (2007)2. 
HAT causative trypanosomes reside exclusively in the bloodstream. When an infected host is bitten by 
Tsetse fly of the Glossinia species, the blood-sucking fly takes a ‘blood meal’, the parasites exist as 
bloodstream trypomastigotes. In the fly’s midgut they become procyclic trypanomastigotes, undergo a 
complex series of changes in shape and metabolism to become epimastigotes as they leave the fly’s 
midgut.  Initially the ingested trypanosomes which are long and slender are not infective until they 
reach the mid-gut of the fly, where they become short and stumpy becoming infective before moving 
on to the fly’s salivary gland as epimastigotes to multiply. These complex changes take three weeks 
from the blood meal on an infected human host to become infective in the fly. It should be noted that 
less than 10% of all Tsetse flies in an endemic area are infected with trypanosomes  
Kennedy (2007)3 
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Figure 1.4: A schematic diagram of the lifecycle of the trypanosome distinguishing between the 
Infective and Diagnostic stages. 
1.11 Drugs used in treatment of HAT:   
Polyanionic compound Suramin (65) developed by Oskar Dressel and Richard Kothe of Bayer, Ger-
many in 1916  as reported by Black and Seed (2001). Pentamidine (66) formulated as aerosolized salt 
developed in 1994 was originally an insulin mimetics, later discovered to possess anti-parasitic proper-
ties Elliot (2011).  Melarsoprol (67) developed by Friedheim in 1949 by reacting melarsen oxide with 
2,3-dimercaptopropanol, however  it was not until 1990 before it became the drug of choice for second 
stage (CNS  infections) with T.b.gambiense Seed and Hall (1992). Eflornithine (68) developed in 1990 
in the US by Sanofis-Aventis under the trade name Ornidyl as a parenteral antitrypanosmal agent.  It 
also has a topical form useful in treatment of facial hirsutism, and most recently Nifurtomox (69) use-
ful in treatment of Chagas disease. A safer and more effective combination therapy with Nifurtimox 
(69) and Eflornithine (68) was developed in 2009, it is now the goal standard treatment for second-
stage African Trypanosomiasis infection Priotto (2009). 
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Suramin (65) is a polysulphonated symmetrical naphtylamine derivative with urea in the centre. It con-
tains eight benzene rings, amide and sulfone groups and is used in the treatment of HAT parenterally, 
as it is highly hydrophilic, that is a molecule that is  polar and thus dissolves in water. It is ionic in na-
ture, possessing six negative charges. It is administered as a single weekly intravenous injection once 
for 6 weeks. This involves an initial administration of 200 mg  test dose which if well tolerated is fol-
lowed by 1 g per day dosages on day 1,3, 7 , 15 and 21 or 1 g weekly for 6 weeks. It is highly bound to 
plasma proteins and Low Density Lipoproteins (LDL). It was hypothesized that uptake of Suramin (65) 
is through endocytosis when bound to LDL, which explains the slow accumulation of the drug in tryp-
anosomes Vansterkenburg et al., (1993). Several trypanocidal mechanisms of action have been pro-
posed, but not proven. It is believed to inhibit a number of glycolytic enzymes Wierengaet al., (1987). 
It does not enter the central nervous system, thus is not effective in treatment of advanced disease. It is 
pharmacokinetics is complex, it has a short initial half-life as well as a lengthy terminal half-life of 
about 50 days, and it is slowly cleared from the body by renal excretion Katzung (2004). 
The other licensed use of Suramin (65) is in the treatment of onchocerciasis.  Clinical use  is  however 
associated with 50% chance of developing drug-induced adrenal cortical damage  capable of triggering 
anaphylaxis, as well as fever, rash, headache, paraesthesia, neuropathies, seizures, severe GI upset, 
haemolytic anaemia, agranulocytosis and kidney damage.  With these worrisome adverse side effects, 
it is imperative to attempt to develop new anti-trypanosomal agents.  
The second anti-trypanosomal agent in line of development was pentamidine (66). It is formulated as 
an anti-microbial salt which acts through uptake of parasite purine receptors, accumulating within the 
parasite to inhibit essential enzymes and infer with DNA to kill the parasite. Its dosage parenterally is 
2-4 mg/kg daily up to 15 doses and sometimes a second course might be needed. It is a highly toxic 
drug and 50% of patients receiving 4mg/kg of the drug tend to experience severe side effects Katzung 
(2004). These side effects includes sever hypotension, tachycardia, dizziness and dyspnoea so the drug 
is administered slowly usually over 2 hours with patient in recumbent position and monitored closely 
drug treatment. Other common side effects includes pancreatic toxicity as well as hypoglycaemia sec-
ondary to inappropriate insulin release which often occurs 5-7 days after treatment. Reversible acute 
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kidney injury has also been reported. Other less severe side effects includes fever, rash, metallic taste, 
gastrointestinal upset, deranged liver function tests, acute pancreatitis, hypoglycaemia, thrombocyto-
penia, hallucinations and cardiac arrthymias. Other type of preparation of pentamidine, Inhaled pen-
tamidine has documented side effects such as cough, dyspnea and bronchospasm.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
Pentamidine (66) other licensed uses include prevention and treatment of Pneumocystis pneumonia 
(PCP) caused by Pneumocystis jirovecci previously known as Pneumocystis carinii; Visceral leishman-
iasis, Leukaemia, as well as parasitic infections like Acanthamoeba granulomatous encephalitis in im-
munocompromised persons. As an anti-trypanosomal agent for Trypanosoma brucei gambinese infec-
tions predominantly, it is only effective for early stage infection. 
Melarsoprol (67) is an organo-arsenic compound which crosses the blood brain barrier, making it par-
ticularly effective against late stage of T .brucei gambiense in the CNS, as well as late stage of T. 
brucei rhondinese infection. The mechanism of action of Melarsoprol (67) is not totally understood, 
but it is believed to kill the parasite by inhibiting an essential energy metabolism pathway. It is admin-
istered intravenously at dosage of 3.6 mg/kg/day for 3-4 days with repeated courses weekly should the 
need arise. Clinical use is limited in humans due to the life-threatening encephalopathy: Sub- acute 
Sclerosing Panencephalitis (SSPE) it possesses, this occurs within the first week of therapy with clini-
cal features like cerebral edema, seizure, coma and eventually death. Other common side effects in-
clude fever, vomiting, abdominal pain, and arthralgia. This accounts for mortality in 20% of patients 
receiving Melarsoprol (67) for treatment of the two varieties of HAT. Recently high failure rates to 
treatment have been reported raising the possibility of drug resistance 
Eflornithine (68) also known as DFMO, is only effective in the treatment of T brucei gambiense.  It is 
administered intravenously and has good central nervous system penetration, peak plasma concentra-
tion is achieved rapidly and elimination half-life is about 3 hours. The dosage is usually about 100 
mg/kg every 6 hours for 1-2 weeks. It acts by inhibiting ornithine decarboxylase. Ornithine decarbox-
ylase is essential in the survival of the parasite as it catalyses the synthesis of essential amine-based 
compounds involved in cell division and cell differentiation. Reported side effects notably are diar-
rhoea, vomiting, anemia, thrombocytopenia, leucopenia and seizures. These side effects are usually 
reversible Katzung (2004). 
To combat this limitation, combination therapy of Eflornithine-Nifurtimox was developed in 2009.  
Niturtimox (69) is a nitrofuran compound effective in the treatment of South American variety of the 
human disease, Chagas disease. It is well absorbed orally and eliminated with plasma half-life of 3 
hours. It is administered at a dose of 8-10 mg/kg/day divided into 3-4 doses orally for 3-4 months, it 
has poor central nervous system penetration. Reported adverse effects includes nausea, vomiting, ab-
dominal pain, fever, rash, restlessness, insomnia, neuropathies and seizures as documented by Katzung 
(2004). 
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It has been noted that one in every 20 patients suffering  from African Trypanosomiasis  taking the cur-
rent first line drug Melarsoprol (67), tend to die from  the side effects rather than the disease itself 
Kennedy (2007)1. With all these limitations in mind, the need to find new anti-trypanosomal agents to 
combat these huge burden diseases (HAT and Chagas disease) is of paramount importance. 
Table 1.1 showing stages and their effective drugs in the treatment of HAT, Kennedy (2013). 
Stage HAT specie 1st line treatment 2nd line treatment 
 Early stage (Haemo-
lymphatic)  
T.brucei rhondesiense 
T. brucei gambiense 
Suramin IV (65) 
  Pentamidine IM (66)                                                                       
Pentamidine IM (66)                                                                       
Suramin IV(65)
Late stage (Menin-
goencephalitic)  
T.brucei rhondesiense 
T. brucei gambiense 
Melarsoprol  IV (67) 
 Eflornithine IV(68) 
plus oral Nifurmatox 
(69) 
 
None  
Melarsoprol  IV (67) 
 
 
NB: IV Intravenous, while IM is Intramuscular. 
 
1.12 Potential anti-trypasomal drug targets 
1) Enzymes 
a.Trypanosomes contain an essential reductant known as trypanothionine which has two gluthathione 
peptides conjugated to spermidine. This reduction is NADPH-dependent and mediated by trypanthi-
onine reductase which is a prime drug target. Blocking production of glutathione which is essential 
for survival of trypanosomes is a proven target for anti-trypanosomal drugs. 
b. Ornithine decarboxylase: Inhibition of ornithine decarboxylase in the parasite makes it unable to 
make critical substances called polyamines that are essential to the survival of the parasites. 
2. Glucose metabolism: Metabolism of the infective procyclic trypanosomes in the fly’s mid-gut  
requires glucose metabolism, that is these blood stream forms are totally dependent on glycolysis  
regulated by glycolytic enzymes through the Tricarboxylic Acid (TCA) cycle, and oxidative  
phosphorylation. The inhibition of these glycolytic enzymes can be targeted by potential drugs as a 
mechanism of action 
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3. Essential proteins like proline, alanine and so on are important for the survival of the trypanosomes 
as these proteins are energy sources for the parasite; they are regulated by proteases which can also be 
good drug targets. 
4. Reactive oxygen intermediates and free radicals. Trypanosmes are sensitive to high levels of 
 reactive oxygen intermediates and free radicals; this is the mechanism through which Nifurtimox 
works. 
5. Cell membrane disruption: Interfering with synthesis of key fatty components of the parasite’s cell 
membrane is another probable anti-trypanosomal drug mechanism of action. 
6. Target  T. brucei rhondesiense‘s natural defence system: By blocking the serum resistance factor 
(SRA) which is used by T brucei rhondesiense to resist natural ability of the human serum to destroy it, 
robs the parasite of one  of  the  most important  innate defence mechanism it has against human host. 
7. Targeting the Blood Brain Barrier (BBB): The normal course of the CNS-type East African variety 
Human Trypanosmiasis is for the trypanosomes to cross the BBB within weeks of infection, targeting 
and preventing this essential stage in the course of the human disease is another probable mechanism 
of action potential anti-trypanosomal drugs could exploit. 
1.13 Molecular modelling 
Molecular modelling describes the theoretical methods and computorial techniques used to model or 
mimic the behaviour of bioactive molecules. It forms the bedrock of fields such as computorial  
chemistry, computorial biology and drug design.  Methods used include molecular mechanics, which 
utilise classical and Newtonian mechanics to describe the physical basis of molecules by analysis of 
spring-like interactions which represent chemical bonds and Van der Waals forces. As an effective 
drug development tool; molecular modelling investigates protein folding, enzyme catalysis, protein 
stability, conformational changes associated with bimolecular functions and molecular recognition of 
proteins, DNA, and membrane complexes. 
1.13.2 Molecular modelling studies on phytochemical compounds for anti-trypanosomal activity 
Ogungbe and Setzer (2012) reported a molecular docking study carried out on phytochemical com-
pounds used traditionally to treat parasitic infections or known to have in vitro anti-trypanosomal activ-
ity.  916 compounds from 19 Nigerian medicinal plants were investigated using in-silico molecular 
docking technique on validated Trypanosoma brucei protein targets that were available from the Pro-
tein Data Bank (PDB): Adenosine kinase (TbAK), pteridine reductase 1 (TbPTR1), dihydrofolate re-
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ductase (TbDHFR), trypanothione reductase (TbTR), cathepsin B (TbCatB), heat shock protein 90 
(TbHSP90), sterol 14α-demethylase (TbCYP51), nucleoside hydrolase (TbNH), triose phosphate iso-
merase (TbTIM), nucleoside 2-deoxyribosyltransferase (TbNDRT), UDP-galactose 4' epimerase 
(TbUDPGE), and ornithine decarboxylase (TbODC).  The study revealed anthraquinones, xanthones, 
and berberine alkaloids docked strongly to pteridine reductase 1 (TbPTR1), chromenes, pyrazole and 
pyridine alkaloids docked notably to triose phosphate isomerase (TbTIM), while indole alkaloids 
showed significant docking energies with UDP-galactose 4' epimerase (TbUDPGE). E. chlorantha 
compounds investigated in the molecular modelling studies include atherosperminine (70), colum-
bamine (78), jatrorrhizine (42), lanuginosine (72), liriodendronine (73), palmatine (41), isololdine (74), 
isocorydine (75), 7, 8-dihydro-8-hydroxypalmatine (38), O-methylmoschatoline (), pseudocolubamine 
796), pseudopalmatine (80). 
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1.14 Previous phytochemical studies on E. chlorantha 
The Annonanceae family are known to produce a wide range of phytochemicals including alkaloids 
and non-alkaloidal compounds. In terms of production of alkaloids they are particularly known to   
produce benzylisoquinoline alkaloids. Some of such alkaloids previously isolated from E.chlorantha 
are outlined below in Table 1.2. 
Table 1.2 Benzylisoquinline alkaloids previously isolated from E. Chlorantha 
 
Compound Structure and molecular formula Reference 
Atherosperminine C20H33NO2 (72) 
N
CH3
CH3
H3CO
OH3C
 
Leboeuf et 
al.,(1980) 
Atherospermidine 
C18H11NO4 (71)
N
O
O
CH3O
O
 
 
Leboeuf et 
al., (1980) 
Columbamine C20H21NO4 (78) 
N+
H3CO
R
OCH3
OCH3
 
               (78) R = OH 
 
 
Hamonniere 
et al., 
(1990) 
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Jatrorrhizine  C20H20NO4 (42) 
N+
R
OCH3
H3CO
OCH3  
                                                                                                                                
       (5) R=OH                                                                                                                              
Hamonniere 
et al., 
(1990) 
Lanuginosine C18 H11 NO4 (72) 
N
O
O
O
H3CO
 
Guinaudeau 
et al., 
(1994) 
Liriodendronine C16 H9 NO3  (73) 
N
O
HO
HO
 
Guinaudeau 
et al., 
(1994) 
Lysicamine 
C18 H13 NO3 (77)
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H3C
O
 
Guinaudeau 
et al.,(1994) 
Palmatine C21H24NO4 (41) R= OCH3                                                                                                             
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R
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H3CO
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Hamonniere
et al.,(1990) 
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Isoboldine C19 H21 NO4 (74) 
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6a,7-dehydro -7-hydroxy-1,2-
dimethoxy-7-hydroxy-N-methyl-
aporphine 
C19 H19 NO3 (39) 
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Wafo et 
al.,(1990) 
6a,7-dehydro -7-hydroxy-1,2-
dimethoxy-7-hydroxyaporphine 
C18 H17 NO3 (40) R=H 
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Isocorydine C20 H23 NO4 (76) 
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7,8-dihydro-8- hydroxypalmatine C22H22NO4    (38) 
N
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Tan et al., 
(2000) 
O-Methylmoschatoline C18 H13 NO4  (85) 
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Guinaudeau 
et al.,(1994) 
Pseudocolumbamine C20H20NO4   (79) 
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N+
H3CO
H3CO
OCH3
OCH3
 
Tan et 
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1.14.2   Protoberberine alkaloids reported from E. Chlorantha stem bark and their pharmacolog-
ical properties. 
Four similar protoberberine alkaloids namely; palmatine (41), jatrorrhizine (42), and columbamine (78) 
and pseudocolumbamine (79) were isolated from stem bark of E. chlorantha Hamonniere et al., (1990). 
N+
H3CO
R
OCH3
OCH3
 
                                                       (78) R = OH 
                                                       (79) R = H3CO 
 Palmatine(41), jatrorrhizine(42) and columbarine (78) isolated from stem bark of E. chlorantha have 
been reported to have preventive and curative effects on artificially provoked liver injury Virtanem et 
al., (1988). Palmatine(41) was investigated as a pharmaceutical drug for treatment of viral hepatitis as 
reported by Virtanen et al., (1993) ; the  reduced form, tetrahydropalmatine (80) is one of the major  
bioactive components in Corydalis yanhusuoW.T Wang, a well-known traditional Chinese medicine 
with potent analgesic, sedative-tranquilizing and hypnotic properties Hsu (1962). 
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                                                                            (80) 
Bourdat-Deschamps (2004) had reported the isolation of the four very polar quaternary protoberberine 
alkaloids: palmatine (41), jatrorrhizine (42), columbarine (78) and pseudocolumbamine (79), as very 
challenging, because their adsorption on silica was very high and their chemical structures very closely 
related. Hence, the need to use High Performance Centrifugal Partition Chromatography (HPCPC) to 
isolate the four protoberberine alkaloids from E. chlorantha. 
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 Isolated protoberberine alkaloids from E. chlorantha with their interesting properties have been re-
ported to attract attention of medicinal chemists to synthesize derivatives of these alkaloids for struc-
ture activity relationships studies McCall et al., (2002) Vennerstrom et al., (1998) and Iwasa et al., 
(1996).  A bioactivity based fractionation of E. chlorantha root and stem bark led to the isolation of 
palmatine chloride and jatrorrhizine chloride as the major antimicrobial constituents.  Minimum Inhibi-
tory Concentrations of these isolated compounds were found to be superior to those of well established 
broad antibiotics like ampicillin and ciprofloxacin against some of the organisms tested Moody et al., 
(1995). 
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Chapter 2: Materials and Methods 
2.1 Materials 
2.1.1 Plant Materials 
 
Stem bark samples of E. chlorantha were obtained from the suburbs of Ile Ife, Osun State in South 
Western Nigeria. The botanical identification and authenticity of samples were carried out at the  
herbarium of Department of Plant Biology, University of Ilorin, Nigeria with voucher specimen NM 
325 kept for purpose of reference. The plant materials were collected in summer and winter to see vari-
ation in the types of compounds synthesized by plants in different parts of the year. 
 
2.1.2 Chemicals, Reagents and Laboratory wares 
2.1.2.1 Solvents used for extraction, chromatographic separation, TLC and isolation purposes: 
1. Ethyl Acetate (HPLC grade) 
2. n-Hexane (HPLC grade) 
3. Methanol (HPLC grade) 
4. n-Pentane (HPLC grade) 
5. Acetone (HPLC grade) 
6. Acetic acid (Analytical grade) 
7. Dragendorff reagent (Sigma-Aldrich) 
The solvents were obtained in 2.5 L bottles from Fisher Scientific UK limited and VWR UK Limited. 
 
2.1.2.2 Chromogenic reagents 
1. Anisaldehyde-Sulfuric acid spray solution was used for identification of sugars, steroids, terpenes 
and phenols in mixtures on TLC plates. 
2. Drangendorff spray solution was used for identification of alkaloids 
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2.1.2.3: Table 2.1: Deuterated solvents used for NMR 
Solvent Chemical formula 1H shift (ppm) 13C shift (ppm) Peak trace for 
water (ppm) 
Deuterated chlo-
roform 
CDCl3 7.26 77.00 1.50 
Deuterated Ace-
tone 
(CD3)2CO 2.05 29.92 2.80 
Deuterated 
DMSO 
(CD3)2SO 2.50 92.43 3.30 
 
2.1.3 Laboratory wares 
 
TLC Plates and Tank 
Pre-coated TLC aluminium plates (Merck, Silica gel PF254) were cut to appropriate sizes to fit into a 
TLC tank, containing the solvents for separation of the extract mixtures into components compounds. 
UV lamp 
Mineral light Lamp used:  Model UVGL -58, Multiband UV 254/896 nm (Upland CA91786 USA) 
Heat Gun 
Model: Power Craft 5969 (Clobaltronics GmbH & Co KG, China) 
Rotary evaporator (Buchi) 
 
Column Chromatography 
1. Glass columns: (1a) diameter (3 cm), length (60 cm), (1b) diameter (2.5 cm) length (90 cm). 
2.  Column grade silica gel (silica gel 60, mesh size 20-200 µm, Merck, Germany)  
3. Weighed sample(s): crude extracts. 
Gel Filtration Chromatography (Sephadex) 
1. Glass column: diameter (1.5 cm), length (90 cm) 
2. Sephadex LH-20 (GE Health Lifescience UK) 
Preparative TLC 
1. Glass plates 20 cm by 20 cm. 
2. TLC grade silica gel (60H, Merck, Germany)  
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Reverleris IES Flash Chromatography 
Reveleris® X2 Flash Chromatography System 
 
Reverse phase HPLC 
Reverse phase HPLC gradient system: 
1. Degasser 
2. HPLC Pump mixer (Spectra System P2000) 
 3. Auto Sampler (Spectra System AS3000) 
 4. Column (ACE 3 C18 dimension 150 X 3.0 mm internal diameter, Batch No: V10-2659) 
5. Detector (Spectra System UV2000) 
6. 2.5 L bottles to collect waste 
7. Computer to record and analyse the data using the Chromquest Software version 2.53 (ThermaQuest 
Corporation, UK). 
Normal Phase HPLC system 
Normal Phase HPLC System: 
1. Nylon 66 membrane. 
2. 1ml loop on Rheodyne injection valve where all samples were manually injected into. 
3. Pump Gilson Model 302 Isocratic HPLC Pump (Model 802C manometric module). 
 4. Column (ACE 3 C18 dimension 60 X 21.20 mm 10 u Luna silica Part No 03R-9391-P0,S/N 
324722G. 
5. Detector Waters 2487 Dual λ Absorbance detector at 254 nm. 
6. 2.5 L bottle to collect waste. 
7. Computer to record and analyse the data using the Dionex PeakNet Software version 4.30. 
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2.2 Methods  
2.2.1 Pre- extraction sample preparation 
The outer portion (dark brown) cork of the stem bark was peeled with aid of a knife to separate the in-
ner (green yellow) bark to differentiate compound(s) isolated from the cork to those of the bark. 
 
Figure 2:1: Ground bark of E. chlorantha stem bark.  
 
Figure 2.2:  Bark of stem bark of E. chlorantha. 
Subsequently, they were cut into small pieces (about 2 by 4 cm) and air-dried (spread on paper to be-
come drier through contact with room air under a fume hood  for 72 h. This was to ensure the 
plant materials were free from water which could constitute a source of impurity. It was how-
ever worthy of note there was hardly any difference in the weights of the plant material after 
72 h under the fume hood and before, as they were brought from Nigeria already dry. 
The plant material was ground to become fine powdered materials (cork and bark) and weighed to ob-
tain cork (735.8 g) and bark (804.5 g). 
Extraction and Isolation 
2.2.2 Extraction and partitioning 
Soxhlet Extraction: Soxhlet extraction is a method developed in 1879 by Franz von Soxhlet. In the 
case of this present study. Soxhlet extraction was carried out at 50o C for hexane and ethyl acetate ex-
tracts and 70 oC for methanol extracts at 2 cycles per hour. 
The finely ground (cork and bark) samples were loaded in cellulose ‘thimble’ and placed in the main 
chamber of the Soxhlet extractor. Solvent of choice was poured into the main chamber using a funnel. 
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Hexane, ethyl acetate and methanol were used successively for the extraction. This is based on the 
premise that hexane will extract mostly the non-polar compounds, ethyl acetate the medium polar and 
methanol the polar compounds.  
As the chamber flowed compounds dissolve in the solvent, thereafter the chamber was emptied 
through the side arm and the cycle was then repeated several times until exhaustive extraction was 
achieved (usually 48-72 h) as reported by Saleem et al.,(2013). For hexane extracts they were run at 2 
cycles per hour lasting 18 hours (36 cycles), ethyl acetate (24 cycles) and methanol (18 cycles). At the 
end of this process the liquid extract was then decanted from the round bottom flask of the extractor for 
further processing. 
2.2.3 General analytical methods 
2.2.3.1 Post-Extraction separation and analysis. 
Rotatory evaporation  
The rotatory evaporator was used to evaporate the extracts obtained from the Soxhlet extraction close 
to dryness. Concentrated extracts were thereafter collected in small labelled vials and kept in the fume 
cupboard to evaporate to dryness for weighing. 
Thin Layer Chromatography (TLC) development 
TLC is a simple and quick method of defining the number of compounds in a mixture and to identify a 
single pure compound using pre-prepared TLC plates (Merck Precoated Silica gel PF254). It works by 
capillary action when immersed in the appropriate solvent mixture in a TLC tank to separate compo-
nents. 
Thin Layer Chromatography (TLC) was carried out on the extracts to determine the possible number 
and types of compound(s) in the crude extracts. Plant extracts, chromatographic fractions or pure com-
pounds were initially dissolved in appropriate solvent e.g. chloroform for non-polar samples, methanol 
for very polar samples. They were thereafter spotted approximately 1 cm above the bottom edge of a 
TLC plates using capillary tubes. Spots were applied as band and kept narrow to reduce chance of 
overlapping as well as aid easy identification of resulting components of the mixture(s).  Filter paper 
was placed in the tank to aid saturation. 10 ml mixtures of hexane and ethyl acetate in ratio 50/50, 
60/93, 70/30, 80/20 or as appropriate was poured into the TLC tank using a measuring cylinder to ob-
tained a good resolution of bands which was achieved at Rf value of 0.3. The prepared TLC plates were 
gently placed into the appropriate hexane/ethyl acetate solvent system in the TLC Tank. The appropri-
ate solvent systems were allowed to ascend from the bottom of the plate to near the top by capillary 
action to develop of the spotted TLC plates.  
Thereafter, the TLC plates were removed from the tank and dried with a stream of warm air using the 
heat gun. The developed TLC plates were initially visualized with the naked eye, under UV light and 
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finally sprayed with appropriate chromogenic reagent; Anisaldehyde and Dragendorff reagents. This 
was because some of the compounds on the developed TLC plates were UV active, thus were not  
visible to the naked eye and  had to be observed under UV using the UV lamp at shortwave length 254 
nm and/or long wave 896 nm Stahl and Mangold(1975), Stock and Rice (1974).  Shortwave length was 
particularly useful for the detection the aromatic alkaloids isolated in this study. 
 
Choosing appropriate mobile phase for TLC plates development 
Mixtures of solvents were used for developing spotted TLC plates. Different combinations of solvent 
systems were tried until a desirable resolution between bands was obtained. For analysis of fractions 
from Open column or Flash chromatography separation techniques RF value of 0.4-0.5 as shown in 
Table 3.1 was used, while for HPLC fractions RF value of 0.3 was used. 
 
2.2.3.2 Nuclear Magnetic Resonance (NMR) Spectroscopy  
It is a method which uses the magnetic properties of certain nuclei of compounds. Two types are of 
immense importance in Organic chemistry: 1D Proton NMR and 13 Carbon NMR. It is programmed to 
produce information useful in identifying functional groups in a mixture or pure compound. The num-
ber and types of chemical entities in a molecule can also be detected from it.  2D NMR spectral in form 
of HMBC, HSQC and COSY were also carried out in the process of structure elucidation. 
All NMR experiments were carried out using a JOEL (JNM LA400 MHz and Bruker (Avance) 600 
MHz using 5 mm NMR tubes (Wilmad-Labglass).  Samples were dissolved in about 1 ml of deuterated 
solvents and pipetted into NMR tubes for the experiments.  Too much or too little volume was avoided 
to prevent shimming problems.  Samples of low yield had NMR experiments carried out in Shigemi 
tubes (Sigma-Aldrich UK Limited) using about 0.2 ml of deuterated CDCl3 or DMSO solvents. While 
for 1 ml TMX tubes 1 mg of the fractions were dissolved in 0.1 ml of deuterated solvent for 1D and 2D 
NMR spectroscopic studies. Structure elucidations were carried out using 1D and 2D NMR spectros-
copy for known compounds spectral data were compared with published spectral data for compounds 
identification, while the NMR spectral were processed using the MNOVA software. 1H NMR experi-
ment was the primary means of 1D NMR experiment used for structure elucidation, using the chemical 
shifts and integrations to determine the number and type of protons present in the compound. The other 
ID experiment was 13C NMR which was useful in determining the number of carbons present in the 
compounds.  
The 2D NMR experiments carried out were COSY (Correlation Spectroscopy) which showed 1H-1H 
correlations. Heteronuclear Single Quantum Coherence (HSQC) spectroscopy, the 1H-13C NMR exper-
iment showing one-bond 1J correlations and  NOESY (Nuclear Overhauser Enhancement  Spectrosco-
py)  which recorded all 1H-1H NOE correlations  in the molecule of interest, this helped in determining 
protons in close proximity to one another. Lastly HMBC (Heteronuclear Multiple-Bond Correlation), it 
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is the NMR experiment which is set with time delay (1/2J) with pulse sequence programmed in a way 
that J value is in the range of 3JCH and 2JCH correlations Breitmaier (1993). 
 
As an effective analytical chemistry technique Nuclear Magnetic Resonance (NMR) spectroscopy is 
used in for determining the constituents and purity of a sample, as well as its molecular structure. NMR 
can be used quantitatively for analysing known compounds from mixtures. For unknown compounds, 
with the aid of vast spectral libraries, NMR can either be used to match them to attempt to determine 
what they are or to infer the basic structure directly. After the basic structure is determined, NMR can 
be used analyse physical properties such as conformational exchange, phase changes, solubility, and 
diffusion. It can also be used to determine molecular conformation in solution as well as. 
 
The basis of NMR 
NMR operates on the basis that all nuclei are electrically charged ,most nuclei have spin, thus when  an 
external magnetic field is applied, an energy transfer occurs  between the base energy to a higher ener-
gy level . This energy transfer takes place at a wavelength that corresponds to certain radio frequencies 
and when the spin returns to its base level, energy is emitted at the same frequency. The signal that 
matches this transfer is measured and processed to produce an NMR Figure for the nucleus concerned. 
This leads to the concept “Chemical shift”. 
 
Chemical shift 
At the nucleus the precise resonant frequency of the energy transition is dependent on the effective 
magnetic field. This field is affected by electron shielding which depends on the chemical environ-
ment. Therefore analysis of the resonant frequency can give information about the nucleus' chemical 
environment. As a general rule, the more electronegative the nucleus is, the higher the resonant fre-
quency. Other factors which affect the frequency shifts are ring currents (anisotropy) and bond strain 
affect.  The norm is to adopt tetramethylsilane (TMS) as the proton reference frequency. This is be-
cause the magnetic field used determines the precise resonant frequency shift of each nucleus. Howev-
er frequencies are not easy to remember (for example, the frequency of benzene might be 400.132869 
MHz), so chemists decided to define chemical shift to yield a more convenient number such as 7.17 
ppm. 
δ = (ν-ν0)/ν0 
Using this equation the chemical shift  is not dependent on the magnetic field and it is convenient to 
express it in ppm where (for proton) TMS is set to ν0 thereby giving it a chemical shift of zero. For 
other nuclei, ν0 is defined as Ξ νTMS,  Ξ (Greek letter Xsi) is the frequency ratio of the nucleus, for 
example it is  25.145020% for 13C. 
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In analysing 1H NMR Figure electronegative functional groups resonate at low frequencies and there-
fore the most electronegative would resonates at the lowest chemical shift.  Aromatic groups such as 
phenol which are highly electron donating (electropositive) would have the highest chemical shift. 
However, if the chemical shift of the aromatics were due to electropositivity alone, then they would 
resonate between four and five ppm.  
 
 
Factors affecting chemical shifts 
Chemical shifts of the same sample differ when under different conditions such as solvent, tempera-
ture, etc. Chemical shifts are also affected slightly by isotopic substitution. This leads to the concept 
known as Spin-spin coupling 
  
Spin-spin coupling 
The orientation of neighbouring nuclei affects the effective magnetic field. This effect is known as 
spin-spin coupling.  It causes splitting of the signal for each type of nucleus into two or more lines. The 
size of the splitting (coupling constant or J) is measured as an absolute frequency in (Hertz), it is inde-
pendent of the magnetic field. The number of chemically bonded nuclei in the vicinity of the observed 
nucleus is indicated by the number of splitting.  
  
Ortho, para and Meta coupling 
“Ortho” substitution the two substituents are next to one another, while in “Meta” it is position 1 to 3 
and in “Para” substitution it is position 1 and 4 with the two substituents occupying opposite ends. 
 
Two Dimensional NMR Spectroscopy 
The invention of multi-dimensional spectral (2D NMR Spectroscopy) was a major leap in NMR Spec-
troscopy as it has led to additional spectral dimensions which gives extra information to make elucida-
tion of structures of unknown compounds much easier. In addition to 1D experiments’ preparation and 
detection, the 2D experiment has an indirect evolution time t1 and a mixing sequence. This can be sim-
plified in four stages as: a. preparation b. evolution c. mixing d. detection. 
Preparation is the first step, thereafter the spins process freely for a given time t1 where the magnetiza-
tion is labelled with the chemical shift of the first nucleus. During the third stage, the mixing time’s 
magnetization is transferred from the first nucleus to a second one.  This mixing sequences for magnet-
ization transfer involves two mechanisms: scalar coupling or dipolar interaction (NOE). Direct evolu-
tion time are collected as data are acquired at the end of the experiment in the detection phase, the 
chemical shift of the second nucleus during this time labels magnetization. 2D FT yields the 2D Figure 
with two different frequency axes.  
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A diagonal of signals divides the Figure in two equal halves. Symmetrical to this diagonal, there are 
more signals (X), called cross signals, these cross signals contain the really important information use-
ful in intrepreting 2D NMR spectra.  
 
Homonuclear 2D experiments: 
There are three homonuclear 2D spectra which are widely used for the structure elucidation 2D COSY, 
2D TOCSY and 2D NOESY. 
 
2D COSY: 
Unique to 2D COSY experiments is the fact that scalar coupling transfers magnetization. Protons that 
are more than three chemical bonds apart show no cross signal because the 4 coupling constants are 
close to 0. Thus, only signals of protons which are two or three bonds apart appear in a COSY Spectral. 
 
2D TOCSY: 
Whereas in the TOCSY experiment, magnetization is dispersed over a complete spin system of the 
functional group by successive scalar coupling. The TOCSY experiment correlates all protons of a spin 
system. Therefore, in addition to signals  that are visible in a COSY Spectral, there are also additional 
signals from the interaction of all protons of a spin system that are not necessarily connected via three 
chemical bonds. 
 
2D NOESY: 
The NOESY experiment is particularly useful in elucidation of structure of compounds with close pro-
tons in spatial arrangement. The Nuclear Overhauser effect, NOE using the dipolar interactions of 
spins is used for correlation of protons. The intensity of the NOE is in first approximation proportional 
to 1/r6, where r is the distance between the protons: The correlation between two protons depends on 
the distance between them, usually a signal is only observed if their distance between two protons is 
smaller than 5 Å. The NOESY experiment correlates all protons which are close enough. It also corre-
lates protons close in space due to tertiary structure. Therefore it is a very useful spectral for the deter-
mination of protein structures.  
 
 
Heteronuclear NMR spectroscopy: 
 The use of these hetero nuclei allows some new features in NMR which facilitate the structure deter-
mination especially of larger molecules (> 100 AA). Therefore, two strategies are used for Heteronu-
clear NMR Spectroscopy includes Isotopic enrichment of these nuclei in proteins and enhancement of 
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the signal to noise ratio by the use of inverse NMR experiments in which the magnetization is trans-
ferred from protons to the hetero-nucleus.  
Thus the most important inverse NMR experiment is the HSQC (heteronuclear single quantum correla-
tion) correlates the nitrogen atom of an NH group/ the carbon atom in CH with the directly attached 
proton. Each signal in a HSQC Figure represents a proton that is bound to a nitrogen atom or carbon 
atom as the case may be.  
 
2.2.3.3 Column Chromatography (CC) 
Depending on the quantity of crude extract(s), 100-300 g of silica gel packed glass columns containing 
a slurry of column grade silica gel (silica gel 60) prepared using the appropriate solvent system. The 
glass column was filled to half capacity with the chosen solvent system, and then the slurry applied as 
a thin stream allowing for gradual flow of solvent to ensure homogenous packing of the silica gel. The 
plant extract had previously been dissolved in an appropriate solvent system mixed with column grade 
silica gel to give smooth flowing powder, which was then applied gently onto the top of the packed 
column to allow for elution isocratically or gradient-wise.  Hexane-ethyl acetate and ethyl acetate-
methanol solvent systems were used for hexane and ethyl acetate extracts, while ethyl acetate and ethyl 
acetate -methanol mixture were used for the methanol extracts. The fractions obtained were subse-
quently subjected to TLC, visualized under UV lamp and sprayed with appropriate chromogenic rea-
gents Braithwaite and Smith (1996) 
Subsequently, NMR and Mass spectroscopy studies to determine the type of compounds in the result-
ing fractions were carried out. Further attempts to isolate the alkaloids as pure compounds were carried 
out using Flash Chromatography(C-18  Reversed Phase Flash Chromatography), Gel Filtration Chro-
matography , Prep TLC, Reveleris IES  Flash Chromatography, Reverse Phase  and Normal Phase 
HPLC. 
2.2.3.4 Gel Filtration Chromatography 
This chromatographic method separates molecules such as proteins, peptides, alkaloids,  
oligonucleotides and so on, based on their sizes as the molecules move through beds of porous beads 
(Sephadex, in this case).  Small molecules tend to move slower through the beds, while large  
molecules move faster. Molecular weight and 3-dimensional shape also contributes to the movement 
through the beds and degree of retention of compounds in the column. 
Forty grams (93 g) of sephadex LH 20 was soaked overnight in methanol and subsequently packed into 
a column. A TLC guided solvent system of 90% chloroform and 10% methanol was used to elute the 
column Determann and Brewer (1975). Fractions obtained were submitted for NMR experiments and 
anti-trypanosomal activity determination. 
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2.2.3.5 C-18 Reverse Phase Flash Chromatography  
Separation of Enantia chlorantha extracts using the reverse phase flash chromatography method works 
on the principle of reversible adsorption of molecules using a stationary phase which is hydrophobic. It 
is a modification to traditional column chromatography in such a way that the solvent is driven through 
the column by applying positive pressure. This allowed most separations to be performed faster, in less 
than 30 minutes as it is the case of this study. It has pre-packed plastic cartridges, and the solvent is 
pumped through the cartridge, with the system linked with detectors and fraction collectors. The intro-
duction of gradient pumps in this chromatography system has resulted in quicker separations and less 
solvent usage. While this chromatographic system is dependent on pressure it differs from Gel filtra-
tion system where separation is based on effective size of analyte molecules as they pass through the 
pores of the stationary phase, silica. 
For this study the Initial Thin layer Chromatography (TLC) on reverse phase C-18 plates showed good 
separation of the mixtures in a solvent system of 95% methanol 5% water to 75% methanol and 25% 
water. So the solvent system of 85% methanol and 15% water was chosen as mobile phase for possible 
Flash Chromatographic separation of E. chlorantha extracts Braithwaite and Smith (1996)2. 
300 mg of the mixture was dissolved in 20 ml methanol and added to 93 g of HMN granules. The vial 
was covered with a small piece of musin and secured with rubber band before placing in the Turbo Vap 
(50 degree Celsius) to remove the solvent under nitrogen for about two hours. 
Thereafter, a pre-primed flash master plunger was attached to the Isolute Flash C-18 pre-packed car-
tridge which had E. chlorantha extracts adsorbed HMN granules loaded onto it gently, a frit was then 
placed on top and pushed slowly to sit directly on the granules and positioned using the frit applica-
tor,before securing the set up using the pre-primed flash master plunger. The set-up was then switched 
on to elute and collect fractions in pre-labelled vials in appropriate volumes according to the ELSD/UV 
Vis detector. 
Operating conditions of C-18 Reverse Phase Flash Chromatography  
Instrument: JONES Flash (Flash Master Personal) 
Column: Isolute Flash C18 
Sample loading method: Pre-loaded on C18 pre-packed cartridge 
Mobile phase: solvent A: water, solvent B: methanol 
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Flow rate: Initially 5 ml/min; later 15 ml/min 
Solvent bottle: Containing 85% methanol and 15% water in a total combined volume of 500 ml 
 Collected fractions, fifty in totals had similar fractions pooled based on TLC and appearance under 
UV light for subsequent NMR experiments. 
This experiment was supervised by Carol Clements, she operated the C-18 Reverse Phase Flash 
Chromatography, while I loaded the extracts and developed appropriate solvent system. 
2.2.3.6 Preparative Thin layer Chromatography 
Preparative Thin Layer Chromatography is another useful method in the separation of mixtures. It is 
carried out  on a glass (as in this study) plastic, or aluminium foil coated with adsorbent material which 
acts as the stationary phase and  are developed in large tanks with solvents previously determined from 
normal TLC. 
The plate in this present study was prepared by mixing silica gel with water, stirred into thick slurry 
form, poured and spread on the TLC glass plates 20 cm by 20 cm using a manual plate spreader, heated 
at 120oC for one hour to fix it. Activated resultant plates had thickness of the dry adsorbent layer of 
about 2.5 mm. With a margin of 1 cm from the bottom of the TLC plates, the alkaloid-rich mixtures 
were applied in a straight continuous line on the adsorbent material and subsequently immersed in a 
TLC tank with an appropriate solvent system Braithwaite and Smith (1996). 
 The four samples (column fractions); DCM 35, ECEB 19-22, ECH 12-26 and ECH 1 had 100 mg 
weighed and dissolved in dichloromethane. 
1. DCM 35 applied on the Prep TLC plate was placed in the preparative TLC tank containing the 
solvent system; 98% dichloromethane and 2% methanol and subsequently allowed to  
separate. 
The DCM 35 plate gave eight bands; their edges were sprayed with Dragendorf’s reagent. Three bands 
gave positive results (orange colour) indicative presence of alkaloids. These three bands; DCM 35-1, 
DCM 35 -2, DCM 35-4 were scrapped off the fifteen plates into a beaker and dissolved in 50% chloro-
form: 50% methanol and allowed to stand overnight. The supernant was decanted and air-dried in the 
fume cupboard to give; 12 mg of DCM 35-1, 8 mg of DCM 35-2 and 10.1 mg of DCM 35-4 
The same procedures were repeated for ECH-1, ECH 12-16, ECEA 19-22. 1D and 2D NMR experi-
ments were subsequently carried out for structure elucidation. 
Extraction and various chromatography separation techniques were carried out by myself under 
supervision of John Igoli, NMR analysis under supervision of Professor Sandy Gray. 
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2.2.3.7 Reversed-Phase High Performance Liquid Chromatography (RPHPLC) 
RPHPLC has a column made of modified silica, making it non-polar by attaching long hydrocarbon 
chains to the silica’s surface- typically with either 8 or 18 carbon atoms. Polar solvent such as  
methanol is commonly used as the solvent system. Because of Van der Waals ’dispersion forces, non-
polar compounds in the mixture tend to form strong bond with the hydrocarbon groups, while the  
Polar compounds form strong bond with the polar solvent. 
Retention time is an important concept in HPLC, it is the time it takes a reference compound to travel 
through the column to the detector. It is the measured time from which the sample is injected to the 
point at which the display shows a maximum peak height for that compound. Different compounds 
have different retention times, thus retention time can be used to identify compounds Clark (2007) 
Reverse Phase HPLC conditions  
Geng and Regnier (1984): The mobile phase used was:  
A. 0.1% Formic acid   B. Acetonitrile 
The flow rate 0.3 ml/min, wavelength: 254 nm. Injection volume was 20 µl. 12 samples were run for 
about 45 minutes apiece with the gradient system in the table below: 
Table 2.2: Reverse Phase HPLC conditions                                                                                                                       
Time A % (0.1% Formic acid) B% (Acetonitrite) 
0 70 30 
5 70 30 
30 0 100 
40 0 100 
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This experiment was supervised by Lorraine Allen, she operated the Reverse Phase HPLC Chroma-
tography, while I loaded the fractions and developed appropriate solvent system. 
 
2.2.3.8 Normal Phase High Performance Liquid Chromatography (HPLC) 
Chromatography can be described as a differential migration process where sample compounds (in this 
case E. chlorantha alkaloid-rich mixtures) were dissolved in appropriate mobile phase and  
separated by being selectively retained by a stationary phase.  Differences in equilibrium distribution 
between the phases will result in components being separated as components as they migrate in the 
mobile phase. 
The column of the chromatograph contains tiny silica particles, which is the stationary phase, and the 
solvent system used is commonly non-polar. This ensures polar compounds in the mixture as they pass 
through the column will stick longer to the polar silica than non-polar compounds. The non-polar ones 
will therefore pass more quickly through the column. The resultant signal is processed by a  
recorder or data handling device i.e. Integrator and the computer with the processing software, that is 
as the each component (in this case alkaloids, sugars and fats elute through the detector, a change in the 
electrical output is produced and displayed as graphs on the PC monitor with peak(s), heights and areas 
directly proportional to the quantity of each components in the mixtures. 
 
Normal Phase HPLC conditions 
An appropriate solvent system with TLC guided Rf value of 0.3 was used in this study to determine the 
appropriate solvent system to separate the benzylisoquinoline alkaloids mixtures into the various con-
stituents, comprising of alkaloids and impurities mainly fats and sugars. 
Mobile Phase: 20% Ethyl acetate in Hexane 
Flow; 7.5 ml/min 
Wavelength (λ): 254 nm 
Pressure: 120 psi 
Injected volume: 900 ul of 20 mg/ml using 80 mg in 4 ml Li et al., (2013). 
This experiment was supervised by Gavin Bain, he operated the Normal Phase HPLC Chromatog-
raphy, while I loaded the fractions and developed appropriate solvent system. 
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2.2.3.9 Reverleris IES Flash chromatography 
Reverleris IES flash chromatography system is a system designed to facilitate increased speed of  
isolation of bioactive molecules from natural products for pharmaceutical, agro-chemical and other 
relevant industries. 
Reveleris IES Flash chromatography conditions 
1. Flow Rate: 25 ml/min     2. ELSD Carrier: Iso-propanol    
3. UV1 Wavelength 254 nm, UV2 Wavelength 280 nm. 
4. Cartridge equilibration 30 minutes. 
5. Extract type: E.chlorantha hexane, ethyl acetate and methanol extracts 
6. Extract solvent: A. Hexane     B.Ethyl acetate  
7. Solvent volume 93 ml      8. Ultar-sonification: 20 minutes 
Operating conditions as reported by Bose, Anderson and Lawrence (2010).  
 
This experiment was supervised by Neil Herbert, he operated the Reveleris IES Flash chromatog-
raphy , while I loaded the extracts and developed appropriate solvent system. 
 
2.2.3.10 Mass spectrometry 
A known method useful in elucidating the elemental composition of a sample or molecule with  
mechanism of action based on ionizing the chemical compound(s) of interest to generate charged 
fragmented molecules whose flight of path is dependent on the mass/electric charge ratio in an  
electromagnetic field. 
MS is made up of:  
1. An ion source which converts compound or sample of interest into charged ions after bombarding 
high energy electrons. 
2. A mass analyser which sorts the ions out by their masses 
3. A detector measures the value in terms of quantity of the fragmented ions making MS an invaluable 
method of quantitative and qualitative analysis in some cases for identifying unknown compounds.  It 
measures mass and identifies corresponding structure by matching the obtained spectra to a library of 
similar compounds. 
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 In the present study EI mass spectra was obtained on a JOEL JMS-7- high resolution mass spectrome-
ter using a direct probe at 70 eV.  Positive ion and negative ion mode ESI experiments were carried out 
on Orbitrap HRESI mass spectrometer. Samples were dissolved in methanol, water or acetonitrite 
(HPLC grade and analytical grade) to obtain a concentration of 100 µg/ml. Sample solutions of 10 µl 
was injected with 0.1% formic acid in acetonitrite: water (90:10) at flow rate 200 µl/min. 
Operating conditions were Tube lens of 90 V for positive mode,-145 V for negative mode, capillary 
temperature of 220 degree Celsius, Sheath Gas flow (bar) 0f 30, Auxiliary Gas flow (bar) of 10. Others 
were source voltage in kV, 4.00 for positive mode and 3.00 for negative mode, source current of 100 
µA and capillary voltage of 35.5 V for positive mode and -48 V for negative mode.  
This experiment was carried out by Dr Tong Zhang, while I loaded the fractions in appropriate sol-
vent system. 
 
2.2.3.11 Minimum Inhibitory Concentration (MIC) 
MIC is the least concentration of a drug or compound to inhibit the growth of target microbes after 
overnight incubation. MICs are important to confirm the resistance of microbes to a drug or  
Compound, and to monitor the activity of a new drug. MICs are used by diagnostic laboratories mainly 
to confirm resistance, but most often as a research tool to determine the in vitro activity of new antimi-
crobials, and data from such studies have been used to determine MIC breakpoints Andrews (2001). 
 
Determination of MIC using Almar TM Blue assay for anti-trypanosomal activity screen 
Anti-trypanosomal activity of the alkaloids was determined using modified Almar blue TM 96 well mi-
croplate assays. The Trypanosome brucei brucei parasites (CMP strain) were isolated from previously 
infected CD1 female mice using method reported by Raz et al., (1997) and Franzblau (1998).  
 At concentration of 20 µM, an initial screen was carried out, subsequently the samples were prepared 
at 10 mg/ml solutions in 100% DMSO and diluted to a concentration of 1 mg/ml using HMI-9 medi-
um. 
Assay wells had 4 µl of test sample added to 96 µl of HMI-9 media to obtain a final concentration of 
1:1 dilution of 20 µM. As control DMSO was in column 1, test samples in 2-11 and positive control 
Suramin (19) in column 12. The non-virulent strain  T.brucei brucei S427 (a bloodstream form of the 
parasite) /mL  was incubated at humidified 5% CO2 atmosphere for 48 h. using HMI 9 media, Almar 
blue indicator, measuring the fluorescence. The surviving trypanosomes were counted using a haemo-
cytometer.  MICs were carried out in triplicates to ensure reliability and MIC concentrations were cal-
culated as the concentrations which had <5% of control values. 
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This experiment was carried out by Carol Clements, while I supplied the extracts and fractions in 
appropriate developed solvent system. 
 
2.2.3.12 Molecular modelling studies 
Eight alkaloids of interest comprising of seven aporphine-derived alkaloids and one protoberberine 
type (palmatine) were investigated using GRIP molecular docking technique on Vlife molecular  
Design suite (Vlife MDS 4.2) on seven validated Trypanosoma brucei protein targets that were availa-
ble from the Protein Data Bank (PDB). The validated targets were. Brucei Glutathione  
Synthetase, Glutathione peroxidase-type tryparedoxin peroxidase, oxidized form, Glutathione  
peroxidase-type tryparedoxin peroxidase, reduced form, Sterol 14-alpha demethylase (CYP51) from T. 
brucei in complex with the tipifarnib derivative 6-(4-chlorophenyl) (methoxy) (1-methyl-1H- 
imidazol-5-yl) methyl)-4-(2, 6-difluorophenyl)-1-methylquinolin-2(1H)-one, T. brucei Ornithine  
Decarboxylase, Riboflavin kinase, Trypanothione reductase from T. brucei.  
Vlife engine module was used for the alkaloids drawn in 3D forms for their energy minimization to 
achieve the most stable conformations.  Five best conformers from each alkaloid were subjected to 
docking studies using the GRIP technique of Vlife Biopredicta module, the resulting multiple 
 Interactions with the seven validated proteins were subsequently reported and analysed. Subsequently 
the Discovery Studio 3.5 visualizer and OpenBabel 2.3.2a Microsoft windows_installer were used to 
generate 2D forms of key protein-ligand interactions. Gold 5.3.2 software was thereafter used to model 
ornithine decarboxylase as protein target against the alkaloids as ligands to generate 3D interactions 
and docking scores used to evaluate the alkaloids’ binding affinity for their most potent proven protein 
target. 
This experiment was carried out by myself and Murray Robertson 
Log P values for the eight aporphine-derived alkaloid and palmatine were also calculated.  Log P is the 
Partition coefficient used in estimating the distribution of drugs within the body. It gives an idea of 
how hydrophilic “water-attracting” or hydrophobic “water-resistant” a compound is. 
2.3.2.13 ChemBioDraw 
Structures elucidated from 1D and 2D NMR spectral interpretation were drawn using the software 
ChemBioDraw in a 2D fashion. I draw all 2D structures myself 
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2.3.2.14 Lipinski’s rule of 5 
Bioactive molecules in the initial stages of drug development that conform to Lipinski’s 
rule of 5 tend to have low attrition in clinical trials later. Therefore the rule acts as a guide 
in pursing further drug development studies considering the cost involved. 
Lipinski's rule states that to be an orally active drug a bioactive molecule in development should 
not violate more than one of the following criteria: 
1. Have not more than 5 hydrogen bond donors (the total number of nitrogen–hydrogen and ox-
ygen–hydrogen bonds) 
2. Have not more than 10 hydrogen bond acceptors (all nitrogen or oxygen atoms) 
3. The ideal molecule should have a molecular mass less than 500 daltons 
4. The ideal molecule should have an octanol-water partition coefficient [5] log P not greater than 
5 
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Chapter 3: Results 
Separation techniques and yield 
In this study 805.4 g of ground bark of Enantia.chlorantha was extracted in Soxhlet to give three ex-
tracts from ground plant material. The three extracts obtained had their solvent removed at reduced 
pressure to give solid residues. The three extracts solid residues were subsequently subjected to column  
chromatography and other appropriate separation techniques to give fractions, which were weighed to 
give percentage yield of based on the dry plant material weight of 804.5 g as shown below in Table 
3.1. Following soxhlet extraction and evaporation under pressure using the rotatory evaporator  of  
804.5 g of starting stem bark plant material ,ethyl acetate crude extract 16.5 g (2.05%) methanol 88.7 g 
(11%)  and Hexane 17.6 g (2.2%) were obtained.  
 Weighed 10 mg of the fractions from the various separation techniques were dissolved in 1 ml of deu-
terated Methyl sulfoxide-d6  (DMSO) or chloroform (CDCl3) for 2D NMR studies to characterize the 
alkaloids described in this chapter. In most cases 1-120 vials were collected from each column run over 
a period of 4 weeks. For the initial 1-25 vials fractions, NMR analysis revealed they were fats, sugars, 
while vials number 60-120 were tannins, sugars and likes indicating the termination of collection of 
vials from the column chromatography. This was based on result of initial anti-trypanosomal screen 
which revealed fats, sugars, tannins, saponins did not possess any anti-trypanosomal activity. 
On TLC ECP-17 and other alkaloids described here below gave had different Rf  values as shown 
above in Table 3.1, as well as  one prominent spot in UV at λ 254 nm with blue fluorescence.  On 
spraying with Dragendorff’s reagent, the spots were positive, indicating they were alkaloids. The same 
findings were observed in other alkaloidal fractions to be described later in this chapter. 8 alkaloids 
isolated with their structures elucidated were: (ECP-17) 7,7’- Bisdehydro-O-methylisopiline,(ECM-1); 
the protoberberine alkaloid palmatine,(ECP-19) 1,1',2,2',3-pentamethoxy-6-methyl-5,5',6,6'-
tetrahydro-4H,4'H-7,7'-bidibenzo[de,g]quinoline and (ECHE-45) : 8-(1,2,3-trimethoxy-5,6-dihydro-
4H-dibenzo[de,g]quinolin-7-yl)-6,7-dihydro-5H-[1,3]dioxolo[4',5':4,5]benzo[1,2,3-
de]benzo[g]quinoline. Others were (ECH-56 )7-methyl-8-(1,2,3-trimethoxyl-5,6-dihydro-4H-
dibenzo(de,g)quinolin-7-yl)-6,7-dihydro-5H-(1,3)dioxolo(4’5’:4,5)benzo(1,2,3-de) benzo(g)quinoline, 
(ECF 5-10) O-methyl moschatoline,(ECP-23)7-dehydro-nornuciferinyl-7’-dehydro-O-
methylisopiline, and (ECH-B 17-18) Urabaine. 
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Table 3.1: Extracts, separation techniques, Fry values and % yields. 
Extract Fraction Separation  
Technique 
Solvent  
System 
Rf value Yield 
Ethyl  
acetate(EC) 
ECP-17(88) Column  
chromatoraphy(CC) 
Hexane/EC 
50:50 
0.42 0.0002% 
Methanol ECM-1(41) CC EC/Methanol 
95:5 
0.45 0.28% 
Ethyl  
acetate(EC) 
ECP-19(89) CC Hexane/EC 
35:65 
0.93 0.00029% 
Ethyl  
acetate(EC) 
ECHE 
45(90) 
CC Hexane/EC 
60:93 
0.50 0.00062% 
Hexane ECH 56(91) CC Hexane/EC 0.44 0.00062% 
Hexane ECF 5-
10(92) 
CC/FC Hexane/EC 
85:15 
0.42 0.00082% 
Ethyl  
acetate(EC) 
ECP 23(93) CC Hexane/EC 
30:70 
0.50 0.0026% 
Hexane ECH-B 17-
18(94) 
CC/Normal Phase 
HPLC 
Hexane/EC 
55:45 
0.45 0.002% 
 
The yields in % were obtained by dividing the resultant chromatography fractions weight by the start-
ing ground plant material weight, for example 20 mg obtained from a chromatography fraction was 
divided by 804.5 g starting plant material and the result expressed in percentage to obtain the yield per-
centages in the table above. 
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3.1.1: Characterization of Compound 88: ECP-17  
The 1H  NMR spectrum of  ECP-17 (Figure 3.1) gave sufficient information for it to be identified as a 
dehyroaporphine system. The NMR spectral were processed used Mnova software. 
Figure 3.1: 1H NMR (400MHz, CDCl3) of ECP
 
 1H NMR Spectrum showed the aporphine alkaloid  had a strongly deshielded proton δH 9.59 ppm ( 
doublet,J= 6.8 Hz,H-11), completing the four-spin aromatic system were δH  7.90 ppm ( doublet of 
doublet of doublet J=6.8,5.6,0.8 Hz , H-10), 7.24 ppm ( doublet of doublet of doublet ,J = 
6.8Hz,5.6Hz,0.8Hz ,H-9), 7.17 ppm ( doublet of doublet, J= 6.8,0.8Hz ,H-8). The fact that there are 
only these four aromatic protons, three methoxy signals (4.01 ppm, 4.08 ppm, 4.15 ppm) and aliphatic 
methylene resonances which appeared as a complex multiplex between δH 3.23 ppm (H-4) and doublet 
of doublet H-5 (J= 6.24Hz, 9.28Hz) at 3.29 ppm completed the structure of an aporphine alkaloid as 
shown in (81a) below, implying that there is no proton at position 7 as described by Connolly JD et al., 
(1996). 
 
 
 
 
[87] 
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                                                                           (88a) 
                                                                        X-Unknown.  
X  is stated as unknown because structure elucidation  was done in such a way that one could build 
piece by piece the full structure of ECP-19 in a sequential manner.  
 
The 13 C NMR Spectrum (Figure 3.2, Table 3.2) was as expected for an aporphine alkaloid with 19 
carbons. It had four aromatic methines (123.1 ppm, 123.8 ppm, 126.8 ppm, and 127.2 ppm), two  
methylene (23.9 ppm and 93.8 ppm), and three methoxy carbons (60.4 ppm, 60.9 ppm and 61.3 ppm)  
together with  ten quaternary carbons (120.5 ppm, 121.8 ppm,122.1 ppm,122.8 ppm,125.8 ppm,132.9 
ppm, 192.4 ppm 146.9 ppm,148.8 ppm and 151.4 ppm). 
 
[89] 
 
 
. 
Figure 3.2: 13C NMR Spectrum (400MHz, CDCl3) of ECP 17. It is a J –modulated spectrum like other 
13 C spectral discussed in this thesis, C-1 and C-3 carbons were facing upwards, while C (quaternary 
carbon) and C-2   were facing downwards. 
[90] 
 
The 1H-1H COSY NMR Spectrum (Figure 3.3) showed 9.59 ppm (H-11) was ortho-coupling to (H-10) 
7.90 ppm, while the latter was further coupled (ortho) to 7.24 ppm (H-9) and 7.17 ppm (H-8) (Meta). 
 
 
Figure 3.3: COSY NMR (400MHz, CDCl3) of ECP 17 
 
 
The HSQC Spectrum as shown below was consistent with an aporphine with three methoxys, two  
aliphatic methylenes and four aromatic protons as listed in Table 3.4. 
H-11/H-10 
H-10/H-11 
[91] 
 
 
 
 
Figure 3.4: HSQC NMR (400MHz, CDCl3) of ECP 17 
 
 
The HMBC Spectrum as shown in Figure 3.5a and 5b, the most deshielded aromatic proton δ11 9.59 
had 3J coupling in ring D with carbon at 126.8 ppm (C-9) and 132.7 ppm (C-7a). Proton 11 is the most 
deshielded proton because it is the most stearically hindered of the four aromatic protons. The latter  
carbon also showed strong 3J coupling with H-9 (δ 7.24) and this proton was coupled to C-11(127.3 
ppm). The other correlations within ring D involving H-8 and H-10 are given in Table 3.2. 
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Figure 3.5a: HMBC NMR (400MHz, CDCl3) of ECP 17 
 
[93] 
 
 
 
Figure 3.5b: HMBC NMR Spectrum (400MHz, CDCl3) of ECP 17 (aromatics) 
 
H-11(δ 9.59) correlated with a carbon outside ring D at 122.5 ppm which must be C-1a on the ring 
junction between ring A and C. In a similar fashion H-8 (δ 7.17) showed further strong (3J) coupling 
with carbon-7 (108.3) in ring C. 
Each of the three methoxys showed 3J correlations to their respective aromatic oxygenated carbons (see 
Table 3.2). The methylene protons of C-4 and C-5 had correlations to each other’s carbon and both 
showed strong correlations to a single aromatic carbon which could only be C-3a (122.9 ppm). The 
methoxy protons of position-3 (δH 4.01) had an NOE with the protons at δH 3.23 (H-4), while the 
methoxy δH 4.08 (C-1 OMe) NOEed a proton at δH 9.59 (H-11). This confirmed the assignments of the 
methoxys and their associated chemical shifts. There was a very weak correlation with a quaternary 
carbon at 192.6 ppm which must be C-6a carrying the nitrogen. This set of data implies an aporphine 
alkaloid but with C-7 as a quaternary carbon (108.3 ppm), it was not clear what was attached at that 
position. 
The expected mass of dehydro-O-methylisopiline would be 308. However the ESI MS Figure of Com-
pound 35 gave a quasi-molecular ion in positive ion mode at 615.20 (M+H)+ indicating that this was 
actually a symmetrical dimer connected via C-7/C-7’. 
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                                                                         (81) 
This compound, 7, 7’- Bisdehydro-O-methylisopiline obtained from column chromatography was   
previously isolated from Malaysian peninsula Polyalthia bullata ethyl acetate extract as reported by 
Connolly JD et al., (1996), although there are some differences between the assignments of some  
proton/carbon shifts made by the above authors and those reported in this thesis. For example, the C-7 
carbon assignment in the current data based on 2D NMR correlations, was 108.3 ppm [compared with 
120.1 ppm reported by Connolly JD et al., (1996) as well as C-8 at 123.8 ppm [127.2 ppm],C-10 
at123.1[123.8 ppm], C-11 at127.3 ppm [123.1],1-OMe at 60.9 ppm [60.4 ppm],2-OMe at 60.4 ppm 
[60.9 ppm],C-1 at 151.1 ppm[148.6 ppm] and C-3 at148.6 ppm [151.1 ppm]. 
Thus ECP-17 (81) was identified as 1,1’,2,2’,3,3’-hexamethoxy-5,5,6,6’-tetrahydro-4H,4’H-7,7’-
bidibenzo[de,g]quinoline also known as 7,7’- Bisdehydro-O-methylisopiline and this is the first report 
of this compound in E. chlorantha. 
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Table 3.2: 1H and 13C chemical shifts of  ECP-17 
Position 1H (ppm) 13C (ppm) 
1-OMe,1-MeO’ 4.01 60.9 
2-OMe,2-MeO’ 4.08 60.4 
3-OMe,3-MeO’ 4.15 61.4 
C-1,C-1’ - 151.1 
C-1a,C-1a’ - 125.5 
C-1b,C-1b’ - 123.4 
C-2,C-2’ - 146.7 
C-3,C-3’ - 148.6 
C-3a,C-3a’ - 121.9 
C-4,C-4’ 3.23 23.9 
C-5,C-5’ 3.29 93.6 
C-6a,C-6a’ - 192.6 
C-7,C-7’ - 108.3 
C-7a,C-7a’ - 132.7 
C-8,C-8’ 7.90 123.8 
C-9’,C-9 7.24 126.8 
C-10,C-10’ 7.14 123.1 
C-11,C-11’ 9.59 127.3 
C-11a,11a’ - 122.5 
 
Table 3.2 HMBC correlations of ECP-17 
Position 1H(ppm) 13C(ppm) 
1-OMe 4.08 1 (151.1) 
2-OMe 4.15 2 (146.7) 
3-OMe 4.01 3 (148.6) 
4 3.23 5(93.6) 3a(121.9) 
5 3.29 4(23.9),3a(121.9) 
8 7.90 8(123.84) 11a(125.5) 
9 7.24 7a(132.7),8(123.1)11(127.3) 
10 7.17 11(127.3),11a(125.5)7(108.3) 
11 9.59 7a(132.7),9(126.8),1a(122.5) 
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3.1.2: Characterization of ECM-1, Compound 41, as the protoberberine alkaloid Palmatine. 
ECM-1 was obtained from column chromatography as described in Table 3.5 and  mass was  
confirmed by ESI-MS  Figure which gave a quasi-molecular ion (M+H)+ at region m/z 352.30 with 
predicted molecular  formula of C21H22NO4 . 
N+
OCH3
OCH3
OCH3
H3CO
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2, 3, 9, 10-tetramethoxy-5, 6-dihydroisoquinolino [2, 1-b] isoquinolin-7-ium 
                                                                   (41) 
The 1H NMR Spectrum ( Figure 3.6a- b (500 MHz in DMSO-d6) indicated a protoberberine system as 
previously described by Wafo (1998) with four deshielded methyl groups at δH3.85 (3-OMe),3.92 (2-
OMe), 4.05 (10-OMe) and 4.09 (9-OMe). 
 
 
 
Figure 3.6a: 1H NMR (500 MHz, CDCl3) Figure of ECM-1 (methoxys) 
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Figure 3.6b 1HNMR (500 MHz, CDCl3) of ECM 1 (41) 
[98] 
 
The protoberberine unit had strongly deshielded  protons δH  9.87 (singlet , H-8), and 9.04 (singlet, H-
13),  two deshielded ortho -substituted protons 8.18 ppm  (doublet J= 9.08 Hz,H-11) and 8.02 
ppm(doublet ,J= 9.08 Hz,H-12)  on ring D as shown in the 1H/ 1H COSY Spectrum (Figure 3.7), while  
aromatic ring A had two protons para- substituted 7.69 ppm (singlet, H-1),  and 7.06 ppm ( 
singlet, H-4) with the two methoxys attached to complete the ring. Completing the protoberberine unit 
were two vicinal methylene groups at 3.22 ppm (H-5) and 4.95 ppm (H-6) shown to be coupling in the 
1H/ 1H COSY Spectrum (Figure 3.7).   
 
 
                                         Figure 3.7: 1H-1H-COSY NMR (500MHz, CDCl3) of ECM-1(41) 
 
The 13 C NMR Spectrum (Figure 3.8) with 13C chemical shifts as shown in Table 3.4 correlates as ex-
pected for a protoberberine. 
    H-6/H-5 
H-5/H-6 
[99] 
 
 
 
Figure 3.8: 13C NMR (500MHz, CDCl3) Spectrum of ECM-1(41) 
This spectrum like its 1H spectrum indicated that this is not a pure compound, as it has an associated 
protoberberine alkaloid tagging along as source of impurity. 
 
The HSQC Spectrum (Figure 3.9) confirmed the methoxy protons were attached to 13C carbons 2-
MeO, 3-MeO, 10-MeO and 9-MeO at 56.6, 56.4, 57.5 and 62.4 ppm, respectively, and the fact that the 
[100] 
 
9-MeO methoxy was the most deshielded methoxy indicated it was sterically hindered.
 
Figure 3.9: HSQC NMR (500MHz, CDCl3) Spectrum of ECM-1(41) 
The HMBC Spectrum (Figure 3.10a) revealed the four methoxys showed strong 3J couplings to 
their respective aromatic oxygenated carbons. The proton δH 8.02 showed a strong 3J coupling to a 
carbon at 150.7(C-10) as well as carbons 121.8 ppm (quaternary carbon, C-8a) and aromatic me-
thine 120.4 ppm (C-13).  It also had weak correlations to aromatic methine 127.2 ppm (C-11) and 
quaternary carbon 133.6 ppm (C-12a). 
The proton δH 8.17 showed strong 3J coupling to the quaternary carbons 133.6 (C-12a) and 144.1 (C-9). 
The latter carbon was coupled to the methoxy δH 4.09 which bore the sterically hindered methoxy. The 
proton δH 8.17 also showed weak 2J coupling to the neighbouring aromatic carbons 123.9 (C-12) and 
quaternary carbon 150.7 (C-10). The proton δH 9.04 showed strong 3J couplings to quaternary carbon 
121.8 ppm (C-8a) and aromatic carbon 123.9 ppm(C-12). This proton also had further correlations to 
carbons at 119.4 ppm (C-13b) and 191.1 ppm (C-13a). 
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Figure 3.10a: HMBC NMR Spectrum (500MHz, CDCl3) of ECM-1(deeper levels) 
 
 
Another highly deshielded aromatic proton singlet δH 9.87(δC145.8 ppm from the HMBC   
Spectrum also showed strong 3J coupling to two carbons 133.6 ppm (C-12a), 144.1 ppm (C-9) as 
well as quaternary carbon 191.1 ppm (C-13a) and an aliphatic methylene carbon at 55.8 ppm. The 
presence of a further aromatic ring bearing two non-sterically hindered methoxy groups and two 
proton singlets was supported by the following: the proton δH7.06 ppm (δC111.7 ppm) had strong 
3J couplings to quaternary carbon 119.4 ppm (C-13b) and quaternary carbon which bore the meth-
oxy at δH 3.92, as well as an aliphatic methylene (CH2 ) at 26.4 ppm (δH3.22). The proton at δH 7.69 
showed strong couplings with carbon at 129.0 ppm(C-4a), 152.0 ppm (C-3) and a further carbon at 
191.1 ppm which was already seen to be coupling with δH 9.87 and 9.04 the most deshielded pro-
tons in the molecule. These data allow the assignment of the structure to the known protoberberine 
alkaloid palmatinepreviously isolated   from a methanol: chloroform extract of E. chlorantha by 
Wafo (1998). The strong deshielding of one set of methylene signals at δH 4.95(t) and the proton δH  
[102] 
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9.87 manifesting the presence of the quaternary ammonium nitrogen in position-6.  The natural 
counter ion to this quaternary alkaloid is not known.  Palmatine was the major alkaloidal secondary 
metabolite found in this study on Enantia chlorantha (0.28 %   yield) and is possibly the main con-
stituent responsible for the strong yellow-orange colour of the stem bark. 
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Table 3.4 ECM-1 (Palmatine’s) 1H and 13 C chemical shifts  
Position 1H (ppm) 13C (ppm) 
1 7.69 109.2 
1a - 119.4 
1b - 191.1 
2 - 149.2 
3 - 152.0 
4 7.06 111.7 
4a - 129.0 
5 3.22 26.5 
6 4.95 55.8 
7 - - 
8 9.86 145.8 
8a - 121.8 
9 - 144.1 
10 - 150.7 
11 8.18 127.2 
12 8.02 123.9 
12a - 133.6 
13 9.04 120.4 
2-MeO 3.92 56.6 
3-MeO 3.85 56.2 
9-MeO 4.09 62.4 
10-MeO 4.05 57.5 
 
 
 
[105] 
 
Table 3.5: ECM-1 (Palmatine) HMBC correlations 
 
Position 
 
1H (ppm) 
 
13C (ppm) 
1 7.69 (3) 152.0,(2) 
149.2,(13a)191.1 
,(4a)129.0,(5)26.5, 
4 7.06 ( (2)149.2, 
13a)191.1(13b)119.4, 
(5) 26.5 
5 3.22 (4a) 129.0 ,(13b) 119.4,(6) 
55.8, 
6 4.95 (4a) 129.0 
8 9.87 (8)145.8,(9)144.1,(13a) 
191.1,(12a)133.56,(13)120.4 
11 8.18 (10)150.7,  (9)144.1, 
(12a)133.6,(13) 120.4 
12 8.02 (10) 150.7, (9) 144.1, (12a) 
133.6, (8a) 121.8. 
13 9.04 (13b) 191.1(8a) 121.8, 
(1a)119.4 
2-MeO 3.92 (2)149.2 
3-MeO 3.85 (3) 152.0 
9-MeO 4.09 (9) 144.1 
10-MeO 4.05 (10) 150.7 
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3.1.3: Characterisation of  Compound 89: ECP-19 as 1,1',2,2',3-pentamethoxy-6-methyl-5,5',6,6'-
tetrahydro-4H,4'H-7,7'-bidibenzo[de,g]quinoline. 
ECP 19 was obtained by column chromatography over silica gel as illustrated in Table 3.1.  It was 
highly suggestive from the 1H NMR Spectrum that ECP-19 (Compound 89), unlike ECP-17 ( 
Compound 88) which was symmetrical with two identical sets of NMR data, was likely to be an 
asymmetric dimer. ECP-19 showed two strongly deshielded aromatic protons at 9.73 ppm H-11’ 
(broad doublet, J=8.49Hz) and 9.57 ppm H-11(broad doublet, J=8.91Hz), also there was an aromatic 
proton a singlet H-3’ at 7.18 ppm. The other aromatic protons were doublet of doublet  H-8 at 7.23 
ppm(J= 1.58,8.50),H-8’ at 7.14 ppm, H-9 at 7.28 ppm ,H-9’ at 7.25 ppm H-10 at 7.34 ppm, H-10’ at 
7.45 ppm,as well as five methoxys (4.15 ppm ,4.09 ppm,4.08 ppm,4.02 ppm and 4.00 ppm). The ali-
phatic protons were at 3.23 ppm H-4’, 3.21 ppm, H-4 and multiplet at 3.32 ppm H-5. 
 
                                         Figure 3.11: 1H NMR Spectrum (400MHz, CDCl3) of ECP-19 
 
The 1H-1H-COSY 2D NMR Spectrum (Figure 3.12) showed the highly deshielded proton 9.57 
ppm was ortho-coupling with position 10’s 1H (7.34 ppm), of the 1st A,B,C, D spin system and the 
highly deshielded proton 9.73 ppm H-11’of the A’,B’,C’,D’ spin system was ortho-coupled to H-
[107] 
 
10’(7.45 ppm) . 
 
Figure 3.12:   COSY NMR Spectrum (400MHz, CDCl3) of ECP-19 
The 2D NMR HSQC Spectrum (Figure 3.13) showed 1J 1H -13C coupling as shown in Table 3.7. 
There was a singlet at 2.51 ppm (42.0 ppm) for N-Methyl group, three aliphatic methylenes: H-4’ 
(δH 3.23, δC24.1), H-4 (δH 3.21, δC23.98), a complex multiplet H-5(δH 3.32,δC93.6). There were al-
so five methoxys(δH 4.15,4.09, 4.08,4.02 and 4.00), nine aromatic methines H-11’ (δH 9.73, 
δC127.9),H-11 (δH 9.57, δC127.2),H-10 (δH 7.34, δC122.5),H-10’(δH 7.45, δC125.4),H-9 (δH 7.28, 
δC127.1)H-9’ (δH 7.25, δC 126.9),H-8(δH 7.14, δC123.8),H-8’ (δH 7.23, δC126.3),H-3’ (δH 7.18, 
δC112.5). 
[108] 
 
 
                     Figure 3.13: HSQC NMR Spectrum (400MHz,CDCl3) Spectrum of ECP-19 
 
Completing the 2D NMR analysis of this aporphinoid alkaloid was the HMBC Spectrum (Figure 
3.14a) which showed that H-11 (δH 9.57) had strong 3J coupling to a quaternary carbon C-7a 
(133.6 ppm) and 2J couplings to  aromatic carbon C-10 (122.5 ppm) and  weak 2J coupling to qua-
ternary carbon C-11a (125.4 ppm). The most deshielded aromatic methine for the A’, B’, C’, D’ 
spin system H-11’δH 9.73 showed 3J coupling to quaternary carbon C-7a’ (133.6 ppm) and aro-
matic methine C-9’ (126.8). While the aromatic proton H-10 δH 7.34 had weak 2J coupling to aro-
matic carbon C-9 (127.1 ppm) and 3J coupling to quaternary carbon which can only be C-11a 
(191.9). 
[109] 
 
 
                          Figure 3.14a: HMBC NMR Spectrum (400MHz, CDCl3) of ECP-19 
 
The HMBC Spectrum also showed aromatic proton H-9 δH 7.28 to have a 3J correlations to quater-
nary carbon C-7a (133.6 ppm).  The aromatic ring D aromatic proton H-8 δH7.23 showed strong 3J 
couplings to carbons C-7a (133.6 ppm) and C-11 (127.2 ppm). It also showed a weak 2J coupling 
to aromatic methine C-9 (127.1 ppm). The none sterically hindered methoxy on the aromatic spin 
system A’, B’, C’, D’ δH 4.09 (2-MeO) had a strong 3J correlation to aromatic carbon (C-3’, δc 
112.4).  For the aliphatic CH2 ; H-4’δH 3.23, it showed weak 2J correlation to quaternary carbon C-
3a (122.3), while H-4 δH 3.21 showed weak correlation to C-5 (93.5 ppm). While the aliphatic pro-
ton H-5 showed  weak couplings to the neighbouring methylene carbon C-4 (24.1 ppm) , and 3J 
couplings to quaternary carbons C-6a (192.98 ppm), and C-3a (122.3 ppm).  
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Figure 3.14: HMBC NMR Spectrum (400MHz,CDCl3) of ECP-19 (deeper levels aromatics) 
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The HMBC Spectrum also revealed the five methoxys showed strong 3J couplings to their respec-
tive aromatic oxygenated carbons, see Figure 3.14b below. The methoxys other correlations are 
showed in Table 3.6. 
 
 
Figure 3.14c: HMBC NMR Spectrum (400MHz,CDCl3) of ECP-19 (deeper levels aromatics 2) 
 
 
 
The 13 C  NMR Spectrum as shown  in Figure 3.15 and correlations shown in  Table 3.7 below. 
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Figure 3.15: 13C NMR Spectrum (400MHz, CDCl3) of ECP-19 
Table 3.6: HMBC correlations of ECP-19 
Position 1H (ppm) 13C (ppm) 
3’ 7.18 !1-MeO (151.2), 2-MeO 
(145.8), 121.8(1b’). 
4 3.21 93.4(5) 
4’ 3.23 122.3(3a’) 
5 3.32 24.1(4)122.5(3a),192.98(6a) 
8 7.23 120.4(7) 
127.1(9),127.2(11),133.6(7a) 
9 7.25 133.6(7a) 127.2(11),126.3(8) 
10 7.35 127.1(9),133.6(7a) 
11 9.58 122.5(10),133.6(7a),125.4(11a) 
11’ 9.73 126.8(9’),133.6(7a’) 
1-OMe 4.02 148.3(1) 
1’-OMe’ 4.00 145.3(1’) 
2-OMe 4.08 151.1(2) 
2-OMe’ 4.09 151.1(2),112.4(3’) 
3-OMe 4.14 146.4(3), 
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Table 3.7 showing 13C chemical shifts of ECP-19 
Position 1H (ppm) 13C (ppm) 
C1 - 148.4 
C-1’ - 145.3 
C-1a - 125.1 
C-1a’ - 125.3 
C-1b - 121.8 
C-1b’ - 121.9 
C-2 - 151.0 
C-2’ - 151.1 
C-3 - 146.4 
C-3’ 7.18 112.4 
C-3a - 122.3 
C-3a’ - 122.3 
C-4 3.21 23.98 
C-4’ 3.23 24.1 
C-5,C-5’ 3.32 93.5 
C-6a’ - 192.01 
C-6a - 192.96 
C-7 - 108.3 
C-7’ - 105.8 
C-7a - 133.6 
C-7a’ - 132.8 
C-8 7.23 126.3 
C-8’ 7.14 123.8 
C-9 7.28 127.1 
C-9’ 7.25 126.9 
C-10 7.34 122.5 
C-10’ 7.45 125.4 
C-11 9.58 127.2 
C-11’ 9.73 127.9 
C-11a,C-11a’ - 191.99 
1-OMe 4.02 60.4 
1’-OMe 4.00 59.9 
2-OMe 4.08 60.9 
2’-OMe 4.09 56.5 
3-MeO 4.14 61.3 
N-Me 2.51 42.0 
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ECP 19  was obtained also as yellow brown  powder, with predicted  molecular formula as C90 H34 O5 
N2, mass confirmed by ESI-MS  Spectrum which gave a molecular ion M+ at region m/z 601  with two 
units ;C18H16O2 N and C20 H20 O3 N ;suggesting  an asymmetric dimer, It is novel. 
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3.1.4:  Characterization of Compound 90 ECHE-45 :8-(1,2,3-trimethoxy-5,6-dihydro-4H-
dibenzo[de,g]quinolin-7-yl)-6,7-dihydro-5H-[1,3]dioxolo[4',5':4,5]benzo[1,2,3-
de]benzo[g]quinoline. 
ECHE-45 was obtained as yellowish powder from the hexane’s extract with conditions as described in 
Table 3.1. 
The 1H NMR Spectrum (Figure 3.16) had nine aromatic protons , one highly  deshielded proton  at 
9.59 ppm forming part of the ring D aromatic spin system ( 9.59 ppm,7.89 ppm,7.25 ppm and 7.20 
ppm) of the 1st A,B,C, D spin system. The 2nd spin system A’,B’,C’,D’s ,Ring D four aromatic protons 
(9.06 ppm,7.33 ppm,7.23 ppm,7.10 ppm). Ring A’ had an aromatic singlet H-3’δ 7.05, as well as 
methylenedioxy at 6.28 ppm C-1’ and C-2’ substitutions. The ring D of  the 1st A,B,C,D spin system 
had C-1,C-2 and C-3 substitution in form of  three methoxys groups(1-MeO, 2-MeO and 3-MeO ) all 
these data were characteristic of 7,7’-dehyroaporphine system, indicative of an asymmetric dimer. 
 
Figure 3.16:  1H NMR Spectrum (400MHz, CDCl3) of ECHE 45 
The 2D NMR HSQC Spectrum (Figure 3.17) showing 1J 1H -13C couplings revealed   1’OCH2O at 
101.0 ppm,  as well as seven  aromatic methines  H-11 δH 9.59, δC 127.3 ,H-11’ δH 9.06,δC 127.3  ,H-10 
δH 7.35,δC 122.9,H-10’ δH 7.33,δC122.4, H-9 δH 7.22,δC 126.8 ,H-9’ δH 7.25,δC 127.5 ,H-8 δH 7.20,δC 
123.8, H-8’ δH 7.12,δC 123.4  and H-3’ δH 7.05, δC 107.9. There were also the three methoxys 1-MeO 
(4.02 ppm δC 60.4), 2-MeO (4.08 ppm δC 60.9), 3-MeO (4.16 ppm δC 61.4 ) and four aliphatic meth-
[117] 
 
ylene H-4 δH 3.25,δC 23.9 ,H-4’ δH3.23,δC 30.8,H-5 δH 3.33,δC 93.6  and H-5’ δH3.31,δC 94.2 as shown 
in Table 3.9. 
 
Figure 3.17:   HSQC NMR Spectrum (400MHz, CDCl3) of ECHE 45 
[118] 
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8-(1,2,3-trimethoxy-5,6-dihydro-4H-dibenzo[de,g]quinolin-7-yl)-6,7-dihydro-5H-
[1,3]dioxolo[4',5':4,5]benzo[1,2,3-de]benzo[g]quinoline 
                                                          (90) 
 
 
Figure 3.18: 13C NMR (400MHz, CDCl3) of ECHE 45 
The HMBC Spectrum (Figure 3.19a) showed the ring D with a strongly deshielded aromatic proton H-
11 coupled in a 3J fashion to aromatic methine C-9 and quaternary carbons C-1a and C-7a. The most 
[119] 
 
deshielded aromatic proton in ring D’, H-11’ coupled in a 3J manner to aromatic methine C-9’and qua-
ternary carbons C-1a’ and C-7a’. The H-10 aromatic proton had strong2J coupling to aromatic methine 
C-9 and 3J to quaternary carbon C-11a. Further, the aromatic proton  H-9’ showed strong 3J couplings 
to C-7a’ and C-11’, completing the ring D correlations was aromatic proton H-8  which had  strong 3J 
couplings to carbons C-10,C-11a and C-7, while H-8’ also had strong 3J couplings to carbons C-10’,C-
11a’ and C-7’, indicating  the structure was an asymmetrical dimer of two units joined by a C-7/C-7’ 
bridge. 
 
 
Figure 3.19a:  HMBC NMR Spectrum (400MHz, CDCl3) of ECHE 45 
The aromatic proton H-3’ completed the ring A substitutions bearing the methylenedioxy substituent 
6.27 ppm which had 2J correlations to carbons  C-1b’and C-3a’, as well as  3J correlation to the aro-
matic carbon C-4’.Other correlations as shown in Table 3.8 
[120] 
 
 
 
Figure 3.19b:  HMBC NMR Spectrum (400MHz, CDCl3) of ECHE 45 
[121] 
 
1H-1H-COSY 2D NMR Figure (Figure 3.20) showed the highly deshielded proton 9. 59 ppm was or-
tho-coupling with position-101H (7.89 ppm). 
 
Figure 3.20:  COSY NMR Spectrum (400MHz, CDCl3) of ECHE 45 
Table 3.8: HMBC correlations of ECHE 45 
Position 1H (ppm) 13C (ppm) 
3’ 7.05 145.4(2’)142.1(1’),118.2(1b’),30.8(4’) 
4 3.25 93.6(5),128.3(3a)120.2 (1b) 
4’ 3.23 128.3(3a),121.8(1b) 
5 3.33 128.3(3a),193.6(6a) 
5’ 3.31 128.3(3a).30.8(4’) 
8’ 7.12 105.8(7’),124.0(11a’),122.4(10’) 
8 7.20 108.3 (7),122.9 (10),125.4 (11a) 
9 7.23 122.4(10)127.3(11)132.9(7a) 
9’ 7.25 133.1(7a’) 127.5(11’) 
10 7.35 123.8(8),125.4(11a) 
10’ 7.33 124.0(11a’),127.5(9’) 
11’ 9.06 133.06(7a),127.48(9),118.23(1a) 
11 9.59 122.6(1a), 126.8(9), 132.9(7a) 
1,2-OCH2O 6.27 142.1(1’),145.4(2’) 
 
        H-11/H-10 
H-11’/H-10’ 
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Table 3.9: 1H and 13C correlations of ECHE 45 
Position 1H (ppm) 13C (ppm) 
1 - 148.6 
1’ - 142.1 
1a - 122.3 
1a’  117.6 
1b - 121.8 
1b’ - 118.2 
2 - 151.0 
2’ - 145.4 
3’ 7.05 107.9 
3 - 146.5 
3a - 128.3 
3a’  128.3 
4’ 3.23 30.8 
4 3.25 23.98 
5’ 3.31 94.2 
5 3.33 93.6 
6,6’(NH) 4.21 - 
6a - 193.0 
6a’ - 193.8 
7 - 108.3 
7’ - 105.8 
7a’ - 133.1 
7a - 132.9 
8 7.12 123.4 
8’ 7.20 123.8 
9h 7.22 126.8 
9’ 7.25 127.5 
10 7.35 122.4 
11 9.59 127.3 
11’ 9.06 127.3 
11a - 125.4 
11a’ - 124.0 
1,2-OCH2O - 101.0 
 
Thus the structure’s predicted molecular formula was deduced as C89 H30 O5 N2 from the ESI mass Fig-
ure gave a quasi-molecular ion in negative ion mode at 585.23 (M+H)-  corroborating with the fact that 
it was an asymmetrical aporphine alkaloid. A literature search yielded no compound for this structure, 
so that implies ECHE-45,8-(1,2,3-trimethoxy-5,6-dihydro-4H-dibenzo[de,g]quinolin-7-yl)-6,7-
dihydro-5H-[1,3]dioxolo[4',5':4,5]benzo[1,2,3-de]benzo[g]quinoline  is novel. 
 
[124] 
 
 
3.1.5: Characterization of Compound 91: ECH-56 (7-methyl-8-(1,2,3-trimethoxyl-5,6-dihydro-4H-
dibenzo(de,g)quinolin-7-yl)-6,7-dihydro-5H-(1,3)dioxolo(4’5’:4,5)benzo(1,2,3-de) benzo(g)quinoline). 
The 1H NMR Spectrum was suggestive of an asymmetrical dimer similar to the previously described 
Compound 83 with the difference being the presence of an N-methyl group in position-6 of the dehy-
dro-O-methyisopiline unit rather than the NH in Compound 83. However it was isolated in very minute 
quantity, about 6 mg. 
 
.  
NCH3
HN
O
O
H3CO
H3CO
OCH3
1
 
2
 
3
1'
 
2'
7
3a
8
11
8-(1,2,3
-trimethoxy-6-methyl-5,6-dihydro-4H-dibenzo[de,g]quinolin
-7-yl)
-6,7-dihydro-5H-
[1,3]dioxolo[4',5':4,5]benzo[1,2,3
-de]benzo[g]quinoline  
                                                                   (91)                                                  
8-(1,2,3-trimethoxyl-6-methyl-5,6-dihydro-4H-dibenzo(de,g)quinolin-7-yl)-6,7-dihydro-5H-
(1,3)dioxolo(4’5’:4,5)benzo(1,2,3-de) benzo(g)quinolone. The 1H NMR  Spectrum revealed a strongly  
deshielded proton 9.64 ppm in ring A of the A,B ,C ,D spin aromatic system 9.64 ppm( doublet J=  
8.56 Hz) H-11  as well as another deshielded aromatic proton signal H-11’δ 9.06,7.33 ppm( multiplet 
H-10,H-10’),7.23 ppm(multiplet ,H-9,H-9’) and 7.15 ppm (multiplet , H-8, H-8’) and  singlet aromatic 
proton H-3’ 7.04 ppm. The unit with methylenedioxy substituent had its proton 1’2’-OCH2 O at 6.27 
ppm. 
There were also  three methoxy signals (3.99 ppm, 4.05 ppm, 4.13 ppm) as well as  aliphatic methylene 
resonances appeared as duplet signal as proton 3.21 ppmH-4 (J=4.81Hz) and a complex multiplex for 
proton 3.28 ppm. ECH 56’s molecular formula C89 H32 O5N2    confirmed by ESI mass Figure gave a 
quasi-molecular ion (M+H) + at 585 indicating its molecular mass is 584. Other assignments correlated 
[125] 
 
with Compound 83’s chemical shifts. Literature search also revealed ECH-56, (7-methyl-8-(1,2,3-
trimethoxyl-5,6-dihydro-4H-dibenzo(de,g)quinolin-7-yl)-6,7-dihydro-5H-(1,3) Dioxolo 
(4’5’:4,5)benzo(1,2,3-de) benzo(g)quinoline) is novel. 
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3.1.6: Characterization of Compound 92: ECF 5-10 (O-methyl moschatoline). It was a monomeric 
aporphine alkaloid extracted from column chromatography and Flash Chromatography as a fraction 
from the hexane extract with molecular formula C19 H15 O4 N. This was deduced from ESI mass Figure 
which revealed a quasi-molecular ion in positive ion mode (M+H)+ at 322.18  
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                                                                      (92) 
The 1H NMR Spectrum indicated an aporphinoid alkaloid. It had a strongly deshielded proton 9.10 
ppm (doublet, J= 8.92Hz, H-11). Forming the D ring aromatic spin system were (9.10 ppm J= 8.92 Hz, 
7.74 ppm (doublet=7.86 H-10,), 7 .53 ppm (doublet J=7.45, H-9) and 8.57 ppm (J=, 7.83Hz, H-8). 
Completing the ring A and B substitutions were two aromatic protons 8.22 ppm (doublet of doublet, J= 
5.90 Hz, 1.96 Hz H-4), 8.97 ppm (doublet, J= 5.12 Hz, H-5). 
2D COSY Spectrum, Figure 3.21 showed the couplings as expected for O-methylmoschatoline  H-11-
H-8, as well as H-5 ortho-coupled to H-4 in Ring B.  Ring A had C-1, C-2 and C-3 substitution by 
three methoxys which appeared as signals integrating for three hydrogens on the 1H NMR  Figure  as 
signals (4.18 ppm, 4.09 ppm, 4.07 ppm) 
 This correlated with slightly different assignments to O-methylmoschatoline previously reported by 
Guinaudeau (2004) as well as Marsaioli et al., (1979) 
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Figure 3.21: COSY NMR Spectrum (400MHz CDCl3) of ECF 5-10 
[128] 
 
3.1.7. Characterisation of Compound 93: ECP-23 (7-dehydro-nornuciferinyl-7’-dehydro-O-
methylisopiline) 
It was obtained also as yellow brown powder. 
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                                                                            (93) 
The 1H NMR Spectrum, Figure 3.22b showed two highly  deshielded protons at 9.66 ppm (doublet of 
doublet, J= 0.90 Hz,8.60 Hz,H-11), and 9.59 ppm ( doublet,J= 8.60 Hz, H-11’)  completing the two 
four –spin aromatic system were aromatic protons H-8 at 7.19 ppm,H-8’ at 7.15 ppm,H-9 at 7.23 
ppm,H-9’ at 7.25 ppm ,H-10 at 7.89 ppm,H-10’ at  7.34 ppm. The dehydronornnuciferine  unit (86a) 
had two methoxys (4.08 ppm and 4.01 ppm) as well as  aliphatic protons making up ring B  between 
3.18 and 3.34 ppm: 3.22 (singlet 2H-4,2H-4’ and 3.31 (multiplet 2H-5,2H-5’). There was also a singlet 
amine proton at 4.33 ppm as well as a singlet signal for aromatic proton H-3 (7.14 ppm) 
 
NH
H3CO
H3CO
A' B'
C'
D'
 
                                                                        (86a) 
 While the dehydro-O-methylisopiline unit was very similar to the dehydronornuciferine unit with the 
difference being the latter’s three methoxy signals ((4.15 ppm, 4.07 ppm, and 4.00 ppm) in place of the 
former’s two methoxys. 
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Figure 3.22a:  1H NMR Spectrum (400MHz, CDCl3) of  ECP-23 showing the five methoxys. This a 
cut portion of the full spectrum to show the five methoxy region only. 
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Figure 3.22b:  1H NMR Spectrum (400MHz,CDCl3) of  ECP-23 showing the aromatic, methoxys and 
aliphatic protons. 
 
[131] 
 
The COSY 2D NMR Spectrum Figure 3.23 showed the highly deshielded proton H-11, 9.58 ppm was 
ortho-coupling to H-10 (7.34 ppm).   
 
Figure 3.23: COSY NMR Spectrum (400MHz,CDCl3) of ECP-23 
The 2D NMR HSQC Spectrum,Figure 3.24showed 1J 1H -13C coupling as shown in Table 3.10.  
 
Figure 3.24: HSQC NMR Spectrum (400MHz, CDCl3) of ECP-23 
[132] 
 
 
 
Figure 3.25:  13C NMR Spectrum (400MHz, CDCl3) of ECP-23 
 
The 13 C  NMR Spectrum, Figure 3.25 with chemical shifts  as shown in Table 3.14  correlates  with 
expected  dehydro -O-methyl-isopiline unit (86b) with  four aromatic methines (122.5 ppm,123.7 ppm, 
126.9 ppm, and 127.4 ppm),two methylene (23.7 ppm and 93.5 ppm ),and three methoxy carbons ( 
56.5 ppm, 60.9 ppm and 61.4 ppm).  It also had together with ten quaternary carbons (151.6 ppm, 
148.7 ppm, 146.4 ppm, 192.7 ppm, 132.6 ppm, 130.1 ppm, 125.9 ppm, 122.98 ppm, ppm, 118.2 ppm, 
and 106.7 ppm). 
The dehydronornuciferine unit (86a) with had five aromatic methane’s (111.9 ppm,123.4 ppm,124.0 
ppm, 126.9 ppm, and 128.1ppm),two methylene (30.8 ppm and 94.2 ppm ),and two methoxy carbons 
(59.9 ppm and 56.5 ppm),  nine quaternary carbons (151.2 ppm, 145.6 ppm, 192.6 ppm, 133.4 ppm, 
125.6 ppm,122.98 ppm, 121.8 ppm 118.12 ppm and 106.7 ppm).  These carbons were assigned with 
slightly different assignments to those of 7-Dehyronornuciferinyl -7’-dehydro -O-methyl-isopiline was 
previously isolated from Polyalthia bullata reported by Connolly (1996).  
[133] 
 
The HMBC correlations as shown in Table 3.11 revealed the most deshielded proton H-11 δH 9.58 of 
the dehydro-O-methylisopiline unit had strong 3J couplings to C-7a and C-9, as well as 2J coupling to  
C-11a. Aromatic proton H-10 had 3J correlations to C-8, while H-9 showed 3J correlations to C-11 and 
C-7a. Completing ring D correlations was aromatic proton H-8 which had weak 2J correlation to the 
carbon C-7a  and 3J correlation to the quaternary carbon C-7 indicating the dimer was an asymmetrical 
one joined at the C-7/C-7’ bridge.
 
                   Figure 3.26a: HMBC NMR Spectrum (400MHz, CDCl3) of ECP-23 
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Figure 3.26b: HMBC NMR Spectrum (400MHz, CDCl3) of ECP-23 
 
 
 Other HMBC correlations of the dehydronornuciferine unit are shown in Table 3.16. It was previously 
isolated from trunk bark of Oxandra cf major (Arango, 1986) and roots of Piptostigma fugax reported 
by (Achenbach, 1995). ESI mass Figure showed a (M+H) +at m/z 587.27 in positive ion mode indicat-
ing the molecular weight is 586, thus suggesting it was an asymmetrical dimer with molecular formula 
C90 H34 O5 N2. 
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Table 3.10  1H and 13 C correlations of ECP-23                                                                                  
Position 1H (ppm) 13C (ppm) 
C1 - 148.7 
C-1’ - 145.6 
C-1a - 125.9 
C-1a’ - 125.6 
C-1b - 118.2 
C-1b’ - 121.8 
C-2 - 151.6 
C-2’ - 151.2 
C-3 - 146.4 
C-3’ 7.13 111.9 
C-3a - 130.1 
C-3a’ - 121.8 
C-4 3.25 23.7 
C-4’ 3.23 30.8 
C-5 3.31 93.5 
C-5’ 3.32 94.2 
C-6a - 192.7 
C-6a’ - 192.6 
C-7 - 106.7 
C-7’ - 108.4 
C-7a - 132.6 
C-7a’ - 133.4 
C-8 7.15 122.5 
C-8’ 7.19 123.4 
C-9 7.23 127.3 
C-9’ 7.25 126.9 
C-10 7.89 123.7 
C-10’ 7.34 124.0 
C-11 9.58 127.4 
C-11’ 9.73 128.1 
C-11a,C-11a’ - 122.98 
1-OMe 4.01 60.4 
1’-OMe 4.00 59.9 
2-OMe 4.07 60.9 
2’-OMe 4.08 56.5 
3-MeO 4.16 61.3 
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Table 3.11: HMBC correlations of ECP-23 
Position 1H (ppm) 13C (ppm) 
4 3.25 93.4(5) 
4’ 3.22 94.2(5’),111.9(3’),121.8(1b’) 
5 3.31 130.1(3a),192.6(6a) 
5’ 3.33 192.6(3a’) 
8 7.15 106.7 (7),133.4(7a) 
8’ 7.19 126.9(9’),122.98(11a’) 
9 7.25 133.6(7a) 127.2(11),122.5 (8) 
10’ 7.89 123.4(8’) 
11 9.58 122.98(11a),132.6(7a),127.3(9) 
11’ 9.66 126.4(9’),133.4(7a’) 
1-OMe 4.02 148.4(1) 
1’-OMe’ 4.00 145.6(1’) 
2-OMe 4.07 151.6(2) 
2-OMe’ 4.09 151.2(2’),111.9(3’) 
3-OMe 4.14 146.8(3), 
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3.1.8: Characterization of Compound 94: ECH-B 17-18 (Urabaine) 
It was extracted from E. chlorantha stem bark as brown residue with conditions described in Table 
3.1. 
                                                 Urabaine             
NH
H3CO
H3CO
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OCH3
 
1,1',2,2'-tetramethoxy-6-methyl-5,5',6,6'-tetrahydro-4H,4'H-7,7'-bidibenzo[de,g]quinoline 
                                                                              (94) 
The 1H  NMR Spectrum (Figure 3.27) indicated an aporphinoid alkaloid which was substituted at 
position C-1, C-2. Signals centred at (9.68 ppm (doublet J=8.91 Hz, H-11), δH 7.89 ppm (H-10 
multiplet), 7.24 ppm (H-9 multiplet), and 7.19 ppm doublet (J=7.98 Hz) completing the substitu-
tion pattern in ring D. There were also as well as two methoxys (4.02 ppm and 4.09 ppm) in Ring 
A. Ring B had aliphatic protons between 3.21 2H-4,2H-4’ multiplet),3.32 (2H-5,2H-5’ doublet of 
doublet J= 6.83,21.06), completing  ring A’s substitution  was aromatic singlet  proton H-3 δH 7.14. 
There were four aliphatic protons between 3.20 and 3.32 ppm.  
 
[139] 
 
 
Figure 3.27: 1H NMR Spectrum (400MHz, CDCl3) of ECHB 17-18 
The COSY 2D NMR Spectrum, Figure 3.28 showed the highly deshielded proton 9.68ppm was ortho-
coupling with position 10’s 1H (7.89 ppm).  
 
                   Figure 3.28: COSY NMR Spectrum (400MHz, CDCl3) of ECHB 17-18 
[140] 
 
The 2D NMR HSQC Figure Figure 3.29 showed1J 1H -13C coupling as shown in Table 3.12. 
 
 
               Figure 3.29: HSQC NMR Spectrum (400MHz, CDCl3) of ECHB 17-18 
 
 
The 13 C NMR Spectrum, Figure 3.28 shown with chemical shifts  as shown in Table 3.12  correlates 
with a monomeric  aporphinoid alkaloid with  five aromatic methines(111.9 ppm,122.7 ppm, 123.8 
ppm,127.3 ppm,and 128.2 ppm),two methylene (93.97 ppm and 30.7 ppm ), and two methoxy carbons 
(56.5 ppm and 60.0 ppm).  It had nine quaternary carbons (151.5 ppm, 145.7 ppm, 193.0 ppm, 133.7 
ppm, 130.4 ppm, 126.4 ppm, 125.8 ppm, 118.1 ppm, and 106.7 ppm). 
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Figure 3.30: 13C NMR Spectrum (400MHz, CDCl3) ECHB 17-18 
 
HMBC correlations revealed the most deshielded aromatic proton δH 9.68 H-11 had 3J correlations to 
quaternary carbons C-1a, C-7a and aromatic methine C-9. While H-10 aromatic proton δH 7.89 showed 
3J coupling to aromatic methine C-8 and 2J coupling to the C-11 aromatic methine. The H-9 aromatic 
proton showed 3J correlations to  aromatic methine C-11 and quaternary carbon C-7a.Completing the D 
ring correlations H-8 showed 3J correlations to aromatic methine C-10, quaternary carbon C-11a as 
well as quaternary carbon C-7, δC  106.7 ppm, indicating  a possible  structure of a dimer of two units 
[142] 
 
joined by a C-7/C-7’ bridge.
 
Figure 3.31a: HMBC NMR (400MHz, CDCl3) of ECHB 17-18 
 
Ring B bore two aliphatic protons H-4 and H-5, the HMBC Spectrum (Figure 3.31a) revealed they had 
2J correlations to each other, H-5 also had 3J couplings to quaternary carbons C-3a and C-6a. While 
ring A bore the two methoxys which showed strong 3J couplings to their respective aromatic oxygenat-
ed carbons. Ring A aromatic proton H-3 showed3J correlations to quaternary carbon C-1b and C-1, as 
well as 2J correlations to quaternary carbon C-2. Other correlations as shown in Table 3.13. The as-
signments of Urabaine was similar to previously isolated one from Oxandra CF Major ethyl acetate 
extract Arango (1986). The differences in assignments were the C-7/C-7’ quaternary carbon which was 
106.7 ppm in this study compared to Arango et al., 120.4 ppm.  Also the aromatic methine C-11 was 
the most aromatic deshieded carbon at 128.2 ppm compared to 122.4 ppm reported by Arango et al., 
(1986). In this present study Urabaine was obtained as a dark brown powder and ESI MS Spectrum 
gave a quasi-molecule at 557.65 (M+H) + indicating a molecular mass of 556. This indicated the alka-
loid as a symmetrical dimer rather than a monomer  with predicted  molecular formula of C89H32O4 N2 
with two dehyronornuciferine units. 
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Table 3.12 1H and 13C correlations of  Urabaine                                  
Position 1H (ppm) 13C (ppm) 
C-1 - 145.7 
C-1’ - 1457 
C-1a - 126.4 
C-1a’ - 126.4 
C-1b - 118.1 
C-1b’ - 118.1 
C-2 - 151.5 
C-2’ - 151.5 
C-3 7.14 111.9 
C-3’ 7.14 111.9 
C-3a - 130.4 
C-3a’ - 130.4 
C-4 3.21 30.9 
C-4’ 3.21 30.9 
C-5 3.32 93.97 
C-5’ 3.32 93.97 
C-6a - 193.0 
C-6a’ - 193.0 
C-7 - 106.7 
C-7’ - 106.7 
C-7a - 133.7 
C-7a’ - 133.7 
C-8 7.19 123.8 
C-8’ 7.19 123.8 
C-9 7.24 127.3 
C-9’ 7.24 127.3 
C-10 7.89 122.7 
C-10’ 7.89 122.7 
C-11 9.68 128.2 
C-11’ 9.68 128.2 
C-11a - 125.8 
C-11’a - 125.8 
1-OMe 4.02 60.0 
1’-OMe 4.02 60.0 
2-OMe 4.09 56.5 
2’-OMe 4.09 56.5 
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Table 3.13 HMBC correlations of Urabaine                                  
Position 1H 13C 
3 7.14 118.1(1b),30.9(4),151.5(2),145.7(1) 
4 3.21 93.97(5) 
5 3.32 193(6a),130.4(3a),30.9(4) 
8 7.19 122.7(10),125.8(11a),106.7(7) 
9 7.24 128.2(11),133.7(7a) 
10 7.89 128.2(11),123.8(8) 
11 9.68 127.3(9)133.6(7a),126.4(1a) 
1-OMe 4.01 145.7(1),151.5(2) 
2-OMe 4.08 151.5(2),145.7(1) 
 
 
Table 3.14: Molecular modelling results 
Compound 
Binding Affinity Scale [ 1 (Best) to 7(Least)] 
3TIK 2RM6 2RM5 2WYO 1QU4 3BNW 2WOI 
( 81) 6 4 5 3 1 2 7 
(82) 6 4 5 3 1 2 7 
(83) 6 4 5 3 2 1 7 
(84) 6 4 5 3 1 2 7 
 (85) 5 4 6 3 1 2 7 
 (86) 3 6 1 2 4 5 7 
 (87) 6 4 5 3 1 2 7 
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Molecule 
Binding Affinity Scale [ 1 (Best) to 7(Least)] 
3TIK 2RM6 2RM5 2WYO 1QU4 3BNW 2WOI 
(41) 4 6 2 5 1 3 7 
 
Decoded PDBs used in the docking studies: 
2WYO : Trypanosoma brucei Glutathione Synthetase 
2RM5: Glutathione peroxidase-type tryparedoxin peroxidase, oxidized form  
2RM6: Glutathione peroxidase-type tryparedoxin peroxidase, reduced form  
3TIK: Sterol 14-alpha demethylase (CYP51) from Trypanosoma brucei in complex with the tipifarnib 
derivative 6-((4-chlorophenyl) (methoxy) (1-methyl-1H-imidazol-5-yl)methyl)-4-(2,6-difluorophenyl)-
1-methylquinolin-2(1H)-one 
1QU4:  Trypanosoma brucei ornithine decarboxylase  
3BNW: Riboflavin kinase from Trypanosoma brucei 
2WOI: Trypanothione reductase from Trypanosoma brucei 
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Fig 3.32: Active Site for palmatine on 2WOI.tiff (Trypanosoma brucei Glutathione Synthetase) 
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Fig. 3.33: 2D interactions  of palmatine’s protein with 2WOI ligand (Trypanosoma brucei Glutathione 
Synthetase) 
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Fig. 3.34: Active Site for palmatine on 3BNW.tiff (Riboflavin kinase from Trypanosoma brucei) 
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Fig 3.35: Active Site for palmatine on 1QU4.tiff (Trypanosoma brucei ornithine decarboxylase) 
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Fig. 3.36: Active Site for palmatine on 3TIK.tiff (Sterol 14-alpha demethylase (CYP51) from Trypa-
nosoma brucei in complex with the tipifarnib derivative 6- ) (4-chlorophenyl) (methoxy) (1-methyl-1H-
imidazol-5-yl) methyl)-4-(2, 6-difluorophenyl)-1-methylquinolin-2(1H)-one) 
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Figure 3.37: 2D Interaction of palmatine’s protein  3TIK ligand  (Sterol 14-alpha demethylase 
(CYP51) from Trypanosoma brucei in complex with the tipifarnib derivative 6- ) (4-chlorophenyl) 
(methoxy) (1-methyl-1H-imidazol-5-yl) methyl)-4-(2, 6-difluorophenyl)-1-methylquinolin-2(1H)-one) 
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Fig. 3.38: Active Site for palmatine on 2RM5.tiff (Glutathione peroxidase-type  tryparedoxin peroxi-
dase, oxidized form) 
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Fig. 3.39: 2D Interactions of palmatine protein  with 2RM5 ligand 
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Fig. 3.40: Active Site for palmatine on 2RM6.tiff (Glutathione peroxidase-type tryparedoxin peroxi-
dase, reduced form) 
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Fig. 3.41: 2D Interaction palmatine’s protein with 2RM6 ligand (Glutathione peroxidase-type try-
paredoxin peroxidase, reduced form) 
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Fig. 3.42: Active Site for palmatine on 2WYO.tiff (Trypanosoma brucei Glutathione Synthetase). 
 
 
[157] 
 
 
 
Fig. 3.43: Interactions of palmatine’s protein  with 2WYO ligand (Trypanosoma brucei Glutathione 
Synthetase) 
 
 
Table 3.15 Docking studies  results of Palmatine 
 
Molecule 
PLP Score(Docking Score) 
3TIK 2RM6 2RM5 2WYO 1QU4 3BNW 2WOI 
Palmatine -66.33 -48.55 -77.68 -54.69 -81.71 -69.88 265.51 
Glutathione(GSH) ND ND ND -56.54 ND ND ND 
Tipifarnib Derivative(JKF) -98.96 ND ND ND ND ND ND 
 
Molecule 
Binding Affinity Scale [ 1 (Best) to 7(Least)] 
3TIK 2RM6 2RM5 2WYO 1QU4 3BNW 2WOI 
Palmatine 4 6 2 5 1 3 7 
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This docking studies revealed palmatine had the strongest affinity towards ornithine decarboxylase of 
Trypanosoma brucei brucei of the seven validated protein target docked. Riboflavin kinase, try-
paredoxin peroxidase (oxidized form) and sterol 14α-demethylase showed significant affinity as poten-
tial targets of palmatine. It will also be safe to hypothesize that there would be minimal like hood for 
Trypanosoma brucei brucei to express resistance against palmatine since it is multiple targeted.  
Docking studies of Palmatine with Trypanothione reductase from Trypanosoma brucei (2WOI) 
Palmatine was found to have van der waals interactions with Glu489C, Ile490C, Ile491C, Gln492C, 
Ala493C, Val494C, Phe454C, Ala465C, Glu466C, Glu467C, Leu468C, Cys469C, Glu489D, Ile490D, 
Ile491D, Gln492D, Ala493D, Val494D, Phe454D, Ala465D, and Leu468D. It also had hydrophobic 
interactions with Glu489C, Ile490C, Gln492C, Ala465C, Glu466C, Leu468C, Cys469C, Leu429D, 
Glu489D, Ile490D, Ile491D, Gln492D, Ala493D, Val494D, Val443D, and Ala465D, Leu468D amino 
acid residues of 2WOI and hydrogen bonding with Gln492C of Trypanothione reductase of T. bruce 
brucei. 
Docking studies of Palmatine with riboflavin kinase of T. brucei (3BNW) 
Palmatine was found to have van der waals interactions with Phe29B, Pro30B, Thr31B, Val51B, 
Ser77B, Glu92B, Tyr94B, Arg117B, Phe122B, Ile132B, Asp135B as well as hydrophobic interactions 
with Phe29B, Pro30B, Thr31B, Val51B, Ala75B, Leu128B, Ile132B, Asp135B amino acid residues of 
riboflavin kinase of T. brucei.brucei. In addition, palmatine also had aromatic interaction with Tyr94B, 
charge interaction with Glu92B and hydrogen bonding with Arg117B of 3BNW.   
Docking studies of Palmatine with ornithine decarboxylase of T. brucei. (1QU4) 
Palmatine was found to have van der waals interactions with Leu893C, Ser200D, Gly201D, Arg277D, 
Tyr331D, Asp332D, His333D, Ala334D, Val335D and hydrophobic interactions with Leu893C, 
Gly199D, Ser200D, Gly201D, Asp332D, His333D, Ala334D, Val335D amino acid residues of orni-
thine decarboxylase of T. brucei.brucei.  Palmatine also had aromatic interaction with His333D amino 
acid residues of 1QU4.  
Docking studies of Palmatine with sterol 14-alpha demethylase (3TIK) 
Palmatine had van der waals interactions with Tyr103A, Phe105A, Met106A, Pro210A, Val213A, 
Phe290A, Ala291A, Met890A, Met460A, Val461A, Hem482A and hydrophobic interactions with 
Met106A, Pro210A, Val213A, Phe290A, Ala291A, Leu356A, Met890A, Met460A, Val461A amino 
acid residues of sterol 14-α demethylase i.e. 3TIK. Reference ligand i.e.  tipifarnib derivative was 
found to have van der waals interactions with Tyr103A, Phe105A, Met106A, Phe110A, Ala115A, 
Tyr116A, Leu127A, Glu205A, Leu208A, Ala287A, Phe290A, Ala291A, Thr295A, Leu356A, 
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Met358A, Cys422A, Met460A, Val461A, Hem482A and  hydrophobic interactions with Met106A, 
Leu208A, Ala287A, Phe290A, Ala291A, Thr295A, Leu356A, Leu359A, Met460A, Val461A, 
Hem482A amino acid residues of 3TIK. It also had hydrogen bonding with Hem482A of sterol 14-α 
demethylase.    
Docking studies of Palmatine with Glutathione peroxidase type tryparedoxin peroxidase, oxi-
dized form (2RM5) 
Palmatine was found to have van der waals interactions with Ala44A, Lys46A, Cys47A, Gly48A, 
Tyr49A, Thr50A, Tyr54A, Glu55A, Phe98A and hydrophobic interactions with Ala44A, Lys46A, 
Cys47A, Gly48A, Tyr49A, Thr50A, Tyr54A, Phe98A amino acid residues of glutathione peroxidase 
type tryparedoxin peroxidase, oxidized form. Palmatine also had aromatic interaction  with Tyr49A 
and hydrogen bonding with Cys47A of 2RM5.  
Docking studies of Palmatine with Glutathione peroxidase type tryparedoxin peroxidase, re-
duced form(2RM6) 
Palmatine exhibited van der waals interactions with Lys126A, Ile129A, Arg153A, Phe154A, Ser155A, 
Gly157A, Ala158A and hydrophobic interactions with Ile129A, Phe154A, Ser155A, Pro156A, 
Gly157A, Ala158A amino acid residues of 2RM6. In addition, palmatine also had hydrogen bonding 
with Ser155A of glutathione peroxidase type tryparedoxin peroxidase, reduced form.  
 Docking studies of Palmatine with Trypanosoma brucei Glutathione Synthetase(2WYO) 
Palmatine’s docking studies also revealed van der waals interactions with Met29A, Arg119A, 
Asn145A, Ile147A, Ser150A, Phe151A, Glu264A, Arg265A, Asn266A, Tyr327A and hydrophobic 
interactions with Met29A, Asn145A, Ile147A, Arg265A, Asn266A, Tyr327A amino acid residues of 
glutathione synthetase of T. brucei brucei. It also had aromatic interactions with Tyr327A of 2WYO.  
 
3.2.1 Further docking studies of Aporphine Alkaloids 
Fourteen aporphine alkaloids comprising of the eight whose structure elucidation were discussed in 
details in the thesis, as well as six derivative monomeric alkaloids were subjected to molecular model-
ling studies at the University of Strathclyde. Their structures as shown here below 
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1. ECP-23 (86) 
NH
MeO
MeO
H
HN
OMe
OMe
OMe
1,1',2,2',3-pentamethoxy-5,5',6,6'-tetrahydro-4H ,4'H-7,7'-bidibenzo[de,g]quinoline  
 
 
 
2. ECP-19 (82) 
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NH
MeO
MeO
H
MeN
OMe
OMe
OMe
1,1',2,2',3-pentamethoxy-6-methyl-5,5',6,6'-tetrahydro-4H ,4'H-7,7'-
bidibenzo[de,g]quinoline  
 
 
 
3. ECHB17-18 (87) 
NH
H3CO
H3CO
HN
OCH3
OCH3
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4.  ECH 56 (84) 
 
NH
MeN
OMe
OMe
OMe
O
O
8-(1,2,3
-trimethoxy-6-methyl-5,6-dihydro-4H-dibenzo[de,g]quinolin
-7-yl)
-6,7-dihydro-
5H-[1,3]dioxolo[4',5':4,5]benzo[1,2,3
-de]benzo[g]quinoline  
5. ECHE 45 (83)   
 
NH
HN
OMe
OMe
OMe
O
O
8-(1,2,3
-trimethoxy-5,6-dihydro-4H-dibenzo[de,g]quinolin
-7-yl)
-6,7-dihydro-5H-
[1,3]dioxolo[4',5':4,5]benzo[1,2,3
-de]benzo[g]quinoline  
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6. Compound 88   
NMe
MeN
O
O
O
O
7,7'-dimethyl-6,6',7,7'-tetrahydro-5H ,5'H-8,8'-bi[1,3]dioxolo[4',5':4,5]benzo[1,2,3
-
de]benzo[g]quinoline  
 
 
 
7. Compound 89  
 
NMe
MeN
O
O
MeO
MeO
H
8-(1,2
-dimethoxy-6-methyl-5,6-dihydro-4H-dibenzo[de,g]quinolin
-7-yl)
-7-methyl-6,7-
dihydro-5H-[1,3]dioxolo[4',5':4,5]benzo[1,2,3
-de]benzo[g]quinoline  
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8. Compound 90   
NMe
MeN
O
O
MeO
MeO
OMe
7-methyl-8-(1,2,3
-trimethoxy-6-methyl-5,6-dihydro-4H-dibenzo[de,g]quinolin
-7-yl)
-6,7-
dihydro-5H-[1,3]dioxolo[4',5':4,5]benzo[1,2,3
-de]benzo[g]quinoline  
9. ECP 17 (81) 
 
NH
MeO
MeO
OMe
HN
OMe
OMe
OMe
1,1',2,2',3,3'-hexamethoxy-5,5',6,6'-tetrahydro-4H ,4'H-7,7'-bidibenzo[de,g]quinoline  
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10. Compound 91 
NH
MeO
MeO
H
1,2-dimethoxy-5,6-dihydro-4H-dibenzo[de,g]quinoline
 
11. Compound 92 
 
 
 
HN
O
O
6,7-dihydro-5H-[1,3]dioxolo[4',5':4,5]benzo[1,2,3
-de]benzo[g]quinoline  
12. Compound 93 
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NMe
MeO
MeO
OMe
1,2,3-trimethoxy-6-methyl-5,6-dihydro-4H-dibenzo[de,g]quinoline
 
13. Compound 94 
NMe
MeO
MeO
H
1,2-dimethoxy-6-methyl-5,6-dihydro-4H-dibenzo[de,g]quinoline
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14.  ECF 5-10 (85) 
N
O
OCH3
H3CO
H3CO
1,2,3-trimethoxy-7H-dibenzo[de,g]quinolin
-7-
one
1
 
2
3
3a
 
4
 
5
6a
 
7
9
10
 
11
 
 
 
  
 
 
15. Compound 95 
MeN
O
O
7-methyl-6,7-dihydro-5H-[1,3]dioxolo[4',5':4,5]benzo[1,2,3
-de]benzo[g]quinoline  
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Table 3.16 Docking studies results of alkaloids isolated in this study 
Compound 
Binding Affinity Scale [ 1 (Best) to 7(Least)] 
3TIK 2RM6 2RM5 2WYO 1QU4 3BNW 2WOI 
86 6 4 5 3 1 2 7 
82 6 3 5 4 1 2 7 
87 6 3 5 4 1 2 7 
84 6 4 5 3 1 2 7 
83 6 4 5 3 1 2 7 
88 6 4 5 2 1 3 7 
89 6 4 5 3 2 1 7 
90 5 4 6 3 1 2 7 
81 `1 4 5 3 1 2 7 
91 1 6 3 4 2 5 7 
92 1 6 3 4 2 5 7 
93 1 6 4 3 2 5 7 
94 3 6 1 2 4 5 7 
85 1 6 2 4 3 5 7 
95 1 6 4 3 2 5 7 
 
  For all aporphine alkaloids docked except Compounds 85 & 93, ornithine decarboxylase of Trypano-
soma brucei brucei was the preferred target for anti-trypanosomal activity. Compounds 90, 91, 92, 93 
& 94 considerably showed significant binding affinity towards Sterol 14-alpha demethylase (CYP51).  
Riboflavin kinase of Trpanosoma brucei was also a significant targeted protein for compounds 81-89.  
None of the tested phytoconstituents expressed affinity for Trypanothione reductase of Trypanosoma 
brucei brucei. 
Docking studies of aporphine alkaloids with Riboflavin kinase of T. brucei.brucei 
Compound (86) was found to have Van der waals interactions with Ser25B, Leu27B, Pro30B, Tyr94B, 
Phe122B, Leu125B, Leu128B, Ile132B amino acid residues and hydrophobic interactions with 
Ser25B, Leu27B, Pro30B, Tyr94B, Leu128B and Ile132B amino acid residues of riboflavin kinase i.e. 
3BNW. Compound (82)was found to have Vdw interactions with Phe29B, Pro30B, Thr31B, Ala75B, 
Tyr94B, Leu96B, Leu128B, Ile132B amino acid residues and hydrophobic interactions with Ser25B, 
Pro30B, Ala75B, Tyr94B, Leu96B, Leu125B, Leu128B, Ile132B, and Val189B amino acid residues of 
riboflavin kinase. Along with these, Compound (82) also exerted aromatic interactions with Tyr94B of 
3BNW. Compound (81) was found to have Vdw interactions with Ser25B, Leu27B, Phe29B, Pro30B, 
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Thr31B, Val51B, Ala75B, Ala76B, Tyr94B, Arg117B, Phe122B, Leu128B, Ile132B, Val189B amino 
acid residues and hydrophobic interactions with Ser25B, Leu27B, Pro30B, Val51B, Ala75B, Ala76B, 
Tyr94B, Leu125B, Leu128B, Ile132B, Asp135B, Val189B amino acid residues of riboflavin kinase. 
Compound 81 also had aromatic interactions with Tyr94B of 3BNW. Compound (83) was found to 
have Vdw interactions with Leu27B, Phe29B, Pro30B, Ser77B, Tyr94B, Phe122B, Leu128B, Ile132B 
amino acid residues and hydrophobic interactions with Phe29B, Pro30B, Ser77B, Tyr94B, Met119B, 
Leu128B, and Ile132B amino acid residues of riboflavin kinase. Compound 84  was found to have 
Vdw interactions with Leu27B, Phe29B, Pro30B, Thr31B, Ser77B, Glu92B, Tyr94B, Leu128B, 
Val129B, Ile132B amino acid residues and hydrophobic interactions with Phe29B, Pro30B, Thr31B, 
Glu92B, Tyr94B, Ile132B amino acid residues of riboflavin kinase. Compound 84 also had aromatic 
interactions with Tyr94B of 3BNW.  Compound 85 was found to have Vdw interactions with Ser25B, 
Phe29B, Pro30B, Thr31B, Tyr94B, Phe122B, leu128B, Ile132B amino acid residues and hydrophobic 
interactions with Ser25B, Pro30B, Thr31B, Val51B, Ser77B, Tyr94B, Ile132B amino acid residues of 
riboflavin kinase. Compound 89 was found to have Vdw interactions with Ser25B, Phe29B, Pro30B, 
Thr31B, Ala75B, Ser77B, Tyr94B, Phe122B, Leu128B, Ile132B, Asp135B amino acid residues and 
hydrophobic interactions with Ser25B, Pro30B, Thr31B, Ala75B, Ser77B, Tyr94B, Ile132B, Asp135B, 
Val189B amino acid residues of riboflavin kinase. In addition to these, compound 89 do exert aromatic 
interactions with Tyr94B of 3BNW. Compound 87 was found to have Vdw interactions with Ser25B, 
Phe29B, Pro30B, Thr31B, Val51B, Ala75B, Tyr94B, Leu96B, Arg117B, Leu128B, Ile132B, 
Asp135B, Val189B amino acid residues, while Compound 87 also had hydrophobic interactions with 
Ser25B, Leu27B, Phe29B, Pro30B, Thr31B, Val51B, Ala75B, Tyr94B, Leu96B, Leu128B, Ile132B, 
Val189B amino acid residues of riboflavin kinase.  Compound 87 had charge interactions with 
Arg117B of 3BNW. Compound 88 was found to have Vdw interactions with Leu27B, Pro30B, 
Thr31B, Tyr94B, Phe122B, Leu128B, Val129B, Ile132B amino acid residues and hydrophobic interac-
tions with Pro30B, Tyr94B, Ser121B, Leu128B, Val129B, Ile132B and Val189B amino acid residues 
of 3BNW. Compound 90 was found to have Vdw interactions with leu27B, Pro30B, Tyr94B, 
Leu125B, Leu128B, Ile132B amino acid residues and hydrophobic interactions with Leu27B, Pro30B, 
Tyr94B, Ile132B amino acid residues of riboflavin kinase. Compound 91 was found to have Vdw in-
teractions with Leu27B, Pro30B, Tyr94B, Phe122B, Leu125B, Leu128B, Ile132B amino acid residues 
and hydrophobic interactions with Pro30B, Tyr94B, Leu128B, Ile132B amino acid residues of 3BNW. 
Compound 92 was found to have Vdw interactions with Ser25B, Leu27B, Phe29B, Pro30B, Leu125B, 
Leu128B, Ile132B amino acid residues and hydrophobic interactions with Leu27B, Pro30B, Tyr94B, 
Leu125B, Leu128B, Ile132B amino acid residues of riboflavin kinase. Compound 93 was found to 
have Vdw interactions with Pro30B, Thr31B, Ser77B, Glu92B, Tyr94B, Met119B and Ile132B amino 
acid residues and hydrophobic interactions with Pro30B, Thr31B, Val51B, Ser77B, and Met119B ami-
no acid residues of riboflavin kinase.  Compound 85 was found to have Vow interactions with Ser25B, 
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Leu27B, Phe29B, Pro30B, Phe122B, Leu128B, Ile132B amino acid residues and hydrophobic interac-
tions with Ser25B, Leu27B, Phe122B, Leu125B, Leu128B, Ile132B amino acid residues of 3BNW. 
Compound 94 was found to have Vdw interactions with Leu27B,Phe29B, Pro30B, Tyr94B, Leu128B, 
Ile132B amino acid residues and hydrophobic interactions with Leu27B, Pro30B, Tyr94B, Leu125B, 
Leu128B, Ile132B amino acid residues of 3BNW i.e. riboflavin kinase.    
Docking studies of aporphine alkaloids with ornithine decarboxylase of T. brucei. 
Compound 81 was found to have Vdw interactions with Gly201D, Thr203D, Pro292D, Gly293D, 
Thr294D, Ala244D, Pro245D, Arg277D, Asp332D, His333D amino acid residues and hydrophobic 
interactions with Ser200D, Gly201D, Pro292D, Gly293D, Thr294D, Ala244D, Ala281D, His333D, 
Ala334D amino acid residues of 1QU4 i.e. ornithine decarboxylase of T. brucei. Compound 81 was 
also found to have aromatic interactions with His333D and charge interaction with Arg277D. Com-
pound 82 was found to have Vdw interactions with Ser200D, Gly201D, Thr203D, Pro292D, Gly293D, 
Thr294D, Ala244D, Pro245D, Arg277D, Ala281D, Asp332D, His333D amino acid residues and hy-
drophobic interactions with Ser200D, Gly201D, Pro292D, Gly293D, Thr294D, Ala244D, Pro245D, 
Leu246D, Arg277D, Ala281D, Asp332D, His333D and Ala334D of 1QU4. Also Compound 82 had 
aromatic interactions with His333D and charge interactions with Arg277D amino acid residues of T. 
Bruce ornithine decarboxylase. Compound 83 was found to have Vow interactions with Leu166D, 
His197D, Val198D, Gly199D, Ser200D, Gly201D, Thr294D, Arg277D, Ala281D, Asp332D, 
His333D, Ala334D, Val335D and Asp915D amino acid residues and hydrophobic interactions with 
Leu166D, Gly199D, Ser200D, Gly201D, Ser202D, Pro292D, Gly293D, Thr294D, Arg277D, 
Ala281D, Ala334D, Val335D, Val919D, Asp915D and Ala918D amino acid residues of ornithine de-
carboxylase. Compound 83 was also found to have charge interactions with Arg277D and hydrogen 
bonding with Ser200D and Val335D amino acid residues of 1QU4. Compound 83 was found to have 
Vow interactions with Gly201D, Thr203D, Pro292D, Gly293D, Thr294D, Ala244D, Pro245D, 
Leu246D, Arg277D, Asp332D, His333D amino acid residues and hydrophobic interactions with 
Gly201D, Pro292D, Gly293D, Thr294D, Ala244D, Pro245D, Leu246D, Arg277D, Ala281D and 
His333D amino acid residues of 1QU4. Compound 83 also had charge interactions with Arg277D and 
aromatic interaction with His333D amino acid residues of ornithine decarboxylase of T. Bruce. Com-
pound 84 was found to have Vow interactions with Ser200D, Gly201D, Thr203D, Pro292D, Gly293D, 
Thr294D, Ala244D, Pro245D, Arg277D, Asp332D, His333D amino acid residues and hydrophobic 
interactions with Ser200D, Gly201D, Pro292D, Gly293D, Thr294D, Ala244D, Arg277D, Ala281D, 
Asp332D, His333D amino acid residues of ornithine decarboxylase. It also had  aromatic interaction 
with His333D and charge interactions with Arg277D amino acids of 1QU4. Compound 85 was found 
to have Vow interactions with Leu166D, Gly199D, Ser200D, Gly201D, Arg277D, Asp332D, 
His333D, Val335D, Arg920D amino acid residues and hydrophobic interactions with Leu166D, 
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Gly199D, Gly201D, Ser202D, Thr203D, His333D, Val335D amino acid residues of 1QU4. Compound 
85 was also found to have charge interactions with Arg277D and hydrogen bonding with Ser200D of 
ornithine decarboxylase. Compound 86 was found to have Vow interactions with Leu166D, Val198D, 
Ser200D, Gly201D, Ala244D, Pro245D, Arg277D, Asp332D, His333D, Val335D, Arg920D amino 
acid residues and hydrophobic interactions with Leu893C, Leu166D, Gly201D, Ser202D, Thr203D, 
His333D, Val335D amino acid residues of ornithine decarboxylase. Compound 86 was also found to 
have charge interaction with Arg277D of 1QU4. Compound 90 had Vow interactions with Leu893C, 
Leu166D, Val198D, Gly199D, Ser200D, Gly201D, Thr203D, Ala244D, Pro245D, Arg277D, 
Asp332D, His333D, Val335D and Arg920D amino acid residues and hydrophobic interactions with 
Leu893C, Leu166D, Val198D, Gly199D, Ser200D, Gly201D, Ser202D, His333D, Val335D amino 
acid residues of 1QU4. It also had hydrogen bonding with Arg920D of ornithine decarboxylase. Com-
pound 87 was found to have Vow interactions with Thr157D, Leu166D, Gly199D, Ser200D, Gly201D, 
Pro292D, Arg277D, Asp332D, His333D, Ala334D and Val335D amino acid residues and hydrophobic 
interactions with Leu166D, Ser167D, Val198D, Gly199D, Ser200D, Gly201D, Ser202D, Pro292D, 
Thr294D, Ala244D, Arg277D, Ala281D, Asp332D, His333D, Ala334D amino acid residues of orni-
thine decarboxylase of T. brucei. Compound 87 also had charge interactions with Arg277D and hydro-
gen bonding with Leu166D, Gly201D and Arg277D amino acid residues of 1QU4. Compound 88 was 
found to have Vdw interactions with Gly199D, Ser200D, Gly201D, Arg277D, Asp332D, His333D 
amino acid residues and hydrophobic interactions with Leu166D, Gly199D, Ser200D, Ser202D, 
Thr203D amino acid residues of 1QU4. Compound 88 also had hydrogen bonding with Ser200D ami-
no acid residues. Compound 89 was found to have Vdw interactions with Gly199D, Ser200D, 
Gly201D, Arg277D, Asp332D, His333D amino acid residues and hydrophobic interactions with 
Leu166D, Gly199D, Ser200D, Thr203D amino acid residues of ornithine decarboxylase. In addition to 
these, Compound 89 was also found to have charge interactions with Arg277D and hydrogen bonding 
with Ser200D amino acid residues of 1QU4. Compound 90 was found to have Vdw interactions with 
Ser200D, Arg277D, Asp332D, His333D, Ala334D, Val335D amino acid residues and hydrophobic 
interactions with Ser200D, Gly201D, Arg277D, Asp332D, His333D and Val335D amino acid residues 
of 1QU4. Compound 94 also had aromatic interactions with His333D, charge interactions with Arg277 
and hydrogen bonding with Arg277D amino acid residues of ornithine decarboxylase. Compound 91 
was found to have Vdw interactions with Val198D, Ser200D, Gly201D, Ser202D, Arg277D, His333D 
amino acid residues and hydrophobic interactions with Gly199D, Ser200D, Gly201D and His333D 
amino acid residues of ornithine decarboxylase. Compound 92 was found to have Vdw interactions 
with Ser200D, Arg277D, Asp332D, His333D, Ala334D, Val335D amino acid residues and hydropho-
bic interactions with Ser200D, Arg277D, Cys328D, Asp332D, His333D, Ala334D, Val335 amino acid 
residues of ornithine decarboxylase. Compound 92 also had charge interaction with Arg277D and hy-
drogen bonding with Arg277D and Val335D of 1QU4. Compound 93 was found to have Vdw interac-
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tions with Leu166D, Gly199D, Ser200D, Gly201D, Arg277D, Asp332D amino acid residues and hy-
drophobic interactions with Leu166D, Gly199D, Ser200D, Gly201D, Ser202D, Thr203D amino acid 
residues of 1QU4. It was also found to have charge interactions with Arg277D and hydrogen bonding 
with Ser200D. 
Docking studies of aporphine alkaloids with sterol 14-alpha demethylase (3TIK) 
Compound 81 was found to have Vdw interactions with Tyr103A, Phe105A, Met106A, Phe110A, 
Ala115A, Tyr116A, Leu127A, Leu130A, Pro210A, Met284A, Val286A, Ala287A, Ala288A, 
Phe290A, Ala291A, Thr295A, Leu356A, Met460A, Val461A, Hem482A amino acid residues and hy-
drophobic interactions with Tyr103A, Met106A, Ala115A, Met123A, Leu127A, Leu130A, Pro210A, 
Met284A, Ala287A, Ala288A, Phe290A, Ala291A, Met890A, Met460A, Val461A, Pro224D, 
Hem482A amino acid residues of sterol 14-alpha demethylase of  T. brucei.  Compound 81 was also 
found to have aromatic interactions with Phe110A, Hem482A and charge interactions with Hem482A 
of 3TIK. Compound 82 was found to have Vdw interactions with Tyr103A, Phe105A, Met106A, 
Phe110A, Leu127A, Leu130A, Pro210A, Met284A, Ala287A, Ala288A, Phe290A, Ala291A, 
Thr295A, Leu356A, Met358A, Met890A, Thr459A, Met460A, Hem482A residues and hydrophobic 
interactions with Tyr103A, Ala115A, Leu127A, Leu130A, Pro210A, Met284A, Ala287A, Ala288A, 
Ala291A, Leu356A, Met358A, Leu359A, Met890A, Ile423A, Met460A, Val461A, Hem482A residues 
of 3TIK. In addition to these, Compound 82 had aromatic interactions with Phe110A, Hem482A and 
charge interactions with Hem482A of sterol 14-alpha demethylase. Compound 83 was found to have 
Vdw interactions with Tyr103A, Phe105A, Met106A, Phe110A, Val114A, Ala115A, Tyr116A, 
Leu127A, Leu130A, Pro210A, Gly283A, Met284A, Ala287A, Ala288A, Phe290A, Ala291A, 
Leu356A, Met358A, Met890A, Ile423A, Met460A, Hem482A residues and hydrophobic interactions 
with Tyr103A, Phe105A, Met106A, Phe110A, Val114A, Ala115A, Leu127A, Leu130A, Pro210A, 
Gly283A, Met284A, Ala287A, Ala288A, Ala291A, Leu356A, Met358A, Leu359A, met890A, 
Ile423A, Met460A, Hem482A residues of sterol 14-alpha demethylase.  Compound 83 also had aro-
matic interactions with Phe110A, Hem482A, charge interactions with Hem482A residues of 3TIK. 
Compound 84 was found to have Vdw interactions with Tyr103A, Phe105A, Met106A, Phe110A, 
Leu130A, Pro210A, Ala287A, Ala288A, Phe290A, Ala291A, Gly292A, Thr295A, Leu356A, 
Met358A, Met890A, Met460A, Hem482A residues and hydrophobic interactions with Met106A, 
Ala115A, Leu130A, Pro210A, Ala287A, Ala288A, Ala291A, Leu356A, Met358A, Leu359A, 
Met890A, Ile423A, Met460A, Hem482A residues of 3TIK. It also had aromatic and charge interac-
tions with Hem482A. Compound 85 was found to have Vdw interactions with Tyr103A, Phe105A, 
Met106A, Phe110A, Ala115A, Tyr116A, Leu127A, Leu130A, Pro210A, Met284A, Val286A, 
Ala287A, Ala288A, Phe290A, Ala291A, Leu356A, Met460A, Val461A, Hem482A residues and hy-
drophobic interactions with Tyr103A, Met106A, Ala115A, Leu127A, Leu130A, Pro210A, Met284A, 
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Ala287A, Ala288A, Phe290A, Ala291A, Met460A, Hem482A residues of 3TIK. In addition to these, 
Compound 85 also had aromatic interactions with Phe110A and Hem482A and charge interactions 
with Hem482A of sterol 14-alpha demethylase of T. brucei. Compound 86 was found to have Vdw 
interactions with Tyr103A, Met106A, Phe110A, Ala115A, Tyr116A, Leu127A, Leu208A, Met284A, 
Ala287A, Phe290A, Ala291A, Leu356A, Leu359A, Met460A, Hem482A residues and hydrophobic 
interactions with Val114A, Ala115A, Leu127A, Met284A, Ala287A, Ala288A, Ala291A, Leu356A, 
Leu359A, Met460A, Val461A, Hem482A residues of sterol 14-alpha demethylase. It also had charge 
interactions with Hem482A and hydrogen bonding with Tyr103A residues of 3TIK. Compound 87 was 
found to have Vdw interactions with Tyr103A, Met106A, Phe110A, Leu127A, Leu130A, Pro210A, 
Met284A, Ala287A, Ala288A, Phe290A, Ala291A, Thr295A, Leu356A, Met358A, Met460A, 
Val461A, Hem482A residues and hydrophobic interactions with Met106A, Leu127A, Leu130A, 
Pro210A, Met284A, Ala287A, Ala288A, Met289A, Ala291A, Leu356A, Leu359A, Ile423A, 
Met460A, Hem482A residues of 3TIK.  Compound 87 also had aromatic and charge interactions with 
Hem482A of sterol 14-alpha demethylase. Compound 88 was found to have Vdw interactions with 
Tyr103A, Met106A, Phe110A, Ala115A, Tyr116A, Leu127A, Pro210A, Met284A, Ala287A, 
Ala288A, Met289A, Phe290A, Ala291A, Thr295A, Leu356A, Leu359A, Met460A, Val461A, 
Hem482A residues and hydrophobic interactions with Tyr103A, Met106A, Ala115A, Leu127A, 
Leu130A, Pro210A, Met284A, Ala287A, Ala288A, Met289A, Phe290A, Ala291A, Leu356A, 
Leu359A, Met460A and Hem482A residues of sterol 14-alpha demethylase. It also had aromatic inter-
actions with Phe110A, Hem482A and charge interactions with Hem482A residues of 3TIK. Compound 
89 was found to have Vdw interactions with Tyr103A, Phe105A, Met106A, Phe110A, Ala115A, 
Leu127A, Leu130A, Pro210A, Met284A, Ala287A, Ala288A, Met289A, Phe290A, Ala291A, 
Thr295A, Leu356A, Leu357A, Met358A, Leu359A, Ile423A, Met460A, Hem482A residues and hy-
drophobic interactions with Tyr103A, Met106A, Phe110A, Val114A, Ala115A, Leu127A, Leu130A, 
Pro210A, Met284A, Ala287A, Ala288A, Met289A, Ala291A, Leu356A, Leu357A, Leu359A, 
Met890A, Ile423A, Met460A, Val462A, Hem482A residues of 3TIK. It also had aromatic interactions 
with Phe110A, Hem482A, charge interactions with Hem482A and hydrogen bonding with Tyr103A 
residues of sterol 14-alpha demethylase. Compound 90 was found to have Vdw interactions with 
Tyr103A, Met106A, Phe110A, Ala287A, Phe290A, Ala291A, Leu356A, Met460A, Val461A, 
Hem482A residues and hydrophobic interactions with Leu356A, Leu359A, Met460A, Val461A, 
Hem482A , charge interaction with Hem482A residue of sterol 14-alpha demethylase. Compound 91 
was found to have Vdw interactions with Tyr103A, Met106A, Phe110A, Leu208A, Ala287A, 
Phe290A, Ala291A, Leu356A, Met460A, Hem482A residues and hydrophobic interactions with 
Ala287A, Ala291A, Leu356A, Leu359A, Hem482A residues of 3TIK. It also had also charge interac-
tions with Hem482A and hydrogen bonding with Tyr103A residues of sterol 14-alpha demethylase. 
Compound 92 was found to have Vdw interactions with Val102A, Tyr103A, Phe105A, Pro210A, 
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Phe290A, Ala291A, Leu356A, Met358A, Leu359A, Met460A residues while and hydrophobic interac-
tions with Val102A, Tyr103A, Met106A, Leu208A, Pro210A, Val213A, Phe290A, Leu356A, 
Leu359A, Met890A, Met460A, Val461A amino acid residues of sterol 14-alpha demethylase. In addi-
tion, Compound 92 also has charge interactions with Hem482A and hydrogen bonding with Tyr103A 
residues of 3TIK. Compound 93 was found to have Vdw interactions with Tyr103A, Met106A, 
Phe110A, Glu205A, Ala287A, Phe290A, Ala291A, His294A, Leu356A, Met460A, Val461A, 
Hem482A residues and hydrophobic interactions with Met106A, Ala287A, Phe290A, Ala291A, 
Leu356A, Met460A residues of sterol 14-alpha demethylase. It also had charge interactions with 
Hem482A of 3TIK. Compound 94 was found to have Vdw interactions with Tyr103A, Tyr116A, 
Glu205A, Phe290A, Ala291A, His294A, Leu356A, Met460A, Val461A, Hem482A residues and hy-
drophobic interactions with Met106A, Ala287A, Phe290A, Ala291A, Thr295A, Leu356A, Hem482A 
residues of 3TIK. Along with these, Compound 94 also had charge interactions with Hem482A residue 
of sterol 14-alpha demethylase. Compound 95 was found to have Vdw interactions with Tyr103A, 
Met106A, Phe110A, Ala287A, Phe290A, Ala291A, Leu356A, Met460A, Hem482A residues and hy-
drophobic interactions with Met106A, Ala287A, Phe290A, Ala291A, Leu356A, Leu359A, Hem482A 
residues of sterol 14-alpha demethylase. In addition, Compound 95 also had charge interactions with 
Hem482A and hydrogen bonding with Tyr103A residues of 3TIK.  
Reference ligand(The tipifarnib derivative 6-((4-chlorophenyl)(methoxy)(1-methyl-1H-imidazol-5-
yl)methyl)-4-(2,6-difluorophenyl)-1-methylquinolin-2(1H)-one)  was found to have Vdw interactions 
with Tyr103A, Phe105A, Met106A, Phe110A, Ala115A, Tyr116A, Leu127A, Glu205A, Leu208A, 
Ala287A, Phe290A, Ala291A, Thr295A, Leu356A, Met358A, Cys422A, Met460A, Val461A, 
Hem482A residues and hydrophobic interactions with Met106A, Leu208A, Ala287A, Phe290A, 
Ala291A, Thr295A, Leu356A, Leu359A, Met460A, Val461A, Hem482A residues of sterol 14-alpha 
demethylase. It aslo had hydrogen bonding with Hem482A residues of sterol 14-alpha demethylase.      
Docking studies of aporphine alkaloids with Glutathione peroxidase type tryparedoxin peroxi-
dase, oxidized form(2RM5) 
Compound 81 was found to have Vdw interactions with Lys46A, Cys47A, Gly48A, Tyr49A, Thr50A, 
Lys51A, Gly52A, Tyr54A, Glu55A amino acid residues and hydrophobic interactions with Lys46A, 
Cys47A, Gly48A, Tyr49A, Thr50A, Lys51A, Gly52A, Glu55A amino acid residues of tryparedoxin 
peroxidase, oxidized form. Compound 82  was found to have Vdw interactions with Lys46A, Cys47A, 
Gly48A, Tyr49A, Thr50A, Lys51A, Gly52A, Gly53A, Tyr54A, Glu55A, Thr56A, Ser159A amino 
acid residues and hydrophobic interactions with Lys46A, Cys47A, Gly48A, Thr50A, Lys51A, 
Gly52A, Gly53A, Glu55A, Thr56A and Ser159A of 2RM5. Compound 83 was found to have Vdw 
interactions with Lys46A, Cys47A, Gly48A, Tyr49A, Thr50A, Lys51A, Gly52A, Tyr54A, Glu55A, 
Thr56A amino acid residues and hydrophobic interactions with Lys46A, Cys47A, Gly48A, Tyr49A, 
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Lys51A, Gly52A, Gly53A, Glu55A, Thr56A amino acid residues of glutathione peroxidase type try-
paredoxin peroxidase, oxidized form. Compound 84 was found to have Vdw interactions with Lys46A, 
Cys47A, Gly48A, Tyr49A, Thr50A, Lys51A, Gly52A, Gly53A, Tyr54A, Glu55A, Thr56A amino acid 
residues and hydrophobic interactions with Cys47A, Gly48A, Thr50A, Lys51A, Gly52A, Glu55A, 
Thr56A and Val160A amino acid residues of tryparedoxin peroxidase, oxidized form. Compound 85 
was found to have Vdw interactions with Lys46A, Cys47A, Gly48A, Tyr49A, Thr50A, Gly52A, 
Gly53A, Tyr54A, Glu55A,Thr56A, Phe93A amino acid residues and hydrophobic interactions with 
Lys46A, Cys47A, Gly48A, Thr50A, Lys51A, Gly52A, Gly53A, Glu55A, Thr56A amino acid residues 
of tryparedoxin peroxidase, oxidized form. It also had aromatic interactions with Tyr49A of 2RM5. 
Compound 86 was found to have Vdw interactions with Lys46A, Gly48A, Tyr49A, Thr50A, Tyr54A, 
Glu55A amino acid residues and hydrophobic interactions with Lys46A, Cys47A, Gly48A, Tyr49A, 
Gly52A, Glu55A amino acid residues of 2RM5. It also had charge interactions with Lys46A amino 
acid residue of glutathione peroxidase type tryparedoxin peroxidase, oxidized form. Compound 87 was 
found to have Vdw interactions with Lys46A, Cys47A, Gly48A, Tyr49A, Thr50A, Gly52A, Tyr54A, 
Glu55A, Phe93A amino acid residues and hydrophobic interactions with Lys46A, Cys47A, Gly48A, 
Tyr49A, Thr50A, Gly52A, Tyr54A, Glu55A amino acid residues of tryparedoxin peroxidase, oxidized 
form. It also had charge interaction with Lys46A of 2RM5. Compound 88 was found to have Vdw in-
teractions with Lys46A, Cys47A, Tyr49A, Thr50A, Lys51A, Gly52A, Tyr54A, Glu55A, Thr56A ami-
no acid residues and hydrophobic interactions with Lys46A, Gly52A, Tyr54A, Glu55A, Thr56A amino 
acid residues of 2RM5. Compound 88 also had aromatic interaction with Tyr49A of tryparedoxin pe-
roxidase, oxidized form. Compound 89 was found to have Vdw interactions with Lys46A, Gly48A, 
Tyr49A, Thr50A, Lys51A, Gly52A, Gly53A, Tyr54A, Glu55A, Thr56A amino acid residues and hy-
drophobic interactions with Lys46A, Cys47A, Gly48A, Tyr49A, Thr50A, Lys51A, Gly52A, Gly53A, 
Tyr54A, Glu55A, Thr56A amino acid residues of tryparedoxin peroxidase, oxidized form. It also had 
charge interaction with Lys46A of 2RM5. Compound 90 was found to have Vdw interactions with 
Lys46A, Cys47A, Gly48A, Tyr49A, Thr50A amino acid residues and hydrophobic interactions with 
Lys46A, Cys47A, Gly48A, Tyr49A, Thr50A amino acid residues of glutathione peroxidase type try-
paredoxin peroxidase, oxidized form. In addition, Compound 90 also had aromatic interaction with 
Tyr49A of 2RM5. Compound 84was found to have Vdw interactions with Lys46A, Tyr49A, Thr50A, 
Tyr54A, Glu55A amino acid residues and hydrophobic interactions with Lys46A, Tyr49A, Thr50A 
and Tyr54A amino acid residues of tryparedoxin peroxidase, oxidized form. Compound 91 was found 
to have Vdw interactions with Lys46A, Tyr49A, Thr50A, Tyr54A, Phe98A amino acid residues and 
hydrophobic interactions with Lys46A, Thr50A amino acid residues of 2RM5. Along with these, 
Compound 91 also have charge interactions with Lys46A of tryparedoxin peroxidase, oxidized 
form(2RM5). Compound 92 was found to have Vdw interactions with Lys46A, Cys47A, Gly48A, 
Tyr49A, Thr50A, Gly52A, Gly53A, Tyr54A, Glu55A amino acid residues and hydrophobic interac-
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tions with Thr50A, Gly52A, Gly53A, Tyr54A, Glu55A amino acid residues of tryparedoxin peroxi-
dase, oxidized form. Compound 93 was found to have Vdw interactions with Lys46A, Cys47A, 
Gly48A, Tyr49A, Thr50A, Gly52A, Gly53A, Tyr54A, Glu55A amino acid residues and hydrophobic 
interactions with Thr50A, Gly52A, Gly53A, Tyr54A, Glu55A amino acid residues of 2RM5. In addi-
tion, Compound 93 also have aromatic interaction with Tyr49A of tryparedoxin peroxidase, oxidized 
form. Compound 94 was found to have Vdw interactions with Lys46A, Gly48A, Tyr49A, Thr50A, 
Tyr54A, Glu55A amino acid residues and hydrophobic interactions with Lys46A, Thr50A and Tyr54A 
amino acid residues of glutathione peroxidase type tryparedoxin peroxidase, oxidized form. 
Docking studies of aporphine alkaloids with Glutathione peroxidase type tryparedoxin peroxi-
dase, reduced form(2RM6) 
Compound 81 was found to have Vdw interactions with Lys126A, Gly128A, Ile129A, Leu130A, 
Ala131A, Arg153A, Phe154A, Gly157A, Ala158A, Asp162A amino acid residues and hydrophobic 
interactions with Lys126A, Ile129A, Ala131A, Arg153A, Phe154A, Gly157A, Ala158A, Asp162A 
amino acid residues of glutathione peroxidase type tryparedoxin peroxidase, reduced form. In addition, 
Compound 81 also had charge interactions with Lys126A and Arg153A of 2RM6. Compound 82 was 
found to have Vdw interactions with Lys126A, Gly128A, Ile129A, Leu130A, Ala131A, Arg153A, 
Phe154A, Gly157A, Ala158A, Asp162A amino acid residues and hydrophobic interactions with 
Lys126A, Pro127A, Gly128A, Ile129A, Ala131A, Gly157A, Ala158A amino acid residues of try-
paredoxin peroxidase, reduced form. Compound 82 also had charge interactions with Lys126A and 
Arg153A of 2RM6. Compound 83 was found to have Vdw interactions with Lys126A, Pro127A, 
Gly128A, Ile129A, Arg131A, Arg153A, Phe154A, Gly157A, Ala158A, Asp162A amino acid residues 
and hydrophobic interactions with Lys126A, Pro127A, Gly128A, Ile129A, Ala131A, Thr132A, 
Glu152A, Arg153A, Phe154A, Gly157A amino acid residues of 2RM6. In addition, Compound 83 also 
have charge interactions and hydrogen bonding with Lys126A, Arg153A amino acid residues of try-
paredoxin peroxidase, reduced form. Compound 84 was found to have Vdw interactions with 
Lys126A, Pro127A, Gly128A, Ile129A, Arg153A, Phe154A, Gly157A, Ala158A, Asp162A amino 
acid residues and hydrophobic interactions with Lys126A, Pro127A, Gly128A, Ile129A, Phe154A, 
Ser155A, Gly157A, Ala158A amino acid residues of glutathione peroxidase type tryparedoxin peroxi-
dase, reduced form. In addition, Compound 83 was also found to have charge interactions with 
Lys126A of 2RM6. Compound 84 had Vdw interactions with Lys126A, Gly128A, Ile129A, Arg153A, 
Phe154A, Gly157A, Ala158A, Asp162A amino acid residues and hydrophobic interactions with 
Lys126A, Ile129A, Leu130A, Ala131A, Ser155A, Gly157A, Ala158A amino acid residues of 2RM6.  
Compound 84 also had charge interactions with Lys126A and Arg153A as well as hydrogen bonding 
with Lys126A amino acid residues of tryparedoxin peroxidase, reduced form. Compound 85 was found 
to have Vdw interactions with Lys126A, Gly128A, Ile 
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9. Compound 83 
NH
HN
OMe
OMe
OMe
O
O
8-(1,2,3
-trimethoxy-5,6-dihydro-4H-dibenzo[de,g]quinolin
-7-yl)
-6,7-dihydro-5H-
[1,3]dioxolo[4',5':4,5]benzo[1,2,3
-de]benzo[g]quinoline  
 
10. Compound 88 
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NMe
MeN
O
O
O
O
7,7'-dimethyl-6,6',7,7'-tetrahydro-5H ,5'H-8,8'-bi[1,3]dioxolo[4',5':4,5]benzo[1,2,3
-
de]benzo[g]quinoline  
 
 
11. Compound 89 
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NMe
MeN
O
O
MeO
MeO
H
8-(1,2
-dimethoxy-6-methyl-5,6-dihydro-4H-dibenzo[de,g]quinolin
-7-yl)
-7-methyl-6,7-
dihydro-5H-[1,3]dioxolo[4',5':4,5]benzo[1,2,3
-de]benzo[g]quinoline  
 
 
 
 
12. Compound 90 
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NMe
MeN
O
O
MeO
MeO
OMe
7-methyl-8-(1,2,3
-trimethoxy-6-methyl-5,6-dihydro-4H-dibenzo[de,g]quinolin
-7-yl)
-6,7-
dihydro-5H-[1,3]dioxolo[4',5':4,5]benzo[1,2,3
-de]benzo[g]quinoline  
 
 
13.  Compound 81 
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NH
MeO
MeO
OMe
HN
OMe
OMe
OMe
1,1',2,2',3,3'-hexamethoxy-5,5',6,6'-tetrahydro-4H ,4'H-7,7'-bidibenzo[de,g]quinoline  
 
14. Compound 96 
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NH
MeO
MeO
H
1,2-dimethoxy-5,6-dihydro-4H-dibenzo[de,g]quinoline
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Table 3.17: Log P and MICs values of the above described aporphine and protoberberine alkaloids  
   
(88) 6.25 5.89 4 
(81) 1.27 6.02 2 
(83) 5.62 7.78 2 
(84) 1.90 6.84 2 
(85) 10.66 6.02 1 
(86) 0.67 6.50 2 
(87) 2.49 3.28 2 
(41) 9.66 6.68 1 
 
These initial results indicated these aporphinoid alkaloids had significant activity against Trypanosoma 
brucei brucei for in-vitro, and significant binding affinity for enzyme important for parasite’s survival, 
molecular target Ornithine decarboxylase.   
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Table 3.18 Docking scores of aporphine alkaloids isolated in this study and their  derivatives 
Com-
pound 
Mini-
mized 
Energy 
Gold.PL
P. 
Fitness 
Gold.PL
P. 
PLP 
Gold.PLP.par
t. 
Nonpolar 
Gold.PLP.part.repulsi
ve 
Gold.PLP. 
Lig-
and.clash 
86 183.83 19.8289 -23.0165 -26.294 0.1266 0.028 
93 54.09 27.8489 -28.5311 -22.292 0.0086 1.0293 
95 55.03 38.4616 -38.358 -49.843 0.0084 0 
91 19.17 25.4228 -25.4222 -45.3383 0.0595 0 
92 19.26 32.1024 -30.8562 -40.3994 0.0226 0 
85 44.2 26.5959 -26.7389 -48.0034 0.05252 0 
87 188.55 -25.0265 5.9448 -33.6052 0.0091 16.7714 
84 103.9 -95.1384 93.2236 -41.8056 0.5322 1.1201 
83 83.01 -35.4653 33.9348 -34.0093 7.3672 0 
88 128.83 23.731 -24.3419 -44.0352 13.3665 0 
89 146.38 26.7533 -34.1272 -37.6235 0.2786 6.9648 
90 160.8 8.8294 -10.6011 -27.527 0.1782 0.0346 
81 118.39 27.8819 -33.9287 -36.3287 3.4098 5.4444 
96 44.3 35.8819 -33.7762 -42.8423 0.2444 0 
 
Further lipophilicity assessing tests revealed the monomeric alkaloids had better log P (5 and less) 
compared the dimers between 6 and 7. This implies the monomers  could make good lipophilic mole-
cules (according to Lipinski’s rule of Log P, values less than 5 gives an indication of good lipophilici-
ty), so they have the propensity to be  developed as oral drugs should they progress with desired results 
in further drug development studies. 
Variation in type of compounds isolated based on season. 
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The eight aporphine alkaloids described above were collected in winter, here below are the two pre-
dominant compounds isolated from Enanthia cholorantha plant material collected in summer. 
1. Isocoumarin 
O
OOH
O
8
7
5 4
1
3
1' 5'  
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.510.010.511.011.5
f1 (ppm)
ag/John_ECBC-H9
 
Figure 3. 44: 1H NMR (400MHz, CDCl3) of ECBC H-9 
 
2. The dimeric alkaloid : 7, 7’- Bisdehydro-O-methylisopiline 
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NH
H3CO
H3CO
OCH3
HN
OCH3
OCH3
OCH3
1
2
3
8
11
711a
1a
1'
3'
7'
2'
6a
 
                                                                                              (81) 
                                                                                  7, 7’- Bisdehydro-O-methylisopiline 
The monomeric and other types of dimeric alkaloids with 2 methoxyls substitutions or methylenedioxy 
substitutions were not isolated from the plant material collected in summer as they were in winter. 
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Chapter 4 
Preamble 
Human Trypanosomiasis infection comprises of three forms: African T.brucei gambiense and T.brucei 
rhodesiense alongside the South American variety, Chagas disease. They continue to place a huge 
morbidity and mortality burden on millions of lives in Sub-Saharan Africa, North and Latin American 
countries. 
Enanthia chlorantha is a medicinal herb found in the rainforests of Nigeria, Liberia, Cote d’ Ivoire, 
Cameroun, Gabon and Democratic Republic of Congo among others ( see introductory part of this the-
sis on page 17). This study attempted to use natural product chemistry isolation techniques to isolate, 
purify and identify bioactive compounds from Enanthia chlorantha. Using the flowchart on page 197. 
The bioactivity of natural products stems from the hypothesis that essentially all natural products have 
some receptor-binding activity; the problem is to find which receptor a given natural product is binding 
to. This was the focus of molecular modelling studies in this thesis. This led to the hypothesis that orni-
thine decarboxylase as the most probable mechanism of action of the alkaloids described in this study. 
Designing models to take bioactive compounds from natural product chemistry to combinatorial chem-
istry from the onset should be the target in the science of drug discovery from natural products as at-
tempted in this study. Natural products will continue to provide a complex libraries of unique bioactive 
constituents, analogues to these rich libraries tailored to generate synthetic improved products through 
combinatorial chemistry techniques should be the aim of natural product studies from the scratch. Over 
the years the natural products approach has been complementary to the synthetic approach, each 
providing access to different lead structures to generating new clinical entities.  This implies that com-
binatorial chemistry such as molecular modelling has been an extremely powerful tool for the optimi-
zation of an active natural product pharma core as it was attempted in this study, and the task of the 
natural products chemist should be to identify initial lead compounds of pharmacological interest from 
his vast “natural product libraries” to be handed over to computorial chemist for optimisation, to gen-
erate improved and more potent analogues. 
In this study, natural product chemistry started from extraction to isolation to purification and demon-
stration of anti-trpanosmal activity in-vitro and went on to use combinatorial biosynthetic techniques 
such as molecular modelling to determine the probable mechanism of action of bioactive alkaloids de-
rived from Enantia chlorantha and generate their hybrid modelled analogues for synthesis and future 
studies. 
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Structural diversity is a cogent reason why natural products are of interest to drug development. An 
important additional feature is that they often possess highly selective and specific biological activities 
based on their mechanisms of action, this buttresses the need for molecular modelling studies to at-
tempt to decipher probable mechanism of action. Good examples are drugs in clinical uses namely, 
lovastatin, the HMG-CoA reductase inhibition and paclitaxel, the  tubulin-assembly promotion activity 
, neither of which would have been discovered without the natural product leads and investigation of 
their mechanisms of action through methods such as molecular modelling. A further striking illustra-
tion of the influence of natural products involving the modulation of many of the enzymatic processes 
which probably explains where the alkaloids isolated in this study had good affinity for Ornithine de-
carboxylase and modest affinity inhibition of other trypanosomes enzymes essential for its survival. 
 
Discussion 
Enantia chlorantha has been reported as a rich source of 1-benzyltetrahydroisoquinoline type of alka-
loids.  A good example of such is benzylisoquinoline-derivedprotoberberine type alkaloid found in 
stem bark of E.chlorantha was palmatine (41). This study revealed palmatine (41) was the most abun-
dant alkaloid isolated in this study from E. chlorantha. See Table 3.1 on page 86.  
N+
OCH3
OCH3
H3CO
OCH3  
                                                                      (41) 
It gave a 0.28% yield of dry plant material (see Table 3.1).  As the major alkaloidal secondary metabo-
lite in E.chlorantha in this study, it is responsible for the bright yellow colour of the stem bark (see 
Figures 1.1, 2.2 and 2.3). Also presence of palmatine (41) in E.chlorantha together with the dimers 
probably accounts for the numerous medicinal uses and possibly explains why E. chlorantha is re-
ferred in rural West Africa as ‘Dokita Igbo’ which literally means “Doctor of the forest”. It would be 
interesting in future studies to find what other biological activities the novel dimeric alkaloids may 
have. Extensive research has been carried out on palmatine; it was investigated as a probable pharma-
ceutical drug for treatment of viral hepatitis as reported by Virtanen et al., (1993).  The reduced form 
of palmatine, tetrahydropalmatineis one of the major bioactive components in Corydalis yanhu suo 
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W.T Wang, a well-known traditional Chinese medicine with potent analgesia, sedative-tranquilizing 
and hypnotic properties (Hsu, 1962) among several other uses it was explored for. 
 
Extraction, Isolation purification, structure elucidation and activity testing  
 of bioactive alkaloids from Enantia chlorantha extracts. 
 
 
 
From hexane extracts                          from ethyl acetate extracts                        from methanol extract 
ECH 56 (85)                                           ECP-17(81)                                                     ECM-1(41)  
ECF 5-10 (86)                                         ECP-19(82) 
 ECHB 17-18                                          ECHE 45(83) 
                                                                ECP-23 
 
 
 
Using combinatorial biosynthetic techniques such as molecular modelling and other Translational 
Chemistry approaches to define drug targets in terms of most potent alkaloid in terms of binding affini-
ty for proven anti-trypanosomal enzyme targets. 
 
Ligand           +   proven anti-trypanosomal activity protein targets 
(Alkaloid(s)    Glutathione Synthetase,  
                      Glutathione peroxidase-type tryparedoxin peroxidase,  
                      Glutathione peroxidase-type tryparedoxin peroxidase 
                     Sterol 14-alpha demethylase (CYP51)                       Ornithine decarboxylase(best bound)                           
                     Tipifarnib derivative 6-(4-chlorophenyl) (methoxy) (1-methyl-1                                
                      H-imidazol-5-yl) methyl)-4-(2, 6-difluorophenyl) - 1- methylquinolin-2(1H)-one 
                      Ornithine Decarboxylase,Riboflavin kinase,Trypanothione reductase   
 
  
Optimization of lead modelled alkaloid against active site of Ornithine decarboxylase to generate hy-
brid bioactive analogue(s) 
Synthesis of the lead modelled hybrid lead bioactive alkaloid(s) and analogues 
 
In-vivo parasitized rat model activity studies 
  Further parasitic activity screening looking at the synthesized compounds activity against a variety of 
parasitic infections bioassay templates like malaria, leishmaniasis in addition to trypanosomiasis. 
 Pharmacokinetics and lead compounds safety studies using Stem cell models to predict the bioactive 
alkaloids’ metabolism and toxicity profile in vivo and vitro (this technology is extremely efficient and 
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is now replacing the laborious use of animals to a large extent in pre-clinical activity, toxicity and 
pharmacokinetics screening)   
  
Other alkaloids isolated in this study were six dimeric and one monomeric aporphine alkaloids, they 
were black to brown residues and were isolated in fewer quantities (see Table 3.1), and compared to 
the more abundant, bright yellow protoberberine type alkaloid: palamtine. 
Three of the six dimeric aporphine alkaloids isolated in the course of this study were found to be novel 
:( ECP-19 (89) which had an N-methyl group had MIC of 1.27nm, ECHE 45 (90) without an N-methyl 
group had MIC of 5.62 nm, while ECH 56 (91) also with an N-methyl group had MIC of 1.90 nm. This 
probably infers that the presence of an N-methyl group confers superior anti-trypanosomal activity.  
Others dimeric aporphines  revealed MICs  indicating significant anti-trypanosomal activity, with 
MICs ranging from  1.90 to 5.4 nM  ( see Table 3.17) ,which were  better compared molar for molar 
with the positive control Suramin with MIC  9.6 nM.  Also the other three dimeric aporphine alkaloids 
have been previously reported, though this is the first time in E. chlorantha, whereas the monomeric 
aporphine alkaloid and palmatine have been previously reported in E. chlorantha. 
                                         
NH
H3CO
H3CO
H3CN
OCH3
OCH3
OCH3
1,1',2,2',3-pentamethoxy-6-methyl-5,5',6,6'-tetrahydro-4H ,4'H-7,7'-
bidibenzo[de,g]quinoline
1
2
8
11
7 11a
1a
1'
3'
7'
2'
6a
3
 
                                                                    (89) 
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NH
HN
OCH3
OCH3
OCH3
O
O
1
2
3
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11
 
8
11a
7a
1'
2'
 
3'
7'
 
                                                                        (90) 
        
                                           
NCH3
HN
O
O
H3CO
H3CO
OCH3
1
 
2
 
3
1'
 
2'
7
3a
8
11
8-(1,2,3
-trimethoxy-6-methyl-5,6-dihydro-4H-dibenzo[de,g]quinolin
-7-yl)
-6,7-dihydro-5H-
[1,3]dioxolo[4',5':4,5]benzo[1,2,3
-de]benzo[g]quinoline  
                                                                                 (91) 
 
There is sufficient evidence from the 1D and 2D NMR spectral analysed in this study of the novel di-
meric aporphine alkaloids  that their novelty was conferred by the fact that they were dimers, as well as 
possession of N-methyl groups and C-1’ and C-2’ substitutions by methylenedioxy substituents. The 
presence of methylenedioxy substituents led to change in chemical shifts of the aliphatic methylene as 
seen in ECHE 45 (90) ,where H-4 was at δC 30.8 ppm compared to H-4 at δC 23.4 ppm in dimeric 
aporphine alkaloids without methyelendioxy group. Presence of such methylenedioxy substituents 
however did not confer superior anti-trypanosomal activity compared to dimeric alkaloids with strictly 
methoxys substitutions in positions C-1 to C-3  see Table 3.17. 
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Notable curare-like bisbenzylisoquinolines such as daphnoline (47), cephranthine (46)and an anti-
parasitic benznidazole (48) have been reported as active against Trypanosoma cruzi murine model 
through trypanothione reductase inhibition Fournet et al.,(2000). So it would be a good idea in the fu-
ture to study these alkaloids to see if they are active against Trypanosoma cruzi. 
O
N
O
O
O
N
H3C
CH3
OCH3
H3CO
N+
OH
O NH
H3C
O
OCH3 H3CO
HO
 
                        (46)                                                                       (47) 
                       
H
N
N
N
O
N+
O
-
O  
                             
                                                                            (48) 
 Palmatine(41), being the most polar constituent of E.Chlorantha, was extracted from methanol extract. 
The medium polar alkaloids with methylenedioxy substituents in position C-1,C-2  and dehyroapor-
phine with methoxysubstitutions were isolated from the ethyl acetate extract (ECP-17 (88), ECP-19 
(89) , ECP-23 (93) and ECHE-45 (90),while the least polar aporphine alkaloids were isolated from the 
hexane extracts :ECH-56 (91), ECH-B-17-18 (94)and EC-F 5-10 (92). This implied that a significant 
amount of aporphine alkaloids especially the protoberberine alkaloid isolated from E.chlorantha’s stem 
bark were polar, this is likely to be the reason why difficulties were experienced in the process of puri-
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fying the alkaloids despite numerous separation techniques employed in the course of this study. These 
difficulties could also be due to the fact that aporphine alkaloids had closely related structures and 
masses. This was further supported in observations made by Bourdat-Deschamps (2004) as discussed 
in the introductory chapter. Various separation combination techniques were tried in the course of this 
study, such as column chromatography followed by Gel filtration chromatography, column chromatog-
raphy followed by Reveleris chromatography and column chromatography followed Normal Phase 
HPLC. The latter was the most efficient in achieving the purest fractions using the appropriate solvent 
system with Rf value of 0.3 on TLC. 
Gel chromatography (sephadex LH20) fractions were used to distinguish the anti-trypanosomal activity 
of NMR derived aporphine alkaloids-rich fractions compared to NMR of fractions revealed to contain 
mainly fats and sugars. This showed that fractions ECBE SA 1- ECCHE SA 20 rich in the aporphine 
alkaloids described in the course of this study had MICs ranging from 2.7- to 9.6 nM. While other frac-
tions containing only fats and sugars gave negative reaction to Dragendorff’s and MIC>100µg/ml, the 
implication was that they were not active against Trypanosoma brucei bruceias shown in Table 5.1on 
page 237.  This supports the hypothesis that anti-trypanosomal activity exhibited by the novel and 
known alkaloids isolated in this study was due to their alkaloidal nature. 
 In terms of seasonal variation in types of compounds biosynthesized by the plant based on season, the 
eight aporphine alkaloids described in details in this study  were collected in winter, while Isocoumarin 
and dimeric alkaloid : 7, 7’- Bisdehydro-O-methylisopiline  were the two predominant compounds iso-
lated from Enanthia cholorantha plant material collected in summer. 
Isocoumarin  
O
OOH
O
8
7
5 4
1
3
1' 5'  
Isolation of Isocoumarin belonging to the coumarin class of compounds was particularly interesting, as 
it is very similar in structure to synthetic analogue warfarin widely used clinically as anticoagulant. 
Couramin class of drugs are known to widely used as rodenticidals, it is possible Enantia chlorantha 
synthesizes Isocoumarin to ward off  rodents attack in summer as it’s expected that rodents would be 
more active in summer and less in winter due to harsh weather conditions. 
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 Initial molecular modelling revealed  Ornithine decarboxylase inhibition out of the seven protein tar-
gets from the protein database analysed (see list of protein targets in section 2.2.3.12 on Molecular 
modelling studies)as a probable mechanism of action of these alkaloids, with high binding affinity 
scores of 1-2 for the majority of these aporphine alkaloids and palmatine. 
Subsequent molecular modelling studies of the dimeric and their derived monomeric aporphine alka-
loids as ligands docked on Lysine 69, Ornithine decarboxylase’s active site revealed monomers docked 
far were better than the dimers. This was most likely due to the fact that the monomers are more likely 
to have drugability properties compared to the dimers. The dimers are big molecules with little flexibil-
ity as illustrated in the modelled alkaloids 3D interactions with Ornithine decarboxylase pictures on 
pages 177-190, thus did not dock well. Also monomers comply more with Lipinski’s rule of 5, which  
is useful in evaluating whether or not a drug is likely to be an orally active one in humans, The rule 
suggests that an orally active drug must not have molecular mass more than 500 daltons and partition 
coefficient log P not more than 5. The dimers molecular weights average between 550 and 630, while 
the monomers average 250-330. Log P values of the dimers were between 6 and 7, while that of the 
monomers were less than 6.  Latter docking studies showed the monomers fared better with positive 
docking score of (25-38) compared to the dimers (-95 to 27). This is shown in the 3D interaction pic-
tures modelled showing the dimers as being too big, rigid and less interaction with Lysine 69 the active 
site, see modelled 3D pictures on pages 177-190. Hence poor docking scores is some cases  negative, 
for example Compound 84 with docking score of -95.1384 owing its’ dimeric huge size, rigidity and 
with poor interactions with binding site of Ornithine decarboxylase. The fact that monomers are small-
er, with good molecular weights, reasonable log P values, more flexible and with better docking scores 
compared to the dimers  makes their hybrid modelling optimisation and subsequent synthesis interest-
ing prospects going forward in further drug development studies. Following the flowchart in a step-
wise fashion, the overall aim was to  improved analogues bioactive compounds from natural products 
through techniques described in this thesis. Thus the use of combinatorial biosynthetic techniques, first 
modelling all alkaloids isolated in this study with as many as possible against proven targets, in the 
case of this study seven protein targets The goal of this was to determine the most potent modelled pro-
tein target in terms of binding affinity determined by docking score and 3D interaction of docked pro-
tein and ligand (our alkaloids), which in this case turned out to be  Ornithine decarboxylase. 
We further went ahead in this study to attempt to optimize most potent docked alkaloid keeping it 
pharmacore to be as “perfect fit” as possible to Ornithine decarboxylase active site Lysine 69. This 
was in line with previous studies where application of these combinatorial biosynthetic techniques in 
production of novel analogues of anthracyclines, ansamitocins, epothilones, enediynes, and amino-
coumarins was carried out well documented by Van Lanen and Shen (2012). 
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The next phase of this study which is beyond the scope of the PhD is to attempt to synthesize the hy-
brid modelled optimized alkaloid(s) for in-vivo studies at Garscube’s School of Tertiary Medicine us-
ing parasitized mouse models under the supervision of expert on African Trypanosomiasis and Neurol-
ogist , Professor Peter Kennedy. 
Using this approach which leads to total synthesis would not only generate hybrid modelled bioactive 
alkaloids for future studies, but also circumvented the issue of difficulty in isolating insufficient quanti-
ties of the bioactive alkaloids for future drug development studies, as well as providing the template for 
total synthesis and structural modification of the isolated bioactive analogues as more potent and abun-
dant entities. 
Total synthesis going forward has been proven overtime to be crucial for pharmaceutical companies, 
clinicians and patient populations while conducting clinical trials as adequate supply which would be 
circumvented using this approach could be a serious limiting factor in the preclinical and clinical de-
velopment of naturally-derived drugs. 
 Excellent example were the marine-derived anticancer agent discodermolide , where total synthesis 
provided sufficient quantities for thorough clinical trials, but unfortunately, these were terminated at 
the Phase I/II interface due to lack of objective responses and toxicity  Freemantle (2004). Another 
good example is Paclitaxel which has several modified analogues such as doxitacel in clinical use. 
Paclitaxel if were to be solely gotten from the Yew tree would have worsen global warming and nega-
tively affected climate change. Probably the tree would have been in extinction, if not for its’ semi-
synthetic modification analogs to ensure large scale industrial production and ensure the supply chain 
of dire in need cancer patients is not in any way hampered. 
 Total synthesis can also be beneficial in the sense that it can lead to the identification of a sub-
structural portion of the molecule bearing the essential features necessary for activity (the pharmaco-
phore), which is what would happen in this study leading to generation of optimized modelled ana-
logue(s). 
Thus resulting in synthesis of simpler analogs having similar or better activity than the natural product 
itself.  A very good example is that of the marine derived antitumor agent, halichondrin B where total 
synthetic led to generation of the right hand half of the molecule which retained all or most of the po-
tency of the parent compound, and subsequently led to the synthesis of potent analogue, E7919 (eribu-
lin) which was approved by the FDA in 2010 as reported by Yu (2011). 
Moving forward beyond the scope of this PhD study, we intend to test for activity the synthesized ana-
log of natural products alkaloids described in this study in parasitized mouse models. This is based on 
the premise that clinical trials of the original natural product derived bioactive molecules have been 
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reported in the past to have failed, while totally synthetic analogues drug development  progressed.  A 
classical example was the clinical trials of the marine-derived anticancer agents, dolastatin 10 and do-
lastatin 15, which had to be  terminated for toxicity results, whereas  the synthetic analogue of dolas-
tatin 10, TZT-1027 (auristatin PE and  soblidotin) gave the study a new lease of life with the being 
slight modification  of the natural product scaffold by linking the peptide to specific antibodies using 
tumor specific scissionable linkages, with one antibody-drug complex (ADC) using auristatin F. The 
new clinical entity, brentuximab vedotin was approved as Adcenris by the FDA in 2011 for the treat-
ment of lymphoma as reported by Copeland (2010). 
 
 
Challenges of the study 
1. Flooding of the laboratory by the soxhlet extractor. Owing to rise in water level pressures  
overnight, several times during the course of this study I experienced flooding in the laboratory 
and some cases lost the plant materials in the soxhlet, this was quite frustrating. 
2. Purification of alkaloids isolated. 
This was the man problem I encountered in the course of this study. We tried several tech-
niques to little effect, as the majority of the NMR spectral analysed showed tinge of impurities. 
The problem with this is the fact that once your fraction submitted for activity testing is not a 
totally pure one, one can’t be too sure whether the activity is from the main compound or the 
tinge of impurities. To overcome this we had to try Sephadex separation technique and test the 
fractions rich in saponinins, sugars, flavonoids and fats , all these fractions did not showed an-
ti-trypanosomal activity, thus we  concluded the alkaloids described above were responsible 
for the anti-trypanosomal activity described in this study.  
This challenge was most likely due to the fact that many of the alkaloids isolated were very 
close in molecular weight and closely related in structures, so almost always merged together 
as separation was attempted. Eventually normal phase HPLC as shown in the appendix 
achieved purification, however the yields ended up being too low to be meaningful, as yields 
were as low as 0.5 mg. 
 
3. Molecular modelling studies 
The process of drug discovery involved isolation of bioactive molecules from either synthetic 
or natural source, to verify this activity as well optimize it, one had to carry out molecular 
modelling studies. My background is not anything close to molecular modelling, so getting 
help from India and interpreting the results were quite difficult. 
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4. Column chromatography sometimes runs out of solvent leading to drying up of the extracts 
in the column and subsequent abandoning of the column in use after 20-30 days of collection, 
this was quite frustrating. 
 
5. Scaling up difficulties, poor NMR spectral and activity results 
At onset of the study the plan was to extract isolate( this led to isolation of fats, sugars, tannins, 
saponins and alkaloids)  and test for anti-trypanosomal activity to decipher which groups of 
compounds were responsible for the anti-trypanosomal activity exhibited by the extracts and 
follow all these steps up by scaling up. The aim of scaling up was to obtain more yield of lead 
compounds of interest (bioactive alkaloids) as 800 g of the cork/bark for example yields as lit-
tle as 5-50 mg of alkaloids, ECH 56 for example yielded 6 mg which led to generation of  
NMR spectrum of poor quality. Difficulty in purification made this impossible as rather than 
obtain more yield , substantial quantity were lost to various purification separation techniques. 
With many of the NMR spectrum discussed in this thesis with tinge of impurities this can po-
tentially affect the reliability of activity test results subsequently obtained 
 
6. Multidisciplinary nature of natural product chemistry and combinatorial chemistry was also 
a huge challenge. This led to huge waiting time to get an expert in molecular modelling to find 
time out his busy schedule to put me through steps in modelling the alkaloids. It was as bad as 
at a point we had to carry out the initial molecular modelling work in India by Dr Rajeev Sin-
gla of the Netaji Subhas Institute of Technology 
 
7. Natural product chemistry is time consuming, laborious and monotonous. In the course of 
this study I ran up to 27 column chromatographies. Chopping the plant material into small 
pieces took 1 day. Drying the chopped into pieces plant material took 3 days, separating the 
bark from the cork of the plant material took 1 day, grinding into fine ground particles of both 
cork and bark plant material took 1 day. While soxhlet extraction took 5-6 days, rotator evapo-
ration to viscous plant material took 1 day and lastly column chromatography took 30 days on 
the average, this involved having to sit and manually collect vials from mornings to evening 
daily. Eventual use of Reveleris column chromatography circumvented this laborious and time 
consuming stage, as the whole process of column chromatography was done in a few hours. 
We have been able to generate 3 hybrid analogs of the aporhine alkaloids described in this thesis using 
molecular modelling means described earlier. This way we have circumvented purity and isolation 
challenges encountered using Natural product extraction and isolation means in this study, also further 
bioactivity studies are guaranteed to be foolproof. 
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Conclusions and possible future studies 
The preliminary anti-trypanosomal activity carried out showed ECP-19 (89) as the most active novel 
dimeric aporphine alkaloid with MIC of 1.27 nM. This inferred that the presence of N-methyl group in 
the novel dimeric alkaloids as in ECP -19 (89) was noted to confer superior anti-trypanosomal activity 
compared with dimeric aporphine alkaloids with NH functional groups (See Table 3.17). 
However there was  the binding affinity scales of the monomeric aporphine alkaloids were better com-
pared to those of the dimers r in terms of affinity with Ornithine decarboxylase (see Table 3.16). 
Thus synthesizing a series of dimeric aporphine alkaloids and their analogues  with N-Methyl func-
tional group could be done in the future to quantify the correlation between lipophilicity and anti-
trypanosomal activity. Also synthesizing aporphine alkaloids with methylenedioxy group at C-1 and C-
2 positions for further testing would be a good idea to determine whether  the presence of methylene-
dioxy substituents confer better lipophilicity properties. 
Molecular modelling as a means of deciphering possible mechanism of isolated bioactive compounds 
isolated from natural products helped in the course of this study to attempt to decipher the possible 
mechanism of action of the alkaloids. In this study, molecular modelling has identified potential mo-
lecular target(s) of E. chlorantha aporphine alkaloids. These results could provide the framework for 
synthetic modification of these bioactive aporphine derived and berberine –type alkaloid: palmatine, de 
novo synthesis of structural motifs and analogues, leading probably to further drug discovery studies. 
Further studies in line of determining whether there could be synergism of this group of isolated dimer-
ic aporphine alkaloids with other anti-trypanosomal agents in clinical use could be evaluated in future 
studies. 
Inhibition of Ornithine decarboxylase as probable molecular mechanism of action of these groups of 
alkaloids described provides further impetus in the future to attempt to synthesize these alkaloids for 
pharmacokinetics, efficacy driven metabolomics and in-vivo drug target driven mouse model studies, 
taking them through the entire Figure of the drug discovery science. 
 The next step would be to attempt to use Structure Activity Relationship (SAR) focused molecular 
modelling techniques to “prune the alkaloids to taste” as perfect fit into the pocket of Ornithine decar-
boxylase’s active site. Resultant hybrid molecules would then be synthesized for further in-vivo activi-
ty studies in parasitized mouse models available at University of Glasgow’s Garscube School of 
Vetenary Medicine laboratory. 
This study has buttressed the complexity of natural product chemistry and the structural diversity of 
natural products derived compounds are clearly evident from the result of this study. This study re-
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vealed isolation of alkaloids, fats, sugars, tannins, saponins all from the same medicinal plant and was 
able to isolate and prove the type of compounds (alkaloids) responsible for anti-trypanosmal activity of 
Enantia chlorantha in-vitro and probably in-vivo. 
The business of drug discovery will forever be a multi-disciplinary approach as natural product chem-
ists, synthetic chemists, biologists, pharmacokinetics and toxicity study experts will all have  to contin-
ue to work together to unearth  new medicines in today’s world in the face of multidrug resistance, lack 
of new anti-infective drugs going through FDA and MRHA stringent and rigorous licencing  proce-
dures. 
It has been reported, as documented in the course of this thesis, that medicinal chemists have synthe-
sized the protoberberine alkaloids (and their analogues) reported in this study for their structure-
activity relationships Mc Call et al., (2002), Vennerstrom and Klayman, (1998) and Iwasa et 
al.,(1996).  Such studies in the future on the novel and known dimeric aporphine alkaloids isolated in 
this study with their monomeric analogues could be tailored towards anti-trypanosomal and other anti-
parasitic drug development studies to gain more insight into structure activity relationships. To support 
the notion for further future studies on these alkaloids are buttressed by the fact that I reported previ-
ously, Adesokan Masters’ Thesis (2009), the aporphine -derived alkaloids isolated in course of this 
study were found to be non-toxic to cancer cell lines as well as normal cells. This completes the full 
spectrum of their isolation, structure elucidation, anti-trypanosomal activity tests, molecular modelling 
to attempt to decipher their possible mechanisms of actions as well as toxicity tests.  Anecdotal evi-
dence of the fact that E. chlorantha has been in use orally for centuries in West Africa also indicates no 
inherent toxic effects of these alkaloids. Though the aporphine alkaloids isolated in this study had with 
some structural similarities with some of those isolated from Chinese herbs Mu Tong and Fang chi, 
both of the Aristolochia species producing Aristolochic acid (96). 
NO2
COOHO
O
(96) 
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Which were found to be cancer-promoting and nephrotoxic in human subjects. However Aristochic 
acid and analogues has an active site shown above by the arrow which is electrophilic and capable of 
DNA base pair interactions, this believed to be  responsible for their carcinogenic activity. This active 
site is not available in the group of aporphine alkaloids isolated in this study due to the presence of C-
7/C-7’ bridge, an example is compound (89) here below, so this group of aporphine alkaloids are likely 
to be non-toxic, toxicity studies reported in my Masters’ thesis  which indicated they were non-toxic( 
see results in  appendix), however further toxicity studies are essential. 
NH
H3CO
H3CO
H3CN
OCH3
OCH3
OCH3
1,1',2,2',3-pentamethoxy-6-methyl-5,5',6,6'-tetrahydro-4H ,4'H-7,7'-
bidibenzo[de,g]quinoline
1
2
8
11
7 11a
1a
1'
3'
7'
2'
6a
3
 
                                                                              (89) 
 In conclusion Natural products will continue to be a viable source of new clinical entities as many top-
selling drug class today such as statins, angiotensin converting-enzyme inhibitors, many immunosup-
pressants , anti-cancer agents in clinical uses and in clinical trials at the moment would not have been 
available to physicians and patients if not for natural products drug discovery science. Thus studies 
such as pharmacokinetics, in-vivo toxicity studies, efficacy driven metabolomics and drug target driven 
mouse model studies on the group of aporphine alkaloids isolated in this study alongside their ana-
logues would be an interesting prospect in the future. 
In conclusion this study  completed the entire spectrum of initial drug discovery process from antedoc-
tal evidence of efficacy in West Africa to isolation of the bioactive compounds(alkaloids) from the plant 
material to demonstration of activity in-vitro(anti-trypanosomal studies), demonstration of non-
toxicity( cancer cell line studies see appendix). In addition the study went through docking molecular 
modelling studies targeting seven proteins and finding the one with best affinity, Ornithine decarbox-
ylase. To conclude we have now used molecular modelling techniques to generate 3 hybrid  synthe-
sized anlaogs of the aporphine alkaloids described in this study ( hybrid in the sense that they are ana-
logs with better drugability properties, better docking scores and conforming to Lipinski’s rule of 5 
much better than the isolated dimeric alkaloids). These molecules are available on the AK Scientific 
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and Spec websites for purchase for the further Garscube’s Trypanosomal parasitized animal studies as 
at time of submission of this thesis. 
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Appendix 
 
Overview of Masters’ thesis study as continuum into the PhD:  
To test the anti-trypanosome activity of E. chlorantha extracts and isolated pure compounds determin-
ing  their Minimum Inhibitory Concentration (MIC) compared to Suramin .The anti-bacterial activity 
of the extracts against Mycobacterium marinum and  sixteen other bacterial strains in terms of MICs 
would be carried out alongside anticancer activity  of the extracts and resulting  compounds  . 
  
 Materials and methods:  
Materials 
 Plant Material 
Stem bark samples of Enantia chlorantha were obtained from  a forest located within the suburbs of Ile 
Ife, Osun State of South Western Nigeria (Lat. 60° and 90°N, Long. 20°  3’ and 60° 30’). 
 
 Chemicals and Reagents 
Chemicals used were Ethyl Acetate: Sigma Adrich  27227 (Merck, Germany), n-Hexane: Sigma Al-
drich 34859 (Germany) and Methanol: Fluka 32213 (Germany). 
Reagents used for Phytochemistry includes Visualization Reagents: 
1.Anisaldehyde-Sulfuric acid spray solution (used for identification of Sugars, Steroids ,Terpenes  and 
Phenols  on TLC plate ).It  contains: 0.5ml of Anisaldehyde in 50mls of glacial acetic acid,1ml of 97% 
Sulfuric acid freshly prepared. 
 2. Drangendorff spray solution (used in identification of Alkaloids) made up of: 
Solution A; 2.215 bismuth sulphate with 2.5 ml of Glacial acetic acid, 100ml of Water 
Solution B: 93 g of Potassium iodide, 100 ul of Water.5mls of each of Solution A and Solution B 
freshly prepared is measured in a bottle attached to a pump which acts as the means of delivery onto 
the TLC plate of interest. 
  
[212] 
 
Laboratory apparatus and materials used for Phytochemistry 
TLC Plate and Tank 
TLC plates( pre-coated silica gel plates( 0.063-0.020mm,Kieselgel 60 PF 254 , Merck No. 5554) The 
TLC plates  are  made up  sheet of glass meta with solid adsorbent (aluminium) pieces 8cm by 
6cm.TLC Tank  made of glass  containing  the solvents of interest for separation of the extract  mixture 
into compounds based on their polarity .The TLC tank  is cuboidal in shape measuring 10cm by 10cm 
by 6 cm. Others are 
UV lamp: Mineralight Lamp used:  Model UVGL -58 
Multiband UV 254/896 NM (Upland CA91786 USA) 
Hot Air Gun 
Model: Power Craft 5969 (Clobaltronics GmbH & Co KG China)  
Sartorius weighing balance LC2200P (Sartorius Corp., NY 11717, USA) 
Glass columns 
Vials 
Rotatory evaporator  
Fritsch Grinder (Fritsch GmbH, 55743 Idar –Oberstan, Germany) 
10 ml, 100 ml,200 ml Measuring cylinders  
 Silica gel 154425P (VWR International B-3001 Leuven, Belgium) 
 
Methods 
Sample Preparation 
The outer portion (dark brown), cork of the stem bark was peeled with  the aid of a  pen knife to sepa-
rate it from its inner (green yellow), bark .This is to ensure  specificity with respect to the  compounds  
present in the bark ,coupled with the fact that artefacts and lichens may be present in the cork. 
Subsequently, they were separated into smaller pieces (4 by 2 cm) and air-dried in fume cupboard (72 
h) to ensure the plant materials are free from water which can constitute a source of impurity. 
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 The Fritsch grinder was used to grind separately the samples (cork and bark) and they were weighed to 
obtain the finely powered cork (1.608 kg) and bark (602 g). 
  
 Extraction  
After grinding yield for the bark was 620.2 g .This as well as 800.4 g of the cork(this is half of total 
yield as 800 mg is maximum that can be used in the soxhlet extractor) were used for soxhlet extraction.  
Finely ground (cork and bark) samples were gentle decanted into the thimble ‘paper’ in the main 
chamber of the Soxhlet extractor.  Hexane is expected to extract non polar compounds, ethyl acetate 
medium polar and methanol polar compounds. For both the cork and bark  exhaustive extraction with 
the three solvents were carried out  for 48-72 hours respectively for the six ,two for each of the three 
solvents  to obtain ECHB ( Enantia chlorantha  hexane bark), ECBE ( Enantia chlorantha bark ethyl 
acetate ), ECMB( Enantia chlorantha  methanol bark), EC HC (Enantia chlorantha  hexane cork  ), 
ECEC ( Enantia chlorantha  ethyl acetate cork) ,ECCM (Enantia chlorantha cork methanol)  from 
both E.cholorantha’s  bark and cork respectively 
 
 Post-Extraction Separation and Identification of Compound Types 
Extracts were then decanted from the bottom flask of Soxhlet extractor and evaporated close to dryness 
with aid of a rotatory evaporator. Resultant viscous liquid extracts were decanted into small labelled 
vials and then kept in fume cupboard to evaporate to dryness for weighing. Thereafter Thin Layer 
Chromatography (TLC) was used to determine the possible number and types of compound(s) in the 
extracts for identification of compounds in the mixtures TLC plates, solvents of interest and TLC Tank 
were used. To do this capillary tubes were used to obtain   the extracts from the labelled vials   to spot 
them onto the TLC plate. Varying mixture of hexane and ethyl acetate like 50/50, 60/93, 70/30, 80/20 
making up 10 mL were measured into the TLC tank using a measuring cylinder. The spotted spots on 
the TLC plate  were then numbered and   the prepared pre-coated TLC plate were immersed into the 
hexane/ethyl Acetate mixture ( in successive  ratios  of interest) in the TLC  Tank .The mixture as-
cended from the bottom of the plate to near top by capillary action after  about 5 min. It is then re-
moved and initially blown with hot air using the gun before sprayed with appropriate visualizing rea-
gent (Anisaldehyde and Dragendorff) and re-blown with hot air to aid quick visualization of the ex-
tracts mixture’s separated compounds. Some compounds on the TLC plates are coloured therefore can-
not be detected with the naked eyes easily , so  all   dried prepared TLC plates were  visualized under 
UV light using the Mineralight UV lamp with long wavelength at 254 mm. 
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 Test Organisms for cytotoxicity, antibacterial and anti-trypanosomal activities studies 
 16 strains of Bacteria  namely: Shigella sonnei ,Salmonella typhimurium(3 serotypes),Salmonella java 
,Shigella flexneri(3 serotypes) ,Salmonella enteritidis (4 serotypes), Salmonella oranienburg, Salmo-
nella dublin, Salmonella agona,Escherichia coli ATCC control strain,  and Nocardia farcinica  
Trypanosoma brucei S427 strain was used for the antitrypanosomal activity screen. 
 
 
Cytotoxicity studies 
 
Table 5.1 showing a variety of   cancer cell lines which are outlined in the table below were used in the 
studies: 
Cell line Cell morphology Source MIC µg/ml 
TE671 Epithelial like Human, Caucasian medullablas-
toma 
>100 
A905 Epithelial Human malignant skin melanoma >100 
PC 3 Epithelial Prostatic carcinoma >100 
DU 145 Epithelial Prostatic carcinoma >100 
PNT2A  Epithelial “Normal” prostatic cell line >100 
 
Pre-screening preparation  
The  near to dry E. chlorantha  crude extracts  were made to test solutions using DMSO at concentra-
tion 10 mg/ml. Cancer cells  which were obtained from  patients  were cultured   and  kept in incubator 
at 90°C and 5% CO2.  To keep these the cells for alive for a lengthy period the medium was changed 
every 3-4 days. 
The modification of the Raz et al.,(2000)  and Franzblau S.G.,  et al.,(1997) methods were used the 
activity screening.To screen for cytotoxic potentials of  Enanthia chlorantha’s  bark extracts  , cultured 
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cancer cells were inoculated onto the  specialised activity screening  plate which has 96 wells and la-
belled in rows A-H and columns 1-12. 200 μl of  the plant’s extracts were added to row A, B, C ( hex-
ane, ethyl acetate and methanol respectively) and G wells. The G well designated the experiment’s 
background control was prepared without AlmarBlue indicator unlike the  wells A,B,C had  the ex-
tract(s), 200 μl of the  THP1 media , cancer  cells and the indicator. 200 μl of DSMO were added to 
row D and E. Well F served as the negative control had the listed contents excepts the extract(s), while 
well H  was the positive control .  
A replicate plate in the same fashion was made for E.cholorantha’s cork extracts into wells A, B ,C for 
hexane,ethyl acetate and methanol extracts respectively. With starting concentration of 200 μg/ml, se-
rial dilution to concentrations as low as 0.0009 μg/ml were done on plate’s wells from column 1 to 12. 
After the preparation the plate was placed in incubator for 24 hour at 90˚ C and 5% CO2.  After 24 h, 
100 μl of media were replenished and the two plates returned to incubator for another 24h.Thereafter 
the plate’s row and column contents were read on spectrophotometer at 570 nm and 600nm   with the 
Alamar blue indicator measuring the fluorescence and surviving cancer cells counts were determined 
in vitro. Finally the MIC of the extracts activity against the cancer cells were determined. 
 
 Bacterial strains and activities screening. 
16 bacterial strains were obtained from the laboratory stock cultures of the Department of Microbiolo-
gy Stobhill hospital. To screen for anti-bacterial and anti-trypanosomal activity, the same modification 
of the Raz et al., (2000) and Franzblau S.G., et al., (1997) methods outlined in the cytotoxicity screen-
ing were used.  The only differences were the microbial or parasitic agent replacing the cancer cells  
and as  well as the media used. For the Anti-trypanosomal activity utilising 2-3 x 104 T.brucei S427 (a 
bloodstream form of the parasite)    HMI 9 was the media, A similar protocol was followed for the sev-
enteen bacterial strains using the same serial double dilution approach with Mueller –Hilton broth as 
their media. MICs of the extracts against the seventeen strains including Mycobacterium marinum 
ATCC.BAA535 strain  for anti-bacterial screen and that of the extracts against trypanosomes alongside 
that of Suramin were also determined .The same protocol was followed to determine the MIC  of the 
extracts against Norcardia farcinica obtained from the Strathclyde Institute of Pharmacy and Basic 
Sciences microbiology laboratory  and Gentamycin like Suramin for the trypanosomes was used as 
positive control for the bacterial strains.  
Based on the initial screening   results, only the cytotoxicity, anti-mycobacterium and trypanosomiasis 
screening were done for subsequent resultant fractions gotten from chromatographic separation pro-
cesses. 
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Chemical Structure Elucidation and Identification 
Materials  
       Deuteriated solvents used for One and Two dimensional NMR(Proton and 13 Carbon ) included 
DMSO( Methyl Sulfoxide-d6:Lab Aldrich Chemistry)Germany,  d-CDCl3    (Choloroform-d  Aldrich 
151823-100G)USA. To do this   10-20 mg of the extracts were dissolved in about 0.75- 1 ml of deu-
teriated solvent of choice and transferred into a NMR tube.  Initial NMRs of the extracts were done  to 
reveal  their structural features  and possible compounds of they contain.                                               
Thereafter Open column chromatography E. chlorantha extracts were carried out mixing. The resultant 
dried extracts gotten from the fume cupboard with silica gel and hexane in a conical flask. The column 
fractions were eluted and   TLC done, the ones with similar spots on TLC were pooled together.   
Finally definitive One and Two dimensional Carbon and Proton NMRs and Mass Spectroscopy were 
carried out to elucidate the structures of chemical compounds isolated.  
 
Compound(s) structures elucidation using NMR 
10 mg of each of the extracts or resultant pooled fractions were added to 0.75 ml of deuteriated cholo-
roform or Methyl sulfoxide-d6 (DMSO) depending on the extract’s solubility for the 2D NMR spectro-
scopic studies using the Jeol Eclipse (400 MHz) and Bruker  AMX-500 (500Mhz) 
 
 
Structure elucidation using Mass Spectroscopy. 
  This was used to confirm the molecular weights of structures proposed in the process confirming the 
elucidated structure determined by NMR .This is based on the principle of fragmentation of molecules 
of samples to charged molecular ions and the fragmented spectra read to give the molecular weights of 
the compounds in a given mixture. The electron spray ionization mass spectra (HRESIMS) of all ex-
tract mixtures and resultant pooled Open column chromatography fractions were performed in a 
FTMS- Orbitrap (Thermo Finnigan Bremen, Germany). 
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Results   
The dry extracts yields (following soxhlet extraction and drying in the fume cupboard) as a proportion 
of starting plant material’s weight are shown below in Table 1.1. 
 
Table 5.2: Extracts yield from the plant material 
Plant Code Amount in weight  (g) Yield % 
EC HC 17.6 2.8 
EC CE 16.5 2.7 
EC CM 88.7 14.3 
EC BH 13.0 1.6 
EC BE 24.2 3.02 
EC BM 65.6 8.2 
Key :EC ;Enantia chlorantha, C; Cork, B; Bark, H; Hexane, E ;Ethyl Acetate, M; Methanol. 
 
 
3.1: Screening results  
The preliminary phytochemical and antimicrobial activity screening of the stem bark of Enanthia clor-
antha  carried out showed the hexane, ethyl acetate and methanol extracts had MIC ranging from 3.1-
6.3 µg/mL compared to Suramin 0.06 µM.  
The three extracts were tested at 200 µg/mL, E. chlorantha methanol extract (ECM) showed the least 
MIC of 3.125 µg/mL while the other two had MICs 6.25 µg/mL thus the extracts possess considerable 
significant anti-trypanosomal activity. However, they only showed moderate activity against Esche-
richia coli and Mycobacterium marinum out of seventeen bacterial strains tested and no activity were 
observed for Shigella and Salmonella species at 200 µg/mL. Methanol extract's MIC against E.coli 
was 50 µg/ml. The extracts' MICs against Mycobacterium marinum ranged between 25-100 µg/mL.  
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The extracts activity results are summarized in Table 5.3 here below 
Test organism EC H (MIC (µg/mL) EC E (MIC (µg/mL) EC M (MIC (µg/mL) 
Escherichia coli 25 50 25 
Trypanosoma brucei 3.125 6.25 3.125 
Mycobacterium mari-
num 
25 50 12.5 
Shigella spp >200 >200 >200 
Salmonella spp >200 >200 >200 
A905 100 100 100 
PC 3 50 100 25 
PNTA 50 100 50 
DU145 100 100 100 
TE671 100 100 100 
 
Variety of colours on both TLC and UV lamp were suggestive of presence various classes of com-
pounds in Enantia chlorantha extracts possibly alkaloids, tannins, fatty acids and so on. The reoccur-
rence of blue fluorescence under UV light may be indicative of presence of alkaloids. 
 Column chromatographic separation of the last extract fraction EC BE is ongoing as at the time of put-
ting this report together. 
 
 Spectroscopic studies (NMR and Mass Spectral) results 
Compounds Isolated from the chromatographic separation include: 
1.Palmatine  
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NMR spectral results 
Fig 3.45:Palmatine’s 13 Carbon NMR of Palmatine 
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Fig 3.46 COSY NMR of Palmatine 
 
 
 Fig 3.47 HMBC NMR of palmatine 
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Fig 3.48 HSQC NMR of Palmatine. 
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HSQC and HMBC correlations of Palmatine are shown below in Table 5.4 and Table 5.5 
 
Table 5.4 Palmatine’s HSQC correlations 
 
Position 
 
1H(ppm) 
 
13C(ppm) 
1 7.69 109.22 
1a - 119.4 
1b - 191.1 
2 - 149.22 
3 - 152.0 
4 7.06 111.7 
4a - 129.0 
5 3.27 26.4 
6 4.95 55.9 
7 - - 
8 9.87 145.9 
8a - 121.8 
9 - 144.2 
10 - 150.7 
11 8.17 127.2 
12 8.02 123.9 
12a - 133.6 
13 9.04 120.4 
2 MeO 3.92 56.7 
3 MeO 3.85 56.4 
9 Me O 4.09 62.4 
10 Me O 4.05 57.5 
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 Table 5.5 Palatine’s HMBC correlations 
 
Position 
 
1H(ppm) 
 
13C(ppm) 
1 7.69 (1b)119.4 ,(4a)129.0,(5)26.43 
4 7.06 (1b)119.4,(2)149.22,(5) 26.43 
5 3.27 (1a) 119.4,(4a) 129.0,(6) 55.9 
6 4.95 (4a) 129.0. 
8 9.87 (1b) 191.1,(13) 120.4,(12a)133.6 
11 8.17 (9)144.2,(10)150.7,(12a)133.6,(13) 
120.4 
12 8.02 (8a)121.8,(9) 144.2,(10) 150.7 
,(12a) 133.6, 
13 9.04 (1a)119.4,(1b) 191.1,(8a) 121.8 
2 MeO 3.92 (2)149.2 
3 MeO 3.85 (3) 152.0 
9 Me O 4.09 (9) 144.2 
10 Me O 4.05 (10) 150.7 
  
Interpretation of all of the NMR data above gave rise to the known structure of Palatine. 
 
Subsequent open column  chromatographic fraction analysed yielded known compounds such as 6a, 7-
Didehydro -7-hydroxy-1, 2-dimethoxyaporphine in Fig X  .Its structure shown below. 
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 :6a,7-Didehydro -7-hydroxy-1,2-dimethoxyaporphine. 
Molecular Formula:C19 H19 NO3 
Molecular Weight:309.894. Below are tables showing its HSQC and HMBC correlations 
Table 5.6 HSQC correlations of 6a, 7-Didehydro -7-hydroxy-1, 2-dimethoxyaporphine 
 
Position 
 
1H(ppm) 
 
13C(ppm) 
1 - 145.72 
1a - 117.70 
1b - 98.08 
2 - 151.5 
3 7.113 111.83 
4 1.25 31.1 
5 3.89 93.97 
6 - 42.4 
6a - 128.14 
7 - 189.0 
7a - 122.10 
8 9.60 127.98 
9 7.89 122.64 
10 7.13 123.76 
11 7.18 127.27 
1 MeO 4.00 59.85 
2 MeO 4.09 56.46 
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 Table 5.7 HMBC correlations of 6a, 7-Didehydro -7-hydroxy-1, 2-dimethoxyaporphine 
 
Position 
 
1H(ppm) 
 
13C(ppm) 
3 7.113 (1)145.7 
,(2)151.5,(3a)125.83,(4)31.1 
4 0.98 (5) 93.97,(6) 93.98 
5 3.89 (4) 31.1 
8 9.60 (7) 189, (7a)122.10 
9 7.89 (7) 189.0,(8)127.98,(11) 127.27 
10 7.13 (110127.27 
11 7.18 (1a)117.70,(10) 123.76 
1 MeO 4.00 (1)145.72,(3) 111.83 
2MeO 4.09 (2) 151.50,(3a) 125.83 
 
 Chemical Structure Elucidation 
Carbon and Proton NMR of ECC 1-27 were done for chemical structure elucidation, the results of ECC 
14 and 26 revealed aporphine alkaloids. These aporphines have the same structure as those reported by 
Wafo et al.,1999 but a slightly different stearical configuration in terms of  where the protons and 
methylene groups lies in their NMR spectra .Their spectra are shown below in Figures 11,12,13, and 
14 
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Fig 3.48 Carbon NMR of ECC 14 (6a,7-dehydro-1,2-dimethoxyl-7- hydroxyl-N-methyl-aporphine) 
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 Fig 3.49 Proton NMR of ECC 14 (6a,7-dehydro-1,2-dimethoxyl-7- hydroxyl-N-methyl-aporphine) 
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Fig 3.50 Carbon NMR of ECC 26 ((6a,7-dehydro-1,2-dimethoxyl-7- hydroxylaporphine) 
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Fig 3.51 Proton NMR of ECC 26 (6a,7-dehydro-1,2-dimethoxyl-7- hydroxylaporphine) 
 
CHEMICAL STRUCTURE OF ECC 14 
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6a,7-dehydro-1,2-dimethoxyl-7- hydroxyl-N-methyl-aporphine 
NH
H3CO
H3CO
OH
ECC-26
1
2
3 4
5
3a
6a
1b
1a
7
7a
11a
11
10
9
8
 
6a,7-dehydro-1,2-dimethoxyl-7- hydroxylaporphine 
 
 Analysis of NMR spectra and structure elucidation 
In terms of appearance ECC 14 was pink in colour, while ECC 26 was black. The two compounds gave 
pink coloration  when sprayed with Anisalaldehyde reagent and yellow- brownish colour with Dragen-
dorf reagent indicative of presence of Alkaloids. 
ECC 26 (6a,7-dehydro-1,2-dimethoxyl-7- hydroxylaporphine) was found to be very similar to ECC 
14(6a,7-dehydro-1,2-dimethoxyl-7- hydroxyl-N-methyl-aporphine) with the presence of N-CH3  group 
observed at ð 2.78ppm while  for the latter and N-H group at position ð 2.52ppm in the former being 
the difference. 
The two compounds had two MeO groups at ð 4.00 ppm and ð  4.09 ppm.they also had 1H multiplets at 
3.20,3.34 and 3.32 ppm indicative of the methylene groups at C-4 and C-5.The signal at 7.13ppm was 
due to the aromatic proton at position C-3, while the highly deshielded aromatic proton at 9.66 ppm 
was due to the proton at C-11. This was confirmed by its NOESY interaction with the OCH3  at posi-
tion 4.09ppm.  
 
Further structure elucidation of the fractions compounds using NMR and Mass Spectral would be done 
in the future as in PhD study. However, there are strong indications from the next set of NMR spectral 
being   analysed that are novel alkaloids. These novel compounds  are protoberberine variety of benzo-
isoquinoline alkaloids .Their   structures were confirmed using   Mass Spectral ,which gave  the exact 
molecular weights expected .They are however  about to be subjected to reconfirmation of  their novel-
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ty through X-ray Crystallography and other appropriate methods  , so would be  included  in future re-
sult findings. 
 
Antibacterial Activity  Studies Result . 
We were unable to solubilise 3 fractions EC H B, EC H C and EC E C using freshly prepared DMSO. 
 The extracts solubilised failed to inhibit growth of the sixteen strains of Bacteria at concentration 
10mg/ml down to 0.2mg/ml.However EC M C showed modest activity against E.coli ATCC25922 
at 10mg/ml suggestive of its MIC being greater than 10mg/ml. 
 
Fig 3. 52 The sixteen strains tested in petri dish with extracts: Shigella sonnei , three serotypes of Sal-
monella typhimurium, Salmonella java , three serotypes of Shigella flexneri , four serotypes of Salmo-
nella enteritidis , Salmonella oranienburg, Salmonella dublin, Salmonella agona, Escherichia coli 
ATCC 25922 control strain all failed to achieve MIC at 10 mg/ml. 
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Fig 3.53 EC M C(16th spot) demonstrating some activity against E.coli ATCC 25922 
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However the second phase of Antibacterial activity testing done revealed modest activity against Nor-
cadia farcinica  by the EC H B fraction .The result is shown on the Figure 7 below 
 
Fig 3.54 Bar chart comparing the effect of Enantia chlorantha extracts against the conventional 
antibiotic; Gentamycin against Norcadia farcinica 
NB: 
• The lower the peak the more the activity. 
• 50% as reference point for significant activity. 
 
 
 
Discussion: 
The extracts’ moderate activity against E. coli correlates with its traditional use in treating urinary tract 
infections (UTIs). The significant anti-trypanosomal activity and that of Mycobacterium marinum also 
correlates with the traditional anti-parasitic use in treating malaria and pulmonary tuberculosis. Further 
activity screenings are ongoing with early results showing the purer fractions have equal or more activ-
ity against trypanosomes than the crude extracts. 
These preliminary results have provided a platform for complete isolation and structure elucidation of 
lead novel / pure compounds from the extracts. These novel alkaloids which would require further pu-
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rification and activity screens in terms of cytotoxicity and anti-parasitic potentials. Identified active 
compounds would serve as leads for the synthesis of improved and more potent analogues for further 
anti-parasitic activity screening and subsequent translational work with a view to drug development. 
Future perspectives 
Future use of chromatpgraphic techniques like open column, Flash and Vacuum Liquid Chromato-
graphic separation of the extracts into pure fractions would be undertaken. These fractions when col-
lected would be pooled together based on similarity on TLC plates and subsequently NMR and Mass 
Spectroscopy are done to elucidate their structures, as well determine their exact molecular weights. 
The subsequent stages projected for this PhD study are as outlined below in a flow chart manner: 
 
Cleaning up (stability tests and purification of the lead compounds through Ion exchange separation 
and other appropriate techniques) 
  
Scaling up (this is needed to have more yield of lead compounds of interest, as 800grams of the 
cork/bark for example yields between 10-25 mg of lead compounds.) 
 
                                              Synthesis of the novel lead compounds 
 
                                    Further parasitic activity screening (looking the synthesized compounds activity 
against a variety of parasitic infections bioassay templates like malaria, leishmaniasis in addition to 
trypanosomiasis) 
 
Pharmacokinetics and synthesized compounds safety studies using 3D Hepatocyte and Stem cell mod-
els to predict the compounds’ metabolism and toxicity profile in vivo and vitro. 
 
 Molecular modelling and other translational chemistry approaches to define drug targets in 
terms of compound’s binding protein and enzyme targets. 
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Figure 3.55: Normal Phase HPLC print of fraction Prep ECH 1-1 as a mixture being subjected to puri-
fication 
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Gel filtration chromatography fractions MIC results. 
Out of the 3 Sephadex columns ran, 18 fractions (ECBE SA), 12 fractions (ECCH SA), 59 fractions 
(ECCHE SA) were obtained. The fractions were thereafter submitted Trypanosomiasis screen test 
The screen results are as shown in Table 3.16 here below. 
Table 5.8                      Well         Fraction                    MIC 
 A2 
ECBE 
SA1  12.5 
 A3 
ECBE 
SA2  25 
 A4 ECBE SA 3 6.25 
 A5 
ECBE 
SA4  25 
 A6 
ECBE 
SA5  6.25 
 A7 
ECBE 
SA6  6.25 
 A8 
ECBE 
SA8  1.6 
 A9 ECBE SA12 6.25 
 A10 ECBE SA11 6.25 
 A11 ECBE SA10 1.6 
 B2 ECBE SA14 6.25 
 B3 ECBE SA15 >100 
 B4 ECBE SA16 50 
 B5 ECBE SA17 3.12 
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 B6 ECBE SA18 0.8 
 B7 ECBE SA22 25 
 B8 ECBE SA24 12.5 
 B9 ECBE SA25 25 
 B10 ECBE SA35 12.5 
 C2 ECCH SA1 >100 
 C3 ECCH2 SA1 >100 
 C4 ECCH2 SA3 >100 
 C5 ECCH2 SA4 3.12 
 C6 ECCH2 SA6 1.6 
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Reverleris IES Flash Chromatography  printouts 
  Fig 3.56 ECM fraction run 
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Fig 3. 57 ECH frcation 
 
 
[242] 
 
Fig 3. 58 ECE fraction run 
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Figure 3.59 showing a nearly pure fraction obtained from Normal phase HPLC 
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Figure 3.60 showing another nearly pure fraction obtained from Normal phase HPLC however in very 
small quantity. 
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Table 5.9 HPLC run fractions and retention times 
 
Fraction code Retention time Area 
ECP-19 1.16.825 
2.23.162                                                  
3.30.703 
4.32.058 
5.33.252 
6.34.915 
7.35.498 
472193 
778430 
668001 
796946 
871119 
420942 
602905 
ECH 56 1.5.152 
2.14.702 
3.22.500 
4.26.600 
5.27.312 
6.29.992 
7.33.491 
596299 
1423449 
1090082 
1571781 
1139393 
5252015 
829711 
ECP-17 1.13.245 
2.23.243 
3.26.933 
4.33.278 
5.35.593 
1124428 
2819891 
749077 
1564206 
2458988 
ECHE-45 1.23.555 
2.33.435 
3.34.582 
4.35.702 
7982150 
10589159 
2850813 
8611711 
ECF 5-10 1.2.620 
2.4.812 
3.5.300 
4.20.503 
1105576 
1526884 
50687 
921879 
ECP 23 1.23.587 
2.33.752 
3.34.630 
4.35.748 
 
794659 
752731 
941846 
533593 
ECHB17-18 1.4.877 
2.8.262 
3.12.920 
4.13.452 
5.19.598 
6.26.075 
219980 
249552 
91463 
320789 
192492 
118896 
ECH 59 1.23.295 
2.33.252 
3.34.917 
4.35.498 
7233461 
8301715 
3081333 
6691798 
ECBH 35P 1.17.232 
2.23.232 
3.31.972 
4.33.170 
12125321 
12127997 
4433479 
23591280 
ECBE 72 1.23.491 
2.30.693 
3.33.218 
4.35.467 
1729934 
2608903 
1892601 
2113154 
[246] 
 
 
 
ECH 62 1.4.892 
2.13.483 
3.19.613 
4.20.928 
5.26.612 
6.29.113 
7.30.108 
8.33.518 
112783 
910649 
473922 
5929276 
784693 
350274 
316773 
501551 
ECBE 42 1.16.825 
2.23.162 
3.32.058 
4.33.252 
5.34.915 
6.35.498 
26494353 
21685327 
6288656 
19772185 
4769098 
6297934 
 
 
 
Hepatocytes in vitro metabolism and toxicity studies. 
 
3.42 mg of Palmatine was weighed accurately in a pre-labelled vial. A solution of 10 uM of it dis-
solved in Kreps-Hepes (KH) buffer with PH 7.4. Four clean round bottom flasks were labelled A-D. 
 
Flask a Hepatocytes alone 
Flask B Palmatine alone 
Flask C Hepatocytes and Palmatine 
Flask D Empty  
 
Aliqouts of 100ul of the Palmatine – (KH) buffer were introduced by means of a pipette into Flask B 
and C. 
A stock solution of 25 mls containing 23 mls of KH and 2mls of hepatocytes, 10 ml of this were added 
to contents of Flask C and Flask A. 
 
Krebs-Henseleit buffer solution was made from: 
Distilled H20  -785ml 
16.09% NaCl Solution -200ml 
1.10% KCl solution-     150ml 
0.22 MKH2PO4           - 25ml 
2.74% Mg SO4   7H20   -50ml 
0.12 % CaCl2.6H20             -100ml. 
The KH buffer’s stock solution was stored at 4 oC prior to use in this study. 
 
Perfusion Procedure 
 Handling of animals were done following the UK Home Office Licence regulations and guidelines. 
Hepatocytes were isolated from male Sprague-Dawley (weighing 165-259g) rat liver by means of 
modified collagenase perfusion method Grant (2008). 
 
The buffers: 
Hank’s buffer contains: 
NaCl -80.g 
KCl  - 4.0g 
MgSO4. 7H2O- 2.0g 
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NaHPO4.2H2O- 0.6g 
KH2PO4           -0.6g 
 
 
HI buffer: 
NaHCO3   -1.05g                                                                                                                                                                  
Hepes         -1.50g 
BSA (fraction V)- 3.33g 
EGTA (a chelator) -114mg 
Distilled water – 450 ml 
Hank’s buffer – 50ml 
 
 
 
HII buffer: 
NaHCO3       -1.05g 
Hepes            -1.50g 
CaCl2 2H2O -147mg 
Distilled H2O -450ml 
PH of the mixture adjusted to 7.4 by adding NaOH methodically 
 
Anesthetized rats by means of injection of Phenobarbitone Sodium at dose of 100UL/100g body 
weight .The rats’  peritoneal cavity dissected open  using a mid transverse incision and 0.1ml of hepa-
rin solution 1,000iu/ml( Sigma Chemical co., Poole, Dorset UK) in Phosphate buffer saline (PBS with 
PH 7.4) was injected into the inferior vena cava. 
Thereafter the portal vein was cannulated and perfused in Hank 1 buffer (HI) buffer 150ml without 
recirculation for 3-4 minutes (time it takes to remove the liver from the body) and then recirculation of 
buffer for 10-12 minutes. 
The HI buffer is calcium free with its EGTA (chelator) content during the 1st 10 minutes of recircula-
tion removes Ca2+  thus weaken the bond between the cells  .This is the 1st step in optimising the  rat 
livers for collagenase digestion. 
 
  The next stage involves perfusing the liver with HII buffer (150ml) is added to collagenase type IV  
derived from Clostridium histolyticum 267 units/mg (Gibco BRL Life technologies, Paisley, UK)   
recirculating  for 12 to 20 minutes. 
 
The processed rat liver at this point feels very soft and cells inside the liver sac dissociated, it is then 
dispered carefully using sterile forceps into KA buffer containing 1% (w/v) bovine serum albumin. The 
subsequent cell suspension was filtered using cotton wool gauze to remove connective tissues and 
clump of cells impurities. The resultant filtrate is collected in 200ml volumetric flask and processed 
hepatocytes were allowed to stand under gravity, the supernatant decanted and the processed hepato-
cytes washed once with KH buffer (70ml) 
 
Viability test 
The viability of the processed rat hepatocytes were determined using the Tryptan blue exclusion test , 
above 75% viability was taken as benchmark with yield of viable cells between 20-25 X 106 
 
Water bath at 90oC had the flask A-D rotating by means of rotator evaporator to allow the hepatocytes 
an enabling condition to metabolise the added drug (compound). 
                  
Flask A Hepatocytes alone 
Flask B Palmatine alone 
Fask C Hepatocytes and Palmatine 
Flask D Empty  
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At intervals of 0,15, 30,45,60,90 and 120 minutes aliquots of 100ul were added by means of  pipette 
into Eppendorf’s (vials) and placed as soon as possible into liquid nitrogen prior to being  frozen at -
20oC until LC-MS and HPLC analysis of 
metabolites. 
50ul  aliquots were added by means of pipette  into Eppendorfs from Flask A and C  alongside  50 ul of 
Tryptan blue, the mixture introduced onto the slide and viewed under the microscope to count the sur-
viving cells and determine the viability. 
 
1. Palmatine 
Initial viability prior to water bath conditions is 79.4% 
 
 Table 5.10 Viability results 
 
Time 0 
              Live                      Dead                 Viability % 
A              92                         11                        78 
C               90                         13                        74 
 
Time 60 
A               92                        11                        78 
C                90                        13                        74 
 
Time 120 
A                33                        17                         66 
C                 25                        25                        50 
 
This results could be insight into mode of excretion of  these group of alkaloids described in 
this study and potential half-life, though more detailed and specific studies tailored along such 
lines would be needed to decipher this. 
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Table 5.11: The 24 natural products discovered since 1970 that led to an approved drug in 
1981-2006 
Lead, year  and structural class  Origin Approved drug, and year 
Validamycin, 1970 
Oligosaccharide 
Actinomycete Acarbose, 1990 
Voglibose, 1994 
Midecamycin, 1971 
Macrolide 
Actinomycete Miocamycin, 1985 
Pseudomonic acid , 1971 
Polyketide 
Bacteria Mupirocin, 1995 
Taxol,1971 
Diterpene 
Plant  Paclitaxel ,1993 
Docetaxel, 1995 
Cephamycin C , 1971 
B-lactam 
Actinomycete Moxalactam, 1982 
Cefotetan , 1984 
Cefbuperazone, 1985 
Coformycin, 1974 
Nucleoside 
Actinomycete Pentostatin, 1992 
Echinocamdin B 1974 
Cyclopeptide 
Fungus Caspofungin, 2001 
Micafungin,2002 
Anidulafungin 2006 
Mizoribine, 1974 
Nucleoside 
Fungus Mizoribine,1984 
Rapamycin ,1974 
Polyketide 
Actinomycete Sirolimus, 1999 
Everolimus, 2004 
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Zotarolimus, 2005 
Compactin ,1975 
Polyketide 
Fungus Lovastatin ,1984 
Simvastatin ,1988 
Pravasatin, 1989 
Fluvastatin ,1994 
Atorvastatin  1997 
Cerivasatin, 1997 
Pitavastatin 2003 
Rosuvasatain ,2003 
Cylosporine A, 1975 
Cyclopeptide 
Fungus Cyclosporine ,1983 
Lipstatin, 1975 
Polypeptide 
Actinomycete Orlistat, 1987 
Bestatin, 1976 
Peptide 
Actinomycete Ubenimex, 1987 
Thienamycin, 1976 
B-lactam 
Actinomycete Imipenem,1985 
Meropenem, 1994 
Panipenem, 1994 
Faropenem,1997 
Biapenem,2002 
Ertapenem,2002 
Doripenem,2005 
Artemisinin, 1977 Plant Arteminin, 1987 
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Sesquiterpene 
 
 
Artemether, 1987 
Artenusate, 1987 
Arteether,2000 
Forskolin,1977 
Diterpene 
Plant Colforsin,1999 
Plaunotol,1977 
Diterpene 
Plant  Plaunotol,1987 
Avermectin B1 a , 1979 
Polyketide 
Actinomycete Ivermectin,1987 
SQ26, 180, 1981 
B-lactam 
Actinomycete Aztreonam, 1984 
Carumonam, 1988 
Sperrgualin,1981 
Peptide 
Bacteria Gusperimus,1994 
Arglabin, 1982 
Sesquiterpene 
Plant  Gusperimus,1994 
FK506,1984 
Polyketide 
Actinomycete Arglabin,1999 
Daptomycin,1986 
Cyclodepsipeptide 
Actinomycete Daptomycin , 2003 
Calicheamicin Y1, 1988 
Polyketide 
Actinomycete Gemtuzumab,2000 
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Table 5.12 Rerank Pose scores of antitrypanosomal  protein targets against previously isolated alka-
loids from Enantia chlorantha 
EC 
Compounds 
TbA
K 
TbPTR1 TbDHF
R 
TbTR TbCatB TbHSP90 TbCYP51 
Atherosperminine -23.9 -26.2 -20.8 -23.6 -16.6 -21.9 -20.6 
Columbamine -24.6 -24.2 -19.4 -22.1 -17.4 -22.8 -22.1 
Jatrorrhizine -24.9 -25.8 -21.3 -22.4 -15.7 -23.8 -21.8 
Lanuginosine -24.6 -26.1 -19.9 -24.1 -16.6 -22.5 -20.9 
Liriodenine -22.3 -23.9 -19.2 -22.6 -18.2 -23.2 -18.7 
Lysicamine -23.7 -23.9 -18.1 -22.2 -16.1 -24.1 -18.6 
Palmatine -24.3 -24.7 -20.5 -24.4 -14.2 -23.2 -23.2 
Isoboldine -23.8 -25.0 -21.6 -22.1 -19.4 -23.9 -22.3 
Isocorydine -24.3 -23.9 -20.9 -22.9 -17.3 -24.1 -20.2 
8-hydroxypalmatine -24.2 -26.4 -19.4 -21.1 -16.6 -21.7 -24.0 
O-
Methylmoschatoline 
-23.2 -22.6 -18.0 -23.2 -14.3 -22.5 -18.8 
Argentinine -24.1 -26.1 -22.4 -23.9 -17.3 -24.7 -22.4 
Pseudocolumbamine -21.6 -25.3 -27.5 -20.2 -22.8 -18.3 -23.4 
Pseudopalmatine -25.0 -27.5 -20.9 -23.5 -17.9 -23.4 -20.9 
EC: Enantia Chlorantha   
Antitrypanosomal protein targets: TbAK T.brucei adenosine kinase, 
TbPTR1 T. brucei pteridine reductase 1 T brucei dihydrofolate reductase ,TbTR T. brucei trypanothi-
one reductase ,  TbCatB  T brucei  cathepsin B,  TbHSP90 T brucei heat shock protein 90,TbCYP51 T 
brucei sterol 14α-demethylase 
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Fig 3.61 NOE spectrum employed in structure elucidation of alkaloids in this thesis 
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